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Abstract 
Chronic stress can lead to major depressive disorder (MDD) as well as depression-related 
comorbidities, such as anxiety and memory loss. Frequent treatment failure of the currently 
used conventional monoamine-based antidepressants indicate the urgent need to develop novel 
antidepressants that act by a different mechanism. There is good evidence that pain and 
depression create a vicious cycle. While pain worsens the symptoms of depression, the 
resulting depression worsens the feelings of pain. Opioids are clinically used as the most 
important treatment against severe pain. With the identification of the three classic opioid 
receptors, (mu-opioid receptor (MOP), delta-opioid receptor (DOP) and kappa-opioids 
receptor (KOP)), an increasing number of novel ligands have been described that not only show 
opioid receptor-dependent analgesic but also antidepressant-like effects in pre-clinical models. 
These antidepressant-like effects of opioid receptor ligands are thought to be a consequence of 
their ability to modulate cellular stress responses as well as their effects on learning, memory 
and behaviour.  
On the other hand, it was proposed that oxidative stress plays a relevant role in the pathogenic 
mechanisms underlying MDD. Reactive oxygen and nitrogen species modulate levels and 
activity of multiple neurotransmitters that are involved in the neurobiology of depression. 
Clinical studies in MDD patients reported reduced levels of endogenous antioxidants, impaired 
mitochondrial function and a disturbed redox equilibrium. However, several studies reported 
opioid-induced mitochondrial dysfunction by a mechanism that involves the generation of 
reactive oxygen species (ROS). In line with this, morphine has also been described to increase 
oxidative stress rather than to reduce it. Thus, the connection between opioids, depression and 
oxidative stress appears significantly more complex. 
At present, antidepressant-like effects of both clinically used and experimental MOP or DOP 
agonists have been described in pre-clinical and clinical studies. We therefore hypothesized 
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that opioids that simultaneously activate the MOP and DOP receptor, such as the UTAS-
derived experimental bi-functional opioid 1003 (unpublished data), could also produce 
antidepressant-like effects. To test this hypothesis, we first assessed the behavioural effects of 
morphine (MOP agonist) in models of depression (learned helplessness model, LH), anxiety 
(light and dark model, LD), locomotion (open field model, OF) and pain (hot plate (HP) and 
tail flick (TF) tests). Parallel to previous studies, morphine showed promising antidepressant-
like effects that were similar to the clinically used tricyclic antidepressant imipramine. 
However, morphine also enhanced avoidance learning and produced significantly higher 
physical activity after repeated administrations. This raises the possibility that morphine leads 
to behavioural changes that only mimic an antidepressant-like effect in this specific model. 
Therefore, the interactions between locomotion, learning and the antidepressant-like effects of 
drugs in the LH model require careful analysis and interpretation of multiple parameters. In 
this model, compared to morphine, the same dose of our novel bi-functional opioid receptor 
ligands (1001 and 1003) failed to produce any behavioural effects. Nevertheless, 1001 and 
1003 somewhat reduced the oxidative damage in the dentate gyrus (DG) of both anterior and 
posterior hippocampus (HPC), an area of the brain that is highly involved in the regulation of 
mood, learning and memory.  
Therefore, to understand the relevance of oxidative stress in MDD, a clinically used and much 
more potent antioxidant was assessed in our animal model. In rats that were exposed to repeated 
inescapable foot shocks in the LH model, antioxidant treatment significantly reduced oxidative 
cell damage in the DG of the anterior HPC and at the same time fully reversed the cognitive 
impairment associated with this model. However, this antioxidant treatment did not have any 
effects on the depressive-like symptoms in this model, nor did it modulate pain perception or 
anxiety levels.  
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Overall, these results highlight that opioids could be developed as antidepressants but also 
emphasize the need to investigate their off target effects in much more detail to judge the 
relevance of pre-clinical models before the start of clinical trials. The results of this study 
strongly suggest that oxidative stress in the HPC is a consequence of depression rather than a 
causative pathology. On the other hand, our results indicate that depression-induced cognitive 
deficiencies are a consequence of oxidative stress as antioxidant treatment was able to 
normalize this pathology. In addition to the evaluation of two novel bifunctional opioids for 
their potential use as anti-depressants, this project has provided new data towards the close 
relationship between pain, depression, cognition, and oxidative stress. 
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1.1 Stress-based mental disorders 
1.1.1 Depression  
Major depressive disorder, also known as clinical depression, is a serious mood disorder with 
a lifetime prevalence of 13 % in men and 24 % in women in developed countries (1). In 2007, 
a study from the World Health Organization (WHO) estimated that depression affected health 
more profoundly compared to many other chronic diseases (2). As depression is often comorbid 
with other health conditions, there is an urgency to both improve its treatment and reduce its 
burden. Although clinical symptoms of depression vary, patients generally struggle to cope 
with their daily personal and social lives. They experience a loss of self-worth, disturbed sleep, 
reduced pleasure, reduced ability to concentrate as well as increased fatigue and irritability (3). 
At its worst, depression is an important risk factor of suicide (4). In 2012 alone, depression 
caused a million deaths worldwide and contributed to 12.5 % of all suicide cases caused by 
mental disorders (5,6) This represents a serious but unmet public health problem.  
 
1.1.1.1 Physiological mechanisms of depression 
The complexity of depression is reflected by the variety of known causal factors including 
genetic/epigenetic susceptibilities, environmental factors and medications. In addition, 
depression can also occur as a secondary pathology of other disorders. Although genetic factors 
are thought to be responsible for up to 50 % of depression cases (7), recent advances in the 
epigenetics of depression suggest that regulation of specific genes but not actual sequence 
variations in the form of polymorphisms may contribute to the highly heritable nature of 
depression (8,9). 
It is widely known that chronic stress is associated with the onset of depression (10,11,12). 
Significant evidence suggests that most of the depression cases are likely a consequence of 
prolonged exposure to stressful conditions throughout life (13,14,15,16). This is well 
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established that chronic or lifetime stress can disturb adaptive systems of organisms, which 
lead to pathophysiological changes in brain function and structure as well as the development 
of depressive symptoms (17). The stress-induced adaptive system highly relies on the function 
of the hypothalamic-pituitary-adrenocortical (HPA) axis. Briefly, adrenocorticotrophic 
releasing factor (CRF) and vasopressin (AVP) are secreted from the hypothalamus upon initial 
stress exposure, which in turn activate the secretion of adrenocorticotrophic hormone (ACTH) 
from the pituitary gland to stimulate the secretion of cortisol (human) or corticosterone 
(rodents) from the adrenal cortex. The release of glucocorticoids changes energy metabolism, 
immune and inflammatory reactions that rapidly adapt the brain and body (18). The 
glucocorticoid receptors (GR) in the HPA axis and the limbic system are activated by 
glucocorticoids (19). Subsequently, the limbic system is altered to remember the stressful 
experiences and the corresponding stress responses are recorded for future events.  
However, prolonged stress exposure leads to dysregulation of this stress-induced adaptive 
system and decreases its efficiency to cope with upcoming events, which ultimately will result 
in the development of depression (20). As a consequence, an overstimulated HPA axis and the 
increased levels of glucocorticoids have been frequently reported in patients with depression 
(21,22,23,24,25).  In healthy subjects, plasma cortisol concentration  of 8.6 ng/dl were detected, 
while MDD patients showed 12.9 ng/dl (26), similar to additional clinical studies (27,28).  
To substantiate this connection in a preclinical model, rats were treated with similar 
concentrations of corticosterone (29). Over 3 weeks, daily injection of 40 mg/kg corticosterone  
produced plasma corticosterone levels of 568 ng/dl that were associated with depressive-like 
symptoms (30). In another rat study only 1 mg/kg corticosterone (s.c.) for 4 days generated 
similar plasma corticosterone concentrations of 590 ng/dl. However, despite similar plasma  
levels, this dose did not result in depressive-like symptoms (31). This discrepancy highlights 
that possibly corticosterone administration in pre-clinical models is only of limited use to 
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mimic cortisol dependent effects in patients. Based on the available information from animal 
studies, it is unclear if increased levels of glucocorticoids are causative to the development of 
depression as previously suggested (32), or merely represent a side phenomenon of depression.   
Brain-derived neurotrophic factor (BDNF) is a key protein that regulates the stress response 
(33) and affects the process of learning and memory formation (33). BDNF  acts as a survival 
factor of developing hippocampal neurons, as well as affecting the morphology and viability 
of cultured adult dentate gyrus (DG) neurons (34). In animal studies, the expression of  BDNF 
mRNA and protein was suppressed by corticosterone (35). In rats, a single dose of 1 mg/kg 
corticosterone (given an average weight of  250 g in rats, similar to a human equivalent dose 
of 0.16 mg/kg based on a bodyweight of 70 kg in humans (29)) reduced BDNF mRNA 
expression in the hippocampal DG by 70 % and suppressed BDNF protein levels in the same 
brain region by 17 % (36). Although supportive of a direct effect of corticosteroids on BDNF 
levels, a clear dose-effect for this response not available is so far, since a 10-times higher dose 
of corticosterone (single dose of 10 mg in rats with an average weight of 300 g (approximately 
33 mg/kg, similar to a human equivalent dose of 5.38 mg/kg (29) based on 70 kg bodyweight) 
reduced mRNA expression of BDNF in the rat DG at a similar rate (37). A meta-analysis of 
studies published by July 2004 suggested that a single median dose of 25 mg cortisone 
(approximately 0.35 mg/kg based on a 70 kg person and equivalent to 2.17 mg/kg in a rat of 
300 g) induced memory impairment in humans (38). In parallel, memory  deficits were reported 
in rats that received corticosterone injections at the same equivalent dose (a single dose of 2 
mg/kg in rats, equivalent to 0.32 mg/kg in humans) (39). The link between cortisone-induced 
memory loss and reduced BDNF mRNA and/or protein expression levels in the human brain 
is obviously not easy to demonstrate. Nevertheless, reduced mRNA expression of BDNF was 
detected in saliva in patients with first-episode psychosis, a mental disorder that is highly 
associated with psychosocial stress exposure (40). Those patients also showed reduced 
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cognitive function, when compared to healthy individuals (40), which supports the idea that 
BDNF has a regulatory role in stress circuits and stress-induced cognitive impairment. Another 
possible mechanism of depression-associated cognitive dysfunction is related to the capacity 
of the HPC for neuroplasticity, which is modeled by long-term potentiation (LTP) (41). 
Exposure to sufficiently severe stress, such as during the IS in the LH paradigm, can impair 
LTP in the rodent hippocampal DG (42), which was associated with stress-induced memory 
impairment in those animals (42,43). Despite gaps in our detailed understanding around dose 
effects and causality, the preclinical and clinical data both support the overall hypothesis that 
stress negatively affects synaptic plasticity and memory function. 
Because of this established hypothetical link between stress and depression and depression-
related cognitive deficits, this relationship has been used as the cornerstone for creating animal 
models of depression, which are vital for the study of this disorder as well as to identify and 
develop novel antidepressants. 
   
1.1.1.2 Monoamine hypothesis of depression 
The release of monoamine transmitters from synaptic vesicles is essential for synaptic 
transmission (44). The enzymes that are needed for neurotransmitter synthesis are initially 
produced in the neuronal cell body and are then transported down the axon to the synapse 
cytoplasm. In the presynaptic nerve terminal, neurotransmitters are synthesized from precursor 
molecules (mainly aromatic amino acids such as tyrosine, tryptophan, phenylalanine) (45) and 
stored in synaptic vesicles (46). In response to action potentials, calcium ions from the 
extracellular fluid enter into the presynaptic cytoplasm. This increase in cytoplasmic calcium 
causes the synaptic storage vesicles to fuse with the presynaptic membrane to release 
neurotransmitters into the synaptic cleft which propagates the neurotransmission process (46) 
(Figure 1). The termination of this process takes place by different mechanisms. The primary 
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one is the reuptake of excess neurotransmitters into the presynaptic neuron by perisynaptical 
monoamine transporters (MATs) which act as Na+/Cl- dependent co-transporters. Plasma-
membrane localized Na+/K+ ATPases generate the required ion gradient to drive this process. 
Subsequently, the cytoplasmic neurotransmitters are either incorporated into synaptic storage 
vesicles via the vesicular amine transporter system (47) or are oxidized by monoamine oxidases 
(MAO) that are present on the surface of presynaptic mitochondria (38) (Figure 1). Any 
remaining monoamines in the synaptic cleft can be taken up by the post-synaptic neurons, 
where they are inactivated by the catechol-O-methyltransferase (COMT) by methylation (48). 
In the 1950s, researchers started to pay attention to the link between depression and monoamine 
deficiency and several lines of evidence have provided support for this hypothesis (49,50). 
Reserpine, which is an antihypertensive drug that depletes the monoamine neurotransmitters 
from peripheral sympathetic nerve endings, induced depression in 15 % of patients at higher 
doses (51). This finding suggested that agents that inhibit the depletion or breakdown by 
monoamines in the brain could also ease symptoms of depression. In addition,5-HT(1A) 
receptor agonists that increase serotonin (5-HT) signaling, increased the mood of patients with 
unipolar depression, likely by a post-synaptic mechanism (52,53)Together, these observations 
imply that abnormally low monoamine levels in the brain can cause depression. In the 1960s, 
researchers detected relatively low synaptic levels of norepinephrine (NE) receptors in some 
brain circuits, such as the hypothalamus, locus coeruleus and cortex, in depressed individuals 
(54), which suggested that depression could be treated by up-regulating expression of post-
synaptic NE receptor (55). From the 1990s, research into the relationship between 5-HT and 
depression attracted most of the scientific attention. The distribution of a large majority of cell 
bodies of serotoninergic neurons is restricted to the brain stem of human brain. They are  
predominantly found along the  midline of the raphe nuclei (56,57),  where they are implicated 
in mood regulation (58). These serotoninergic neurons project from the raphe nuclei to many 
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forebrain  structures that participate in the regulation of different functional systems such as 
the motor, somatosensory and limbic systems (59). They have also been associated with a wide 
range of neuropsychiatric and neurological disorders (60). Furthermore, the densities of both 
serotonergic neurons and postsynaptic receptors significantly decreased in patients with MDD, 
compared to healthy subjects (61,62). All of this evidence suggest that monoamine (e.g., 5-HT 
and NE) deficiency can lead to the development of depression (Figure 1). 
 
 
Figure 1. The monoamine theory of depression. 
This theory states that reduced synaptic activities of monoamines (e.g., 5-HT and NE), are the 
consequence of either down-regulated postsynaptic receptor densities or monoamine 
depletion in pre-synaptic neurons. The core hypothesis suggests that the declined synaptic 
activities of monoamines can be regarded as the cause of depression. 
 
This hypothesis is further supported by the therapeutic effects of monoamine oxidase inhibitors 
(MAOIs) in depressed patients. MAOIs have a long history of use in the treatment 
of depression (63). Commonly used irreversible MAOIs such as tranylcypromine, phenelzine 
and isocarboxazid provide a comparable response rate  of 50 to 70 % in MDD patients, similar 
to that of tricyclic antidepressants (TCAs) (64,65). Approximately 50 % of treatment-resistant 
patients respond to MAOIs, which is significantly higher than some of the frequently described 
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TCAs, for example, imipramine (66). Therefore, MAOI are considered a better treatment 
option for treatment-resistant depression at later stages (66). In addition, the response rate of 
first generation MAOIs was also superior to placebo in depression with atypical features  such 
as anxiety, fatigue and weight gain (67). Subsequently, second generation reversible MAOIs 
including selegiline, meclobemide and tyramine were developed to avoid the potential risk of 
hypertension that was associated with intake of specific food items such as cheese (68). Even 
though some of those reversible MAOIs, for example, moclobemide and selegiline, showed 
improved safety profiles while providing similar response rates compared to TCAs, serotonin 
reuptake inhibitors (SRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs), they 
do not replace the role of irreversible MAOIs for the treatment of atypical depression (63). 
Monoamine oxidase (MAO), as the main target of MAOIs, are localized to the outer 
mitochondrial membrane (69,70,71) and play an important role in the metabolism of 
catecholamines, such as dopamine (DA), NE and 5-HT (72). MAO break down catecholamines 
that are not protected by vesicles after re-uptake, which directly results in reduced levels of 
monoamine neurotransmitters in the neuronal synapses (73). Parallel to pre-clinical results, 
increased MAO activity and/or levels have also been reported in patients with depression (74). 
In addition, the metabolism of catecholamines by MAO is accompanied by the generation of 
hydrogen peroxide (H2O2), a cytotoxic agent that can lead to oxidative stress. Oxidative stress 
can in turn cause mitochondrial DNA (mtDNA) damage (75), lipid peroxidation (76), cellular 
damage (77) and eventually, mitochondrial dysfunction (78) (Figure 2). Recent studies 
suggested that the development of various stress-based disorders, including anxiety (79) and 
MDD (80), are highly associated with oxidative stress and mitochondrial dysfunction. This 
observation further supports the involvement of MAO in depression. It also implicates 
disturbed mitochondrial function in the pathology of affective disorders. 
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Figure 2. The role of monoamine oxidase in the development of depression. 
Monoamine oxidase (MAO) metabolises catecholamines, leading to reduced levels of 
monoamine neurotransmitters. Hydrogen peroxide (H2O2) is generated during the MAO-
mediated metabolism of catecholamines, which further result in oxidative-stress-induced 
mitochondrial dysfunction. Both reduced monoamine levels and impaired mitochondrial 
function could contribute to the development of depression. 
 
1.1.1.3 Depression and cognition 
Depression not only changes the way we feel, but also changes the way we perceive ourselves 
and the world around us. According to the current diagnostic criteria, uncontrollable recurrent 
negative thoughts are recognized as symptoms of depression (81). This type of cognitive 
disturbance in MDD has been considered as a key component of depression (82). In 1976, the 
cognitive theory of depression was proposed, which suggests that people’s attitudes, thoughts, 
interpretations, and the way they recall stressful events can trigger the development and 
recurrence of depression (83). According to this theory, one of the most effective interventions 
for depression is to modify cognitive patterns through cognitive therapy, which can also be 
helpful to improve other symptoms of MDD such as sustained negative mood and lack of 
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interest (84). Indeed, cognitive impairment has been reported in patients with depression for 
over a decade (85). This phenomenon was supported by a study in elderly depressed patients 
that exhibited learning deficits (86). Later, more studies reported poor memory tests 
performance in patients with depression at all ages (87,88,89). In depressed patients with 
memory problems, reduced hippocampal volume was described (90). Because the HPC is one 
of the brain regions highly involved in regulating mood and cognitive function (91,92), such 
anatomical changes in the HPC could account for the observed cognitive deficits. . In addition, 
adult neurogenesis in the HPC may also be involved in the learning and memory process (93). 
Under laboratory conditions, many genetic and environmental factors that cause changes in 
cognitive performance affect hippocampal neurogenesis. Mutant mice with impaired 
performance on HPC-dependent learning tasks showed decreased neurogenesis in the 
subgranular zone (SGZ) of the hippocampal dentate gyrus (94,95). Similarly, poor spatial 
memory that was observed in the Morris water maze was associated with reduced SGZ 
neurogenesis across different mouse strains (95,96). In addition to the genetic factors, the 
environment has a big impact on SGZ neurogenesis. It was demonstrated that voluntary 
running increases SGZ cell proliferation and exposure to environmental enrichment promotes 
the survival of immature neurons (97,98). Both factors improve the performance of young and 
aged rodents in the spatial memory task (97,98). Furthermore, an enriched environment is able 
to enhance recognition memory (99). In contrast to physical exercise and environmental 
enrichment, aging and stress, conditions associated with cognitive deficits, negatively affect 
SGZ neurogenesis (100,101). Collectively, in the preclinical studies, adult neurogenesis in the 
HPC shows correlation with the learning and memory function. Similar to rodents, 
neurogenesis has also been described in adult human brains in the SGZ and the subventricular 
zone (SVZ) of the lateral ventricle (102,103,104). The association of adult neurogenesis with 
some physiological and pathological conditions such as epilepsy (105), stroke (106), AD (107) 
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causing cognitive dysfunction has now been investigated using postmortem tissues. In those 
studies, signs of migrated newborn neurons from SVZ to repair the sites of injury and increased 
cell proliferation in the SGZ in patients have been reported (108). Even though direct evidence 
for a link between adult neurogenesis and human cognition is not available yet, the changes to 
neurogenesis in postmortem specimens suggest a potential contribution of neurogenesis in the 
learning and memory function of adult humans.  
 
1.1.2 Anxiety disorders 
Anxiety disorders are widely observed in the general population and have been reported 
globally (109). According to an Australian national household survey in 2007, the prevalence 
of anxiety disorders over a 12-month period was 14.4 % out of 5300 survey responders (110). 
Anxiety disorders are associated with impaired workplace performance and significant 
economic costs (111). For example in Europe, the cost of anxiety disorders to society was 
estimated to be € 74.4 billion in 2010 alone (112).  In addition, anxiety also increases the risk 
of cardiovascular morbidity and mortality (113). A meta-analysis of studies between 1980 and 
2009 suggested that anxiety increases the incidence of cardiovascular disease in otherwise 
healthy individuals by 27 % (114). Fortunately, the diagnostic assessment and treatment 
options for morbid anxiety or anxiety-related disorders have improved considerably in the past 
three decades (115). For example, the use of psychotherapies such as prolonged exposure and 
cognitive processing therapy in America increased by 2 % every 5 years  between 1995 to 2010 
(116). In a 12-week study in the USA in 2008, 81 % of children/adolescent participants showed  
reduced PTSD symptoms when cognitive behavioral therapy  was combined with a selective 
serotonin reuptake inhibitor (SSRI), compared to pharmacological intervention (55 %) or 
psychotherapy (60 %) alone (115).  These data suggest that a combination of psychotherapies 
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and antidepressants treatment is a more effective treatment option against anxiety disorders 
than monotherapies.   
 
1.1.2.1 Anxiety and depression 
Anxiety disorders and depression disorders share many overlapping symptoms such as fatigue, 
impaired concentration, irritability and sleep disturbance (117). They may also share a common 
pathophysiology since exposure to stress is also one of the causes of anxiety disorders (118). 
The US National Comorbidity Survey reported that 58 % of patients with major depression 
fulfilled criteria for at least one anxiety disorder and most patients with primary anxiety 
disorders also experience major depressive episodes (119). Approximately 68 % of individuals 
with co-morbid depression and anxiety had a history of being anxious for at least a decade 
before the development of depression, which suggests common mechanisms between these 
two mental diseases (120). Anxiety and depression seem to have separate symptom clusters 
according to the results of traditional factor analysis from patients with symptoms of either 
depression or anxiety or both (121). The distinction between anxiety and depression  is subject 
to an ongoing debate due to the high comorbidity between these two disorders (122).  One line 
of thought argues that the two disorders manifest different symptoms along a spectrum of 
disorders (123), while others  propose that anxiety and depression are clearly separate entities 
(124).  At present, more research is needed into the pharmacological interventions, diagnostic 
criteria and pathopsychological mechanisms of both disorders, before this debate can be 
decided. 
 
1.1.2.2 Posttraumatic stress disorder 
One of the common seen anxiety disorders is PTSD, which occurs in a group of individuals 
exposed to traumatic events (125). It comprises four clusters of symptoms, including intrusive 
  Overview 
13 
 
symptoms, persistent avoidance of stimuli, changes in mood and cognition and marked 
adjustments to reactivity and arousal (126). Over the past 30 years, numerous studies 
investigated the biological, cognitive and behavioral characteristics of PTSD and have 
established reliable methods for diagnosis and some limited treatment options (127).  
 
1.1.2.2.1 Epidemiology 
According to the Australian National Mental Health and Wellbeing Survey in 2007, the 
prevalence of PTSD was estimated to be around 6.4 % (110). However, there is uncertainty 
towards the robustness of this survey, since a prevalence of 4.4 % was reported in a different 
study (128). In this study, the impact of comorbidities and sociodemographic factors on 
prevalence of anxiety disorders were also considered, apart from targeting the methods of data 
collection and analysis. Over a decade (2007 - 2017), the prevalence of PTSD in Australia 
increased by 3.2 % (129). The likelihood of contracting PTSD is largely depended on the nature 
of potentially traumatic events and the intensity of psychological trauma. Based on the report 
of the Australian Centre for Posttraumatic Mental Health in 2013v war trauma is the biggest 
risk factor for PTSD (130). According to several studies between 1988 and 2008, PTSD has 
been frequently reported in returning American veterans since the Vietnam War 
(131,132,133,134). However, there is also a significant amount of uncertainty regarding the 
reported numbers since the lowest prevalence (2.2%) of combat-related PTSD was reported in 
1988 (131), while the highest prevalence (16.8%) was reported only two years later (132).  
Even though PTSD cases in Australian veterans are lower at present, similar incidences 
compared to US soldiers seem likely (135,136). The 12-month prevalence of PTSD in the 
general Australian population is also associated with other risk factors, such as a history of rape 
(9.2 %), sexual assault (5.5 %), witness of killing or death (0.6 %) and natural disasters (0.3 
%) (137). In addition, the risk for developing PTSD also shows a high gender bias, with a 2 : 
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1 ratio for females over males (138) and there is a higher risk to develop PTSD after 
experiencing traumatic events at a younger age (139). Approximately 2 in 3 children 
experience a traumatic event by the age of 16 and 13.4 % of those will eventually develop some 
symptoms of PTSD (139). 
  . 
1.1.2.2.2 Classification 
PTSD is caused by exposure of individuals to traumatic events that causes them to experience 
intense fear, horror, humiliation and/or grief (140). As defined by the Diagnostic and Statistical 
Manual of Mental Disorders, a traumatic event pertains to an experience of threatened or actual 
death, serious injury or sexual abuse that is either directly experienced or witnessed by the 
individual. However, the description of a traumatic event is very broad, allowing it to 
encompass a range of scenarios. Some examples of traumatic events include natural disasters, 
terror attacks, domestic and sexual violence, repetitive trauma exposure, death of a family 
member or of a close friend (141). In addition to the broad definition of what classifies as a 
traumatic event, the experience of each affected person is unique and highly depended on 
individual differences in processing and interpreting those events. Furthermore, in 
approximately 80 % of individuals with PTSD, their condition is complicated by additional  
psychiatric disorders, such as depression (142), substance abuse (143) and other anxiety 
disorders (144). It is also clear that depression could trigger the development of PTSD once 
the patient is exposed to a similar traumatic event (145). Those comorbidities likely affect the 
presentation and clinical course of PTSD, which is why there is no strict clinical descriptions 
towards the complex clinical presentations of PTSD. This uncertainty largely contributes to the 
difficulty to establish accurate diagnostic criteria and a large degree of PTSD misdiagnosis 
cases due to the associated comorbidities (146).  
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1.1.2.2.3 Clinical presentations and diagnostic criteria 
For a PTSD diagnosis to be considered, it is necessary for a person to exhibit at least one 
symptom out of each symptom cluster (i.e., intrusive symptoms, persistent avoidance of 
stimuli, changes in mood and cognitions and marked adjustments to reactivity and arousal). At 
present, there are four diagnostic criteria used to identify PTSD symptoms. The first criterion, 
the manifestation of intrusive symptoms, is the most identifiable symptom of PTSD, which is 
highly recognised by the public. Intrusive symptoms may present as flashbacks or nightmares 
among other manifestations in the presence of stimuli (140). These symptoms are often 
associated with intense, uncontrollable physical reactions that are similar to those 
supplementary to an anxiety attack (147).  
The second criterion is the avoidance of stimuli and can be immensely disruptive to everyday 
life. Avoidance relates to the conscious decision to elude any reminder of the traumatic event, 
and the extent to which patients might go can often be quite extreme (148).  
Thirdly, negative changes to cognition and mood covers a large range of signs. Changes to 
mood may present as feeling depressed and not being able to feel positive emotions or find 
pleasure in activities formerly enjoyed (147). Changes to cognition may involve symptoms 
such as not being able to remember details of an event or associated situations. This symptom 
cluster also involves feelings of blame (149).  
The final criterion involves symptoms of arousal and reactivity. The person may exhibit 
aggressive behaviour or an increased response to agitation (140). All the presented symptoms 
may be seen as over-reactive response to small everyday issues. The persons ‘flight or fight’ 
response is permanently switched on and the individual is constantly looking out for danger. 
This can cause the individual to be over alert of their surroundings leading, which negatively 
affects their ability to concentrate (147). 
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1.1.2.2.4 PTSD and cognitive dysfunction 
Many individuals that suffer from PTSD also show cognitive disturbances. More than 70 % of 
military veterans undergoing PTSD treatment exhibit poor performance in memory tests (150). 
However, the levels of cognitive dysfunction appear different from patient to patient, which 
can mask its relationship with PTSD. The appearance of memory deficits in PTSD could be 
either similar to those observed in other neurological disorders such as depression-induced 
memory loss, or similar to pure memory impairment observed in dementia (151). The 
identification of a cognitive component of PTSD highly relies on collected sample targets and 
sizes (152). Therefore, the association between cognitive impairment and PTSD is still unclear. 
Yet such association may lead to poorer processing of traumatic memories and thereby 
contribute to subsequent development of PTSD symptoms and also impair therapeutic 
interventions based on fear extinction (FE) learning (153).  
 
1.1.3 Chronic Pain 
According to the International Association for the Study of Pain (IASP), pain is defined as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage” (154). It can be caused by a number of conditions and diseases such as cancer or 
neuropathies (155). This disease remains a primary global public health concern, which is 
reflected by the high numbers of documented patients receiving analgesic treatment (156,157). 
Pain is  classified by the IASP into multiple classes (axis) based on the region of the body that 
is involved (e.g., lower back pain), affected organs (e.g., headache), aetiology (e.g., 
neuropathic pain) and the intensity and duration of pain (e.g., acute or chronic pain) (158). 
Among these, chronic pain, which is used to describe persistent or recurrent pain that lasts for 
over 3 months, can be further classified based on the severity, causes and functional 
impairment. For example, chronic pain can be classified into chronic primary and chronic 
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neuropathic pain. In addition both of those subgroups can be associated with emotional distress 
and disability (159). Therefore, to provide effective therapeutic solutions for chronic pain, a 
variety of physical, psychological and emotional factors need to be considered (160).  Over the 
past decades, brain imaging studies  provided evidence for the preferential involvement of the 
prefrontal cortex in chronic pain (161,162). The prefrontal cortex plays an important role in 
recognition memory (163), working memory (164) and memory formation (165), which 
indicates a cognitive element in chronic pain. For example, 72 out of 170 patients with chronic 
pain complained about poor concentration, forgetfulness and difficulty in problem-solving 
(166). However, most of the established animal models, which largely rely on evoking a reflex 
nociceptive response through inducing noxious stimuli, show little about the cognitive 
component of chronic pain (167). Therefore, it is important to establish more comprehensive 
preclinical models to reflex diverse symptoms of associated chronic pain conditions, in order 
to effectively develop new treatment. 
In addition, a connection between untreated or undertreated chronic pain and the development 
of depressive symptoms is well-established (168). Depression has been reported as a 
concomitant condition in untreated chronic pain, although there is a wide range of incidences 
(10 – 90 %) among neuropathic pain patients (169). The close connection between depression 
and pain is illustrated by the fact that more than 75 % of patients with depression display 
symptoms of untreated pain, whereas patients that suffer from persistent pain are more likely 
to develop depression (170). It seems the association between chronic pain and depression lies 
with two neurotransmitters, i.e., 5-HT and NE. For example, reduction in presynaptic 5-HT 
release and a compensatory upregulation of postsynaptic 5-HT2 receptors were observed in 
depressed patients (171), while reduced presynaptic 5-HT release in chronic pain patients was 
also detected just as in depressed patients (172). Apart from the comorbidity with depression, 
chronic pain also co-occurs with different anxiety disorders, such as generalised anxiety 
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disorder, panic disorder and social phobia (173). Approximately 45 % adult patients with 
persistent pain also experienced symptoms of anxiety according to the US National Health 
Interview Survey in 2010 (174).  
Figure 3. Vicious circles between stress, depression, anxiety and chronic pain. 
 
Exposure to stress can cause mood disturbances and negative thoughts, which can lead to the 
development of anxiety and depression. In addition, increased pain perception that is 
observed in depressed patients, works as a stressor and further worsen the depressive 
symptoms. On the other hand, long-term maladaptive cognitive systems result in the 
development of posttraumatic stress disorder, which, in turn increases stress levels in 
patients. 
 
1.2 Current treatment of stressed-based mental disorders 
1.2.1 Depression 
The molecular pathology of depression is still not well understood and current pharmacological 
treatments rely heavily on the monoamine theory of depression, which postulates that reduced 
brain neurotransmitter levels are linked to the manifestation of depressive symptoms (34). 
Current clinically used antidepressants are largely based on this theory and aim to increase 
levels of monoaminergic neurotransmitters in the synaptic cleft through inhibiting their re-
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uptake or by reducing their metabolism, to ultimately increase the activity of the HPA axis 
(28,35). These drugs include SSRIs, SNRIs, MAOIs and TCAs.  According to a meta-analysis 
until Jan 2016, which studied 21 clinically used antidepressants, all drugs showed positive 
treatment outcomes in adult MDD patients, compared to the placebo groups (175). Among 
those drugs, atypical antidepressants agomelatine, amitriptyline and venlafaxine, SSRIs 
escitlopram and paroxintine, TCA mirtazapine, and SNRI ortioxetine were the most effective 
interventions.  However, compared to other classes of antidepressants, patients better tolerated 
SSRIs such as citalopram and escitalopram during the on average 8-week treatment periods 
(175). However, it seems different studies yielded inconsistent results in terms of side effects, 
efficacy and dropout rates of antidepressants. In another meta-analysis that looked at the data 
until July 2008, escitalopram (SSRI) provided overall more positive outcomes than placebo in 
the 22 trials, although showed no better efficacy and acceptability than other classes of 
antidepressants over the same average 8-week treatment period (176). The differences between 
studies could be due to sample size, the amount of retrieved information, diagnosis criteria 
and/or methods of data review (177). More importantly, those systemic reviews and meta-
analysis arguably fail to provide reliable guidelines to current practice due to the lack of 
consistent results and standardised analysis protocols. Therefore, to overcome the drawbacks 
associated with conventional antidepressants, such as delayed onset and low response rate 
(178) and to provide reliable data for clinicians, improved study protocols to assess efficacy 
and acceptability of antidepressants are urgently needed.   
A new generation of fast-acting antidepressants are under investigation that are developed 
based on neurotransmitters other than serotonin and noradrenaline with different neurological 
causes of depression(179). The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine 
is one of the revolutionary antidepressant alternatives that showed efficacy in patients with 
treatment-resistant depression (TRD) (180). However, the majority of ketamine trials were 
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performed on small scales and variable efficacy has been reports across these studies. The 
initial trial was only conducted in 8 participants, where symptomatic relief was observed in 
depressed patients over the first 3 days after a single dose of ketamine (0.5 mg/kg) (181). 
Similar positive results were demonstrated at the same dose in 33 patients with treatment-
resistant depression (182). In this study, a maximal efficacy of 2-weeks was reported in 2 
patients (182). In a more recent trial, ketamine attenuated depressive symptoms over a one 
week period and provided higher response rates (64 %) compared to the 28 % response rate of  
midazolam (active placebo control) (183). Even though more clinical studies using chronic 
administrated ketamine (up to 19 days) have been conducted, the maximum duration of 
efficacy was only observed up to 28 days, demonstrating only a transient antidepressant profile 
of this fact acting drug (184,185). In addition, the efficacy of ketamine seems to be influenced 
by the administration methods of drug and the individual differences of patients. For example, 
both long-term sublingual (186) and i.v. infused ketamine (185) showed immediate effects for 
symptom relief, while this rapid therapeutical response was not observed using oral 
administration (184). Furthermore, patients with a history of alcohol dependence showed better 
therapeutical outcomes in response to ketamine, compared to MDD patients without alcohol 
abuse (187). The underlying mechanisms of the antidepressant effects of ketamine, as well as 
its variable efficacy in different trials are still not defined yet but more studies are underway to 
understand its molecular mode of action. 
 
1.2.2 Posttraumatic stress disorder 
Current therapeutic strategies for PTSD mainly consist of psychological counselling such as 
cognitive behavioural therapy (CBT) and pharmacotherapy. The implementation of CBT can 
decrease the severity of PTSD symptoms in comparison to a no-treatment group (188). 
Although psychological counselling is shown to be effective in some cases, there are significant 
  Overview 
21 
 
disadvantages. This form of therapy can be a lengthy process as well as an undoubtingly 
confronting experience to the patient. Active treatment approaches that are based on trauma-
focused treatment as well as other methods of CBT have shown a high dropout rate (189) and 
a response rate as low as 50 % (190). The most promising therapeutic approach is proposed to 
be a combination of psychotherapy and pharmacotherapy, as this form of therapy is reportedly 
more effective for treatment of mental disorders than either mono-therapy alone (191). 
SSRIs, which are commonly used for the treatment of depression, are the only class of drugs 
that are prescribed as a first-line therapy for PTSD in Australia (147). SSRIs and other 
conventional antidepressants are thought to only treat the symptoms of PTSD (147). Currently, 
paroxetine and sertraline are the only two drugs that are approved by the Food and Drug 
Administration for use in PTSD patients (192). However, it is common see a combination of 
SSRIs and SNRIs in clinical practice (193). The success rate of single medication treatment 
with an SSRI or SNRI was reported to be around 58 % (194). Although some improvements 
have been achieved by the administration of these drugs in PTSD patients (195), in many cases 
these drugs have shown no efficacy (196). For example, escitalopram (SSRI) failed to reduce 
the onset of PTSD at 9-month post-trauma exposure, compared to placebo control, in a multi-
arm randomised controlled trial (197). A similar lack of evidence of efficacy was observed 
when using antidepressants imipramine and fluoxetine to reduce the symptoms of acute stress 
disorder in paediatric burn victims (198). 
Several additional classes of medication may be useful in the prevention of PTSD. Treatments 
such as the β-adrenergic antagonists propranolol (199) and glucocorticoids such as 
hydrocortisone (200) also exhibited promising PTSD symptom relief in controlled trials. The 
result may support the idea of applying cortisol after trauma to prevent PTSD (201). However, 
conflicting results were seen in those classes of interventions. For example, a meta-analysis to 
February 2014 reported that propranolol showed no significant effect in reduction of PTSD 
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symptoms in total 345 patients compared to placebo (202). What’s more, benzodiazepines such 
as clonazepam, temazepam and alprazolam are used in treating acute trauma (203). 
Nevertheless, the actual practice of using benzodiazepines in treating PTSD has been 
questioned by negative findings in a small randomised placebo-controlled trial (204). In this 
study, life-threatening incidents occurred after administration temazepam, leading to the 
development of PTSD in a large proportion of participants (204). 
The currently accepted view for PTSD treatment is to use available drugs to create some relief 
for patients that undergo psychological treatment. However, conventional pharmacotherapy is 
unreliable and only provides symptomatic relief rather than curing the disease (196). It is 
important to note that the lack of well-validated and predictive preclinical models of PTSD 
significantly delays the development of effective treatment options. Therefore, an accurate and 
authenticated model, which assists in the understanding of the underlying mechanisms leading 
to PTSD, is a requirement for the development of novel pharmaco-therapeutic alternatives. 
 
1.2.3 Chronic pain 
1.2.3.1 History of the use of opiates and opioids 
According to the Australian Medicines Handbook, opioids are strong analgesics and are used 
as first-line therapy for moderate-to-severe cancer pain and postsurgical pain (205). They are 
also recommended as second-line therapy for patients with neuropathic pain  that do not 
respond to other non-opioid treatments (205). The use of opioid therapies in long term 
treatment of chronic pain is limited because of the initiation of analgesic tolerance (206). 
Opiates, derivations of natural poppy plant extracts, go by a variety of names including opiates, 
opioids, and narcotics. The term “opiates” is sometimes used for close relatives of opium such 
as codeine, morphine and heroin, while the term “opioids” includes also semi-synthetic drugs 
such as oxycodone (207) and fully-synthetic drugs such as methadone (208). The psychological 
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and physiological effects of opioids have been known for thousands of years. As early as 1550 
BC, ancient Egyptians mentioned opium and described it as a drug of joy. Opium was also 
used to treat diarrhea, internal bleeding and pain at that time (209). In the  9th century B.C., 
Homer described the pain killing effects of opium in his work The Odyssey (210). However, 
from the 5th century B.C., the adverse effects of opioids were increasingly noticed and opioids 
were considered as toxic compounds, mainly due to their addictive potential and even lethal 
activity (211,212). In 1806, morphine was first isolated from opium (213) and was 
subsequently used as anesthetics in small surgeries following the invention of syringe and 
hollow needle (210). One and half century later, methadone and the first opioid antagonist 
nalorphine were synthesized (214). Nalorphine was the first bifunctional opioid that blocks the 
analgesic effect of morphine (MOP antagonism) but also acts as analgesics on its own due to 
KOP agonist activity (210,215,216,217). Even though nalorphine demonstrated morphine-
equivalent analgesic effects in the clinic, its medical use is largely limited due to its KOP 
receptor-dependent psychological side effects such as dysphoria, anxiety, confusion, 
and hallucinations (218).  
 
1.2.3.2 Endogenous opioid peptides 
With the discovery of the enkephalins in 1975 (219), numerous larger opioid peptides, such as 
beta-endorphin, dynorphin 1 – 17 and peptide E were isolated, which contain the N-terminal 
sequence of either met-enkephalin or leu-enkephalin (220). Now it is clear that all opioid 
peptides derive from three different precursor proteins that include proopiomelanocortin 
(POMC), proenkephalin (PENK) and prodynorphin (PDYN) (Figure 4) (221) and their precise 
structures have been identified using recombinant expression (222). 
POMC is a glycopeptide that is glycosylated towards the N-terminal end of the molecule (223). 
Endogenous peptides derived from the POMC family are mainly produced in the pituitary 
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gland, from where they are released into the blood stream in response to stress and various 
endocrine signals (220). Biosynthetic experiments on isolated rat pituitary cells indicate that 
POMC is processed into beta-endorphin, which is further processed into beta-endorphin 1 – 27 
in the rat intermediate pituitary (224). Beta-endorphin has been proposed to be an endogenous 
ligand for the MOP receptors because of its moderate MOP affinity (225). This peptide itself 
is an opiate-like peptide and has shown naloxone-sensitive antinociceptive activity after local 
administration due to its MOP agonistic activity (226). In addition, beta-endorphin also showed 
promising facilitating effects for the acquisition stage of memory formation in animal models 
(227).  The second precursor proenkephalin (PENK) is cleaved into both Met-enkephalin and 
to a lesser extent, Leu-enkephalin, as well as into several intermediate opioid peptides such as 
peptide E, BAM-22P, -20P, -12P and peptide F (228). These peptides have been isolated and 
sequenced from bovine adrenal medullary tissues (229). Finally, prodynorphin (PDYN) is a 
common precursor of a series of opioid-like peptides such as Leu-enkephalins, α-neo-
dynorphin, dynorphin 1 – 8 and dynorphin 1 – 17 (220). Both PENK - and PDYN - derived 
peptides have a wide range of distribution in the central and peripheral nervous systems, 
including the nucleus accumbens, the median forebrain bundle, the hypothalamus and the 
hippocampus of rat brain and the spinal cord, the adrenal medulla, the sympathetic ganglia and 
the gastrointestinal tract (230).  
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Enkephalins that are processed from either PENK or PDYN possess preferential affinity for 
the MOP and DOP receptors (231),  while all other opioid-like peptides that are derived from 
PDYN, for example, dynorphin 1-8 and dynorphin 1-17, show a selective affinity for the KOP 
receptor (232,233). Beta-endorphin, the end product in the processing of POMC cleavage, has 
affinity for all three opioid receptor systems, but is specifically a highly potent agonist of the 
MOP receptor (234,235). Even though, none of the endogenous peptides are truly selective for 
only the MOP receptor, some of the intermediate PENK-derived peptides , such as peptide E 
and BAM-22P, exhibit a very high affinity to the MOP receptor compared to the other receptor 
types (236) and are able to induce substantial MOP-dependent analgesia after 
intracerebroventricular injection in rodents (228).     
Figure 4. Endogenous opioids and their related precursors, opioid receptors and biological 
effects. 
Precursors of endogenous opioids include proopiomelanocortin (POMC), proenkephalin 
(PENK) and prodynorphin (PDYN). They are secreted after exposure to stress and/or pain. 
These precursors are cleaved into endogenous opioids, which induce different biological 
activities by activating different opioid receptor types. 
 
1.2.3.3 Classification and anatomy of opioid receptors 
 In the 1990s, the existence of three distinct types of opioid receptors was confirmed by 
molecular cloning long after the identification of endogenous opioids in 1975 (231). Opioid 
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receptors belong to the inhibitory Gi linked G-protein coupled receptor subfamily (237). G 
proteins consist of three protein subunits, including α, β, γ subunits. In the inactive state the α, 
β and γ subunits form a heterotrimeric complex. In this complex, the α subunit binds 
guanosine diphosphate (GDP) (238). After an opioid agonists bind to their specific opioid 
receptors, GDP is released from the α-subunit of Gi protein and is replaced by guanosine-5'-
triphosphate (GTP). The binding of GTP activates the α-subunit, leading to its disassociation 
from the βγ-complex. Subsequently, this Gi-α protein inhibits adenylyl cyclases, which 
prevents the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP) (239). This mechanism effectively reduces cellular cAMP levels and leads to a 
decreased firing frequency of action potentials by nociceptive neurons. This process in turn, is 
subsequently responsible for reduced pain signaling (240). The existence of at least three 
different opioid receptor types was suggested, namely MOP receptors, DOP receptors and KOP 
receptors (231,241,242,243). Organ bioassays demonstrated that morphine-like opioids show 
a selective high potency to guinea-pig ileum, which is rich in MOP receptors, whereas 
enkephalins show high potency to the mouse vas deferens, which contains large amounts of 
DOP receptors (243,244). Recently, a fourth receptor type was identified and was termed as 
“opioid receptor like – 1” receptor (ORL1; or nociceptin receptor, NOP).  The NOP receptor 
exhibits moderate structural homology with the typical opioid receptors and is currently 
classified as a member of the opioid receptor family by the International Union of Basic and 
Clinical Pharmacology (IUPHAR) 
(http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320&familyI
d=50&familyType=GPCR). At the cellular level, N/OFQ, the endogenous ligand of the NOP 
receptor, produces similar actions compared to those of the classical opioids resulting in 
reduced neuronal excitability (245) and inhibition of transmitter release (246) in animals. Initial 
studies concentrated on the role N/OFQ and NOP in pain perception. The modulation on pain 
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by the N/OFQ – NOP system is complex. Under laboratory conditions, N/OFQ was described 
to induce pro-nociception behaviours and hyperanalgesia when applied supraspinally. In 
contrast spinally administrated N/OFQ induced analgesic effects (247). Rather than directly 
acting as a pro-nociceptive agent itself, the possible mechanism of N/OFQ anti-analgesic 
activity could lie in an interference with the activity of endogenous opioids or that it counteracts 
stress-induced analgesia during testing procedures in rodents (248). Recently, NOP antagonists 
have been reported to produce a long lasting analgesia, with similar efficacy compared to 
morphine (249). Several of those novel NOP antagonisms also demonstrated mood regulation 
effects as potent antidepressants and/or anxiolytics (250,251), but also prevented the 
development of morphine-induced tolerance (252) in animal models. In NOP receptor 
knockout mice, chronic administration of morphine leads to up-regulation of endogenous levels 
of N/OFQ (253), while selective NOP antagonist also attenuate chronic morphine-induced 
tolerance in rats (249). Therefore, NOP antagonists may be used as novel analgesics or perhaps 
be used as adjuvants to reduce the tolerance associated with classical opioids. However, in spite 
of the structural similarity and similar localization of the NOP receptor with the classical opioid 
receptors, NOP receptor activity is insensitive to the opioid receptor antagonist naloxone, 
which is an important discriminatory feature (254). .  
Opioid receptors are widely distributed in both the central and peripheral nervous systems, as 
well as in the digestive tract (255,256). MOP receptors show the highest densities in the 
forebrain and midbrain of rats, such as the cortex, amygdala, hippocampus, hypothalamic 
nuclei, raphe medianus, locus coeruleus, sensory trigeminal complex, as well as in the rat spinal 
cord dorsal horn (257). This distribution suggests their importance in mediating functions such 
as motor rigidity, autonomic reflexes, endocrine functions, mood and analgesia. At a molecular 
level, MOP receptors are found in the noradrenergic terminals (258), indicating mood 
controlling effects of the MOP system via mediating the release of neurotransmitters. For 
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example, in the rat cerebral cortex, morphine inhibits the release of noradrenaline by directly 
activating the MOP receptors on noradrenergic nerve terminals (259). MOP receptor agonists 
also stimulate postsynaptic transmission in the rat hippocampal DG cells by acting on gamma-
aminobutyric acid (GABA) interneurons   (260). Since dysfunctional GABAergic interneurons 
and noradrenergic neurons are associated with schizophrenia, bipolar disorder (261) and 
depression (262), these results highlight the potential of opioids for the treatment of mood 
disorders such as depression and anxiety (263,264).  
In  preclinical studies, DOP receptors were mainly found on nerve axons (265). They show 
high densities in multiple cortex areas, such as the cingulate cortex, frontal parietal cortex, 
piriform cortex and temporal cortex, whereas in contrast to the MOP receptor, they show much 
lower densities in the hippocampus, thalamus and raphe nucleus (266).  
The KOP receptor is widely distributed in brain regions of pre-clinical animal models such as 
the amygdala, hypothalamus, thalamus and ventral tegmental area, where they are involved in 
motivation, mood control, hormone manipulation and stress regulation (267). Unlike the MOP 
and DOP receptors, KOP receptors show a particularly high expression in the granular layer of 
the hippocampal DG (249), which supports a potential role in the stress response. 
 
1.2.3.4 Opioids in pain management 
Synthesized opioid agonists essentially mimic the activity of endogenous MOP, DOP and KOP 
receptor ligands (268). Although the binding of opioids to the DOP and KOP receptors involves 
in the modulation of pain signals, the MOP receptor is the major opioid receptor that 
responsible for the analgesic effect of opioids (269) (Table 1).  
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Table 1. The distribution of three classic opioid receptors and their endogenous and clinical used exogenous ligands. 
MOP: mu-opioid receptor; DOP: delta-opioid receptor; KOP: kappa-opioid receptor; POMC: proopiomelanocortin; PENK: proenkephalin; PDYN: 
prodynorphin 
 
Opioid 
receptors Receptor distribution 
Precursors of 
endogenous 
ligands 
Endogenous 
ligands 
Clinically used ligands 
Clinical use 
Agonists Antagonists 
MOP 
cingulate cortex, frontal parietal 
cortex, piriform cortex, temporal 
cortex, amygdala, hippocampus, 
hypothalamic nuclei, raphe 
medianus, locus coeruleus, 
sensory trigeminal complex, 
spinal cord, GI track, respiratory 
track 
POMC β-endorphin 
Morphine, codeine, 
oxycodone, fentanyl, 
, tapentadol, 
pethidine, methadone, 
dextropropoxyphene, 
nalbuphine, levorphanol, 
buprenorphine (partial 
agonist) 
Naloxone, 
naltrexone (non-
selective), 
butorphanol (partial 
antagonist), , 
 
Anesthetics, analgesics for mild 
to severe pain, cough (codeine), 
alcohol and opioids dependence 
(naltrexone), opioids overdose 
(naloxone), opioid detoxification 
(methadone), opioids addiction 
(buprenorphine) 
DOP 
cingulate cortex, frontal parietal 
cortex, piriform cortex, temporal 
cortex, spinal cord 
PENK Enkephalins None 
Naltrexone 
(non-selective), 
naltrindole 
Opioid overdose 
KOP 
amygdala, hypothalamus, 
thalamus and ventral tegmental 
area, granular layer of 
hippocampal DG, spinal cord  
PDYN Dynorphins 
Bremazocine, nalorphine 
and pentazocine (weak 
MOP antagonist/full KOP 
agonist), 
pethidine, , 
nalbuphine 
Binaltorphimine  
Moderate-to-severe pain, 
migraine (butorphanol), opioids 
addiction (buprenorphine) 
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1.2.3.5 Side effects of opioids  
Common side effects associated with opioids include constipation, nausea, itching, drowsiness, 
loss of appetite, stomach irritation and dizziness. Typically those symptoms already start after 
24 – 48 h of opioid use (266). The incidence of postoperative respiratory depression induced  
by opioids is only found in less than 1 % of patients (270). Even though the risk of developing 
severe respiratory depression can be reduced in patients by close monitoring, fatal outcomes 
and severe brain damage still occur even after taking precautions (271). So far, naloxone is 
reported to be the only treatment for opioid-overdose-related respiratory depression (272). 
Early animal work suggested that MOP receptors are responsible for the opioid-induced 
respiratory depression (273), with a differential mechanism compared to the analgesic effects 
of MOP agonists (274). However, the DOP agonist (+)BW373U86 reversed respiratory 
depression activity by the MOP agonist alfentanil (275), which suggests that the DOP receptor 
is able to counteract respiratory depression induced by MOP receptor agonists. Later, the 
absence of opioid-induced respiratory depression was observed in rats during co-
administration of the selective KOP agonist U-50,488H with MOP agonists DAMGO and 
morphine (276). This illustrates the cross-modulating effects of MOP and KOP receptors in 
the development of respiratory depression. Apart from the above side effects, long-term 
administration of clinically used opioids, for example, morphine, also results in behavioral 
effects such as physical dependence, tolerance and addiction (265,267). It is generally thought 
that those behavioural side effects of opioids are receptor-type depended (277,278). At present, 
it is believed that the addictive properties of most clinically used opioids are mainly mediated 
by the MOP receptor system, because of its motivational and rewarding properties (279,280). 
Long-term use of MOP agonists causes dependence and tolerance, which leads to decreased 
therapeutic efficacy in patients (281).  Even though DOP agonists have showed some extent 
antinociceptive and promising antidepressant-like effects in rodents, their pro-seizure and 
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convulsive properties limit the therapeutic potential (282). Additionally, DOP agonists are 
showed to reduce gastrointestinal tract motility and cause respiratory depression (283). 
Activation of the KOP receptor system is able to produce addiction and pro-addictive stress 
under laboratory conditions (280,281). Mice subjected to stress show dynorphin release and 
robust KOR activation in both dopaminergic and serotonergic nuclei (284), which suggests a 
general dysphoric effect of KOP agonists. In addition, the KOP agonist salvinorin apart from 
its documented antinociceptive effects in preclinical studies, can result in strong hallucination 
in patients and is therefore also occasionally used as a recreational drug (285). However, this 
adverse effect seriously prohibits its long-term clinical use as an analgesic (286,287). Along 
with the development of highly selective DOP receptor opioid ligands, the previously reported 
roles of DOP receptors have been clarified and novel functions have emerged. Due to the high 
expression of DOP receptors in the limbic system (288), the DOP receptor system appears to 
be the most attractive in term of their potential for  mood control (289). Furthermore, preclinical 
data showed that selective DOP antagonists prevented morphine-induced tolerance, suggesting 
an ability of the DOP receptor to prevent MOP receptor-associated tolerance and dependence 
(290,291).  These novel functions of DOP agonists promise to overcome some of the 
drawbacks of MOP-specific opioids and open therapeutic indications that have not been 
associated with the opioid system so far. 
 
 
1.3 Mitochondria and stress-induced disorders 
1.3.1 Mitochondrial dysfunction, cognitive dysfunction and mental disorders 
Mitochondria, as the main cellular energy factories, provide ATP for all cellular functions. 
ATP, the storage molecule of cellular energy, is produced by a series of oxygen-dependent 
reactions across the mitochondrial inner membrane via the electron transport chain (ETC), 
which works as sites of oxidative phosphorylation (158). The ETC contains five complexes, 
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i.e., reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase (complex I), 
succinate dehydrogenase (complex II), ubiquinone-cytochrome c reductase (complex III), 
cytochrome c oxidase (complex IV) and ATP synthase (complex V) (138). The major functions 
of mitochondria are to produce energy, regulate cellular signalling and maintain the synaptic 
plasticity of neurons (159,160,161). When the respiratory chain is unable to produce adequate 
amounts of ATP, the neurons of the brain becomes particularly vulnerable due to their high 
metabolic activity and consequently increased energy demand (162). 
On the other hand, mitochondria are also a major source of ROS. ROS are the products of 
several cellular metabolic pathways and include the highly reactive superoxide anion, H2O2 
and the hydroxyl radical (OH·). These reactive compounds are formed by one-, two- and three-
electron reductions of molecular oxygen respectively (292). The majority of ROS are produced 
at complex I (NADH dehydrogenase) and complex III (ubiquinone-cytochrome c reductase) of 
the ETC (165). Under normal conditions, 1 – 2 % of the oxygen consumed by the cytochrome 
oxidase is reduced incompletely to form ROS (293). In addition, under physiological 
conditions, ROS are also generated during normal respiration by the mitochondrial oxidative 
phosphorylation process (164). Excessive levels of oxygen radicals can damage intracellular 
proteins, lipids, mtDNA and nuclear DNA (166), which can ultimately exacerbate 
mitochondrial dysfunction and can lead to neurodegenerative and affective disorders, such as 
depression and cognitive dysfunction (160,167,168). Therefore, mitochondria represent a valid 
therapeutic target for pharmacological interventions to treat not only neurodegenerative but 
also affective disorders. However, at present only very few drugs are in development or are 
approved that target mitochondrial function specifically. 
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1.3.2 Oxidative stress, MAO and mitochondrial dysfunction 
The mitochondrial enzyme MAO exists as two isoforms (i.e., MAOA and MAOB) with 
isotype-dependent biological effects (294). Apart from their metabolic function (295), both 
MAO isoforms are involved in the regulation of behaviour and neuroprotection (296,297). In 
early animal studies, pretreatment with selective MAOB inhibitors protected the nigrostratal 
neurons in mice against the damage by neurotoxin and subsequently prevented the 
development of PD (298). In addition, increased MAOB levels are reported in elderly patients 
with AD and aged rodents, suggesting a role of MAOB in aging related cognitive decline (299). 
On the other hand, because MAOA generally metabolizes tyramine, NE, 5-HT and DA (300), 
MAOA inhibitors are typically used in the treatment of depression (301) and some neurological 
diseases such as bipolar affective disorder (302) and panic disorder (303).  Interestingly, during 
the metabolic process of monoamines, MAOs also produce ROS in the form of H2O2, which is 
reported to be involved in a range of bioactivities such as cellular apoptosis and DNA repair 
(304,305). .  
Under normal conditions, damage by MAO-generated H2O2 is kept in check by endogenous 
antioxidant systems including H2O2 detoxification enzymes catalase and glutathione 
peroxidase (306). However, under pathological conditions associated with many 
neurodegenerative diseases (307), MDD (308) and aging (309), the balance between pro-
oxidants and antioxidants is altered. Oxidative damage can occur when ROS (e.g., H2O2 and 
OH· radicals) production exceeds cellular antioxidant defenses (310). Likewise,  inhibiting 
MAO activity can reduce the production of H2O2 and it was suggested that MAOIs can protect 
mitochondrial function (311,312). Mitochondria  regulate cell survival and cell death through 
a variety of anti-apoptotic and pro-apoptotic proteins (313). Excess ROS leads to swelling of 
mitochondria and collapse of mitochondrial membrane potential. Subsequently, mitochondrial 
cytochrome c is released to activate the caspase cascade, which ultimately triggers cell death 
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(314). The MAOB inhibitors rasagiline (315) and selegiline (316) have been shown to protect 
neurons against ROS-induced apoptosis in vitro through activating the anti-apoptotic proteins 
Bcl-2 and Bcl-xL and preventing the release of cytochrome c from the mitochondria. 
Therefore, it is conceivable that MAO inhibition not only increases monoamine levels to 
activate membrane receptors but at the same time, decreases the potential of ROS-associated 
neuronal injury and mitochondrial-dysfunction-mediated cell death.  In addition, the novel 
multifunctional iron chelator and MAO inhibitor M-30 showed inhibitory effects on MAO 
activity in mouse brains (317), as well neuroprotective effects in neuron cell cultures by 
inhibiting OH· radical formation (318,319). However, the neuroprotective effect of M-30 was 
also reported to be independent with its MAO inhibitory activity and could be attributed to its 
iron-chelating properties instead (320). Interestingly, the activity of MAO is influenced by iron 
levels in both animals and humans. In rats, iron deficiency is associated with decreased MAO 
activity (321). In patients with neurodegenerative diseases associated with excess iron 
accumulation such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and Friedreich’s 
Ataxia (FA) (322,323,324), increased MAO activity was detected at the sites of neuronal cell 
death (325). Apart from the MAO-mediated pathway, large amounts of ROS are also produced 
by several other metabolic mechanisms such as the mitochondrial electron transport chain 
(293), xanthine oxidase (326), arachidonic acid metabolism (327), and peroxisomal enzymes 
such as d-amino acid oxidase, fatty acyl CoA oxidase, and urate oxidase (328). Therefore, it 
cannot be expected that inhibition of MAO activity directly results in lower detectable 
oxidative stress levels under physiological conditions. However, mitochondrial ROS 
production via the mitochondrial electron transport chain is directly linked to ROS-induced 
damage of its components (329) (Figure 5). It could therefore be hypothesized that MAOI can 
protect against localized ROS-damage, which would otherwise lead to excess ROS production 
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by a dysfunctional mitochondrial electron transport chain, which would be especially prevalent 
under pathological conditions (Figure 5).  
 
Figure 5. Mitochondrial production of reactive oxygen species. 
There are several sources of ROS in mitochondria. The majority of ROS are produced by 
delocalized electrons at complex I and complex III of the electron transport chain (ETC). The 
mitochondrial outer membrane protein monoamine oxidase A (MAOA) produces ROS in the 
form of hydrogen peroxide (H2O2) during the metabolism of monoamines. MAOA-produced 
H2O2 is majorly metabolised by catalase in the intermembrane space. A small amount of H2O2 
penetrates into the mitochondrial matrix where it reacts with ferrous iron. Accumulated ROS 
cause damage of the ETC and in particular complex I and III, which further increases ROS 
generation. This leads to lipid peroxidation, mitochondrial dysfunction and apoptosis. 
 
 
However, given the important role of MAO as one of the main therapeutic targets in depression, 
a thorough understanding of the relationship between MAO and mitochondrial function 
promises to unravel the mechanisms underlying neurological disorders that are associated with 
both systems, but could also lead to the development of improved antidepressants in the future. 
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At present, this research field has received significant interest and numerous studies are 
performed to understand the interactions of these two systems in the context of depression 
(294,330,331). Nevertheless, pharmacological manipulation of MAO and mitochondria and 
their reciprocal effects still require intensive investigations in the future. 
 
1.4 Novel therapies for mental disorders 
1.4.1 Preclinical and clinical antidepressant-like effects of opioids  
Although opioids are the first-line therapy for clinical pain management, their antidepressant 
effects have also been explored over the last few decades (282). However, not much progress 
has been made towards developing novel opioids as antidepressants or even exploring the 
clinical use of currently available opioids for the treatment of mood disorders like depression 
in depth. Despite numerous in vitro and in vivo studies regarding the effects of opioids on 
serotonergic and dopaminergic systems, only a few studies have explored the antidepressant 
potential of opioids in clinical trials (332). Both MOP agonists and KOP antagonists have 
demonstrated promising antidepressant-like effects in animal models (333,334). Those results 
prompted the idea to evaluate the antidepressant effect of a combination of a MOP agonist and 
a KOP antagonist (335), to increase their efficacy. Buprenorphine, as a partial MOP agonist 
and functional KOP antagonist, draws attention in this context. Interestingly, an early study 
showed that 0.23 % of postoperative patients that were given buprenorphine experienced 
euphoria (336), indicating the that the mood-lifting effect of buprenorphine could contribute to 
the observed analgesic effect in the study. Later, buprenorphine was reported to significantly 
reduce the severity of depression in elderly patients with treatment-resistant depression within 
the first 3 weeks of treatment when compared to the placebo group (337).  In October 2013, 
the FDA granted Fast Track status to ALKS 5461, a combination of buprenorphine and 
samidorphan (a selective MOP antagonist) for the adjunctive treatment of MDD in patients 
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with an inadequate response to standard antidepressant therapies (338).  However,  despite of 
the good safety data of ALKS 5461 (339), there is no reported efficacy data of this combination 
available so far from phase III clinical trials in patients with MDD (Trial numbers 
NCT02158533, NCT02085135, NCT02218008 and NCT02158546) by the end of study period 
( October 2016) which suggests that the trial showed negative results.  Given the non-selective 
nature of buprenorphine, it also remains unclear if a single or a combination of several opioid 
receptors are involved in mediating the putative antidepressant effects described earlier 
(336,337). Another example is the atypical opioid tramadol, which is a mixed MOP receptor 
agonist and a SNRI. Tramadol showed antidepressant effects comparable to venlafaxine, a 
clinically-used SNRI for the treatment of depression (340). Tramadol was considered the ideal 
prototype of an opioid-based antidepressant, due to its dual effects as MOP agonist and its 
presynaptic inhibition of serotonin and noradrenaline uptake (341). However, it was reported 
that co-administration of tramadol with serotonergic antidepressants could increase the risk of 
serotonin toxicity which severely limits its clinical use (342).  
Although large preclinical studies suggested a strong correlation between the activation on 
MOP or/and DOP receptors and the increased activity of serotonergic/dopaminergic pathways, 
the exploration of the antidepressant effects of MOP and DOP receptor agonists in the clinic is 
still quite slow (343). Until now, only a very limited number of studies have investigated MOP 
agonists such as oxycodone and oxymorphone in depression (344) (). Similarly, clinical studies 
on both DOP agonists and KOP antagonists as potential antidepressants are also rare (345). 
 
1.4.2 Importance of developing novel multi-targeting opioids 
Chronic use of opioids that mediated by MOP receptor is associated with multiple side effects 
(346). For example, drugs such as morphine that activate the MOP receptor are mainly used as 
analgesics in clinic, while their use increases the risk of opioid abuse and dependence (143). 
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The behavioural effects associated with long-term use of opioids represent great public health 
concern. Therefore, to achieve optimal analgesic effects while producing minimum side 
effects, multi-targeting opioids are developed, which act on two or more opioid receptor types 
at same time. This idea originates from positive treatment outcomes of co-administrating 
different opioids receptor ligands in both pre-clinical and clinical trials. For example, the MOP 
agonist morphine combined with the selective DOP antagonist naltrindole produced better 
analgesic effects and produced less tolerance and dependence compared to morphine alone 
(144).  Similar results were reported for a combination of the KOP agonists U50,488H and the 
MOP agonist DAMGO in mice (145). Based on these data, the novel bifunctional opioid 
MDAN-21 with MOP agonism and DOP antagonism effects simultaneously, was reported to 
be 50-fold more potent than morphine (146). Collectively, these results highlight the possibility 
of better analgesic outcomes and less adverse effects by multi-targeting opioid ligands. 
 
1.4.3 Bifunctional opioids 
Bifunctional opioids, as one typical example of multi-targeting opioids, bind to two different 
opioid receptors simultaneously (Figure 6). This type of ligand can have either the same or the 
opposing activity towards different receptor types at same time. 
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Figure 6. Schematic illustration of conventional opioids and bifunctional opioids. 
To achieve the expected therapeutic outcomes, opioids A and B have to be given 
simultaneously to act on their specific responsive receptors (1). In contrast, the bifunctional 
opioid C can act on both receptors simultaneously (2). 
 
Opioid agonists with selectivity for any of the three classic opioid receptor types all have 
limitations because of their side effects and/or weak analgesic activity. For example, morphine  
is associated with numerous side effects, such as inhibition of gastrointestinal motility, 
respiratory depression, tolerance and physical dependence apart from the analgesic effect 
(347), which limits its long-term use for pain management (348,349). The potential clinical 
uses of DOP and KOP agonists as alternative analgesics are limited by their convulsive and 
dysphoric effects respectively (350,351,352). So far, there is some evidence that bifunctional 
opioids with novel biological activities exhibit therapeutic analgesic potential with reduced 
side effects. This is based on several lines of evidence. One of those is the observation that the 
selective DOP antagonist naltrindole can reduce the development of morphine-mediated 
tolerance and dependence in rodents (353). Similarly, blockage of DOP receptor expression 
can inhibited morphine-induced tolerance and acute dependence in mice (291). On the other 
hand, chronic administration of morphine upregulates DOP receptor expression in rats (354). 
Furthermore, chronically administrated morphine was able to retain its full analgesic activity 
in DOP KO mice without inducing tolerance (355). Taken together, all these observations 
suggest that a compound that can activate the MOP receptor and block the DOP receptor at the 
same time could be a promising analgesic with low potential to produce tolerance and physical 
dependence. In addition, naltrindole has been reported to enhance bowel movement (356) and 
to reverse respiratory depression induced by the MOP agonist alfentanil (357), which suggests 
that a bifunctional MOP agonist/ DOP antagonist may also be able to reduce MOP-mediated 
side effects of slower gastrointestinal motility and respiratory depression. Compounds with this 
molecular profile (MOP agonist/ DOP antagonist) have been reported. One example is TIPP-
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NH2 (H-Tyr-Tic-Phe-Phe-NH2) (358). However, the development of peptide and non-peptide 
bifunctional MOP/DOP ligands seems to be difficult due to their poor ability to cross the BBB 
(359). . In contrast, the bifunctional opioid Dmt1]DALDA→CH2CH2NH←TICP[ψ] that was 
based on the structure of TIPP-NH2 , is able to cross the BBB. This molecule showed similar 
in vitro receptor binding characteristics as the parental compound TIPP, and demonstrated 
similar analgesic effects in vivo compared to morphine (360). Non-peptide bifunctional opioids 
that simultaneously activate the MOP receptor and inhibit the DOP receptor were also 
investigated. For example, compound SoRI 9409 showed significantly less tolerance 
development compared to morphine, while its derivative SoRI 20411 demonstrated a 10-fold 
analgesic potency compared to morphine and less potential to develop tolerance (361,362,363). 
Interestingly, bifunctional opioids that block the MOP receptor while activating the KOP 
receptor may have the therapeutically potential to treat cocaine abuse. Cocaine-associated 
abuse is partially mediated by increased extracellular dopamine levels in the mesolimbic 
dopamine system (364,365). Both MOP antagonists and KOP agonists inhibit mesolimbic 
dopamine release in animals (366,367), suggesting a positive effect of bifunctional MOP/KOP 
ligands in cocaine abuse. However, no bifunctional molecules that target the MOP/KOP 
recptors have been synthesized so far to test this hypothesis.    
Overall, only a few bifunctional ligands have been investigated with limited success. This is 
mainly attributed to their poor bioavailability, polarity and/or poor stability (368). However, 
with an increased understanding of the opioidergic systems and the promising therapeutic and 
adverse effects profiles of bifunctional opioids, it can be anticipated that the development of 
novel opioids for both pain management and mood control will continue to be explored. 
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1.4.4 Mitoprotective therapies 
Mental disorders and cognitive dysfunction are associated with mitochondrial dysfunction 
(369,370). Therefore, protecting mitochondria from oxidative damage and restoring 
mitochondrial function can also be envisaged as an effective therapeutic strategy for the 
prevention of mental disorders and cognitive deficits. This field is still in its infancy and drugs 
that are specifically designed to restore and protect mitochondrial function have just entered 
the market. The first drug that was recently approved in 2015 by the European Medicines 
Agency for the treatment of a mitochondrial disorder is the short-chain quinone idebenone and 
several similar drug candidates are in phase II and III of clinical development. Theoretically, 
drugs such as idebenone that have potent antioxidant and mitoprotective effects could be 
repurposed for the treatment of depression and cognitive impairment.  
 
1.4.4.1 Idebenone: overview 
Idebenone (2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-cyclohexa-2,5-diene-1,4-dione) is 
structurally similar to Coenzyme Q10 (CoQ10), but displays very different pharmacological 
characteristics (371,372). Idebenone was first synthesized by Takeda Pharmaceuticals in the 
80’s and successfully developed for the treatment of Alzheimer’s disease (AD) as well as 
learning and memory deficits, although its specific molecular activity at this point was largely 
unknown (373). Idebenone can cross the BBB, is well tolerated in patients with AD (374) and 
has a favorable safety profile (375,376). Idebenone has multiple molecular activities that 
include a modulation of mitochondrial respiration, potent antioxidant function and 
cytoplasmic-mitochondrial electron carrier function (372,377,378,379). Moreover, idebenone 
showed neuro-protective properties by maintaining mitochondrial membrane potential, 
improving the activity of the respiratory complexes and cellular energetic levels and inhibiting 
lipid peroxidation (375,380,381). However, in human subjects, idebenone is absorbed rapidly 
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and reaches peak circulating concentrations in 15 minutes in a dose-dependent manner, but it 
is also rapidly excreted. In rats, the plasma half-life of idebenone was reported to be only 30 
minutes, which is believed to be the result of a high first pass effect (382). Despite these 
unfavorable pharmacokinetics, which complicate a rational understanding of its molecular 
mode of action, protection of neurological function by idebenone has been reported in many 
pre-clinical models and clinical trials (383,384). Parallel to the protective effect of idebenone 
against neurotoxin amyloid β-peptide (Aβ) in rat hippocampal neuronal cells (385), 20 mg/kg 
idebenone ameliorated Aβ-induced working spatial memory impairment in rat models (386). 
In addition, degeneration of cholinergic neurons is reported to be associated with impaired 
cognitive function in both aged animals and humans (387,388) and nerve growth factor (NGF) 
seems to play a central role in the survival of cholinergic neurons (389). Twenty mg/kg oral 
administrated idebenone increased NGF content in the frontal and parietal cortex of aged rats, 
and boosted the activity of the cholinergic marker enzyme choline acetyltransferase in striatum 
to the level of young rats (390). In addition, protection of cholinergic neurons and restoration 
of cognitive function by systemic treatment with 10 – 30 mg/kg idebenone were reported in 
other studies (391,392,393). In5 out of 6 large randomized placebo-controlled clinical trials, 
idebenone was able to improve symptoms of neurodegenerative diseases (e.g., AD) at rat 
equivalence doses. For example, a single dose of 120 mg idebenone per day (approximately 
1.71 mg/kg based on a 70 kg person and equivalent to 10.63 mg/kg in a rat of 300 g, based on 
FDA-suggested animal-human equivalence dosing) for 6 months in AD patients showed 
positive treatment effects in improving the cognitive dysfunction (394). In another study, 120 
mg idebenone (tid) (approximately 5.14 mg/kg/day based on a 70 kg person and equivalent to 
31.89 mg/kg/day in a rat of 300 g) provided symptomatic improvements in patients with AD, 
showing better memory and more stable mood state (395). At a lower dose, 45 mg idebenone 
(tid) (approximately 1.93 mg/kg/day based on a 70 kg person and equivalent to 11.96 
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mg/kg/day in a rat of 300 g) also reversed attention and memory deficits in patients with 
Alzheimer’s – type dementia in only 4-month treatment (374). However, one study reported 
that idebenone was ineffective in slowing the decline of cognitive function in patients with AD, 
after a 12-month treatment at doses up to 360 mg per day (approximately 5.14 mg/kg based on 
a 70 kg person and equivalent to 31.89 mg/kg in a rat of 300 g), in spite of the stated good 
safety profile in the study (396). Unfortunately, this was the study sponsored by Takeda 
Pharmaceuticals that was intended to be used for acquiring market authorization. At present is 
is still unclear why this single trail failed to show a protective effect. Nevertheless, the majority 
of pre-clinical and clinical trials suggest that idebenone has the potential to improve cognitive 
function and mood state. Even though it is technically difficult to measure neuronal survival in 
humans directly, the demonstrated positive effects of idebenone in other neurodegenerative 
diseases such as Leber’s Hereditary Optic neuropathy (LHON) (397,398),  indicate a potential 
protective role in preventing neuronal death in patients, which can likely contribute to the 
observed symptomatic improvements.  
 
1.4.4.2 Idebenone: potential in mood control 
The antioxidative effects of idebenone have been widely described. Idebenone decreased non-
respiratory oxygen consumption via inhibiting lipid peroxidation, membrane lysis and 
mitochondrial swelling in rat mitochondria (399). This drug exhibited nearly 7 times higher 
antioxidant capacity than vitamin E in an in vitro assay (400). In glutathione (GSH)-depleted 
neuronal cells, 1 μM idebenone significantly improved cell viability, demonstrating neuro-
protective effects (401). In vivo, idebenone decreased lipid peroxidation and increased catalase 
levels as well as several endogenous antioxidants (402,403). In rat brain synaptosomes, 
idebenone showed similar effects as vitamin E to prevent oxidative stress and mitochondrial 
swelling induced by a ROS-inducing compound (404). Importantly, in the context of 
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depression and cognitive dysfunction, idebenone was also reported to increase 5-HT turnover 
and concentrations of its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in brain regions 
such as the HPC, hypothalamus and cerebral cortex that are important for mood control (405).  
There is some evidence to suggest that depression could be related to increased oxidative stress 
(406). The resulting elevated levels of ROS are likely to damage lipids, proteins and DNA, 
which ultimately leads to impaired mitochondrial function (407). In addition, lower plasma 
levels of the 5-HT precursor tryptophan and abnormalities in 5-HT function are reported in 
patients with depression (408,409). Since idebenone has shown promising antioxidant activity 
and abilities to correct 5-HT abnormalities, idebenone might be tested as potential 
antidepressant in future. In a clinical trial, idebenone improved psychiatric symptoms through 
increased 5-HT turnover in dementia patients (410). In addition, idebenone treatment improved 
psycho-physical wellbeing in patients with chronic cerebrovascular disorders without any 
severe adverse effects (376). Parallel to the clinical findings, idebenone exhibited 
antidepressant-like effects similar to the clinically used tricyclic antidepressant imipramine in 
a rat model of depression (411).  
 
1.4.4.3 Idebenone: learning and memory deficits 
Recent evidence suggests that mutations of mtDNA are associated with neurodegenerative 
syndromes and stroke, indicating a crucial role of mitochondria in age-dependent cognitive 
dysfunction (412,413). Accumulated oxidative stress and altered mitochondrial ETC function 
has also been reported in patients with AD (414,415). What’s more, idebenone reportedly 
improved cerebral energy metabolism and increased the levels of nerve growth factor, which 
are two important factors related to neuronal cell death and memory loss seen in AD patients 
(391,416).  
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Idebenone significantly improved cognitive performance test in patients with Alzheimer type 
dementia in multiple studies (374,395,417,418,419). In pre-clinical rat studies, idebenone 
improved short-memory that was impaired by 5-HT deficiency (393). Similarly, in mice with 
impaired memory due to amyloid β-peptide induced neurotoxicity, idebenone prevented 
learning and memory deficits (420). Collectively, idebenone appears to improve age-dependent 
cognitive function by normalizing the neurotransmitters system and ameliorating energy 
failure due to of oxidative damage. 
 
1.5 Animal models of mental diseases 
Animal models have been utilized to investigate human diseases for many years (421). Even 
though the validity of preclinical models for the study of mental disorders are still questioned 
by different research groups, their use has significantly increased our understanding of specific 
molecular pathologies and also led to the development of novel treatment options for many 
chronic diseases such as asthma, tuberculosis, meningitis and breast cancer. In addition, animal 
models also increased our ability to successfully model complex diseases in different animal 
systems (421,422). To assess the effectiveness and efficiency of an animal model of a human 
disease and to use this model to evaluate drug effects across laboratories, three validity criteria 
were initially introduced by McKinney and Bunney in 1969 (423). 
 
1.5.1 Validities of animal models 
Validity in its definition is a criterion that describes the reliability of a pre-clinical model in 
terms of representing mechanisms of diseases, mimicking drug treatment and its ability to 
predict therapeutically outcomes in the clinic. The validity criteria for depression models has 
been widely discussed and altered by many researchers in the last 30 years (184). At present, 
the validities introduced by Wilner et al in 1984 are widely accepted and include face validity, 
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construct validity and predictive validity (185). The presence of these criteria in an animal 
model provides confidence in the model to accurately reflect the human disease state and is 
essential for comparison across studies from different laboratories. 
 
Face validity 
Face validity requires that the symptoms observed in an animal model replicate clinical features 
of the disease (186). In relation to an animal model of depression, the model should be able to 
include one or several (ideally all) key clinical symptoms. These include failing to escape 
adverse stimuli (learned helplessness), reduced interest towards reward (anhedonia), sleep 
disturbances, decreased libido etc. However, the efficiency of some models, which only 
requires one or two days to produce these symptoms, are questionable when the slow time 
course of developing depressive symptoms in patients is taken into account (187).  
 
Construct validity 
Construct validity refers to the observation that the experimental conditions of the animal 
model can replicate the cause of disease in patients (186). To achieve this validity, researchers 
can re-construct the etiological processes that causes a disease in human patients. Since 
exposure to stress is one of the major causes of depression (29,187,188,189), exposing the 
testing animals to stressful stimuli such as shocks and forced cold-water swimming is expected 
to generate depressive-like symptoms in rodents. In addition, another direct method to achieve 
construct validity is to knock-out known disease-causing genes, as long as the resulting animal 
phenotype accurately reflects the human disease state (190).  
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Predictive validity 
The final criterion centers on the assumption that the animal response to a drugs can predict 
the therapeutic efficacy of a potential drug in patients (186). Predictive validity examines the 
use of therapeutic options of a pharmacological nature and their effect on the symptoms in the 
model (184). An accurate model should be able to demonstrate comparable efficacy of a drug 
in the model compared to a clinical trial (191).  
 
1.5.2 Animal models of depression 
It is widely known that chronic stress is associated with the onset of depression (26,424,425). 
There is significant evidence that most episodes of depression are likely the consequence of 
prolonged exposure to a stressful environment (13,14,15,16). Chronic or lifetime stress is a 
strong predictor for the development of depressive symptoms (17), and is associated with 
pathophysiological changes in brain function and structure. Stressful situations over extended 
periods of time can lead to reduced hippocampal size, a brain area that is specifically involved 
in the regulation of mood in both animals and humans (426). This strong link between stress 
and depressive symptoms has been used as the cornerstone of creating animal models of 
depression, which are vital for the study of this disorder as well as for research into novel 
antidepressant treatment options.   
 
1.5.2.1 Classification 
A number of pre-clinical models are currently used to evaluate the pharmacological effects of 
potential antidepressants (427). These models have been evaluated on the basis of above three 
major criteria, namely construct validity, face validity and predictive validity (428). The more 
valid a particular animal model is, the more accurate and reliable is the data it produces. Current 
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animal models of depression can be generally classified into four main classes based on the 
nature of their induction phase, as shown in Table 2. 
The first class of animal models of depression is based on the application of acute or sub-
chronic stressors for the induction of depressive-like symptoms. It includes behavioral models 
such as the FST and the tail suspension test (TST), which are also called despair-based models. 
They are frequently used in fast drug-screening studies of novel antidepressants, because of 
their easy and economical nature, as well as their acceptable face and predictive validities 
(13,429,430). However, these models lack the essential construct validity and only produce 
limited short-lasting depressive-like symptoms (430). The LH model of this class is probably 
the only one that stands out, since it offers stronger validation and medium-term lasting 
behavioral and related cognitive symptoms. Nevertheless, the electrical shocks that are used in 
this model and the comprehensive equipment that is required to establish this model limit the 
use of this model.  
The second class of animal models of depression is based on long-term exposure to various 
stressors to trigger the manifestation of depressive-like symptoms such as anhedonic-like 
behavior, aversion towards activity and changes in appetite etc. It includes three main animal 
models of depression: the chronic mild stress (CMS), the chronic social defeat (CSD) and the 
chronic social isolation (CSI) models. The CMS model demonstrates particularly strong 
validities, in term of generating anhedonic-like symptoms in stressed animals (431). However, 
anhedonic-like behavior, a crucial index of depressive mood in this type of models, is not only 
specific to depression but also seen in schizophrenia and substance withdrawal (432,433,434).  
The third class of pre-clinical depression models applies various biochemical and 
pharmacological concepts to mimic clinical observations. The models in this class are named 
according to the pathophysiological and molecular pathways of depression that they 
manipulate. They manifest either potential molecular sources of the depressive symptoms or 
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adaptive/responsive mechanisms of depression, such as the function of the HPA axis 
(435,436,437). In rodents, retinoid receptors are concentrated in limbic areas that have been 
associated with depression, including the amygdala, the prefrontal cortex, and the hippocampus 
(438). Retinoids are known to influence neurotransmitter systems that have been associated 
with depression, in particular dopamine but to some extent also serotonin and norepinephrine 
(439). This connection is supported by clinical observations that acute depressive symptoms 
have been associated with retinoic acid therapies (440). This provides a causal association 
between increased level of retinoids and the development of MDD.  In addition, impaired 
immune function and hypersecretion of cytokines such as IL-1β, IL-6 and γ-IFN have been 
observed in patients with MDD (441,442). In a pre-clinical model, IL-1 injection induced 
chronic immobilization under mild stress condition, which is indicative of a worsening of 
depressive symptoms (443). Therefore, this third class is not only designed to generate 
depressive symptoms, but also serves as a tool to study the pathophysiology of depression and 
the involvement of particular molecular pathways. However, the major limitation of these 
models is that they are associated with a wide range of behavioral abnormalities, which may 
be not be specific to depression (444,445). 
The fourth class of animal models of depression involves the application of genetic and surgical 
techniques, which can permanently change animal phenotypes and behavior. Those models 
include olfactory bulbectomized rodents (446,447), genetically modified strains such as the 
stress-sensitive Flinders rat (448) and specific receptor-knockout mice that show depressive-
like symptoms (for a thorough review on genetically modified mice strains used as animal 
models of depression see Cryan and Mombereau’s study (449)). Although these animal models 
are particularly useful when studying specific aspects of the pathophysiology and 
pharmacology, they offer very poor construct validity compared to other classes. Generally, 
models of secondary depression and the immutable models of depression are not only able to 
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produce various stress-induced symptoms, but also can be used to study depression-induced 
cognitive changes by combining them with models of learning and memory (450). In addition, 
these pre-clinical models can be used in combination with other rodent models of depression, 
such as the FST (451). These combinations can help to investigate the onset mechanisms of 
depression without inducing additional physical stimuli.
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Table 2. Classification of current animal models of depression and description of their main pros and cons as described in the literature.  
FST: forced swimming test, TST: tail-suspension test, LH: learned helplessness, CSI: chronic social isolation, CSD: chronic social defeat, CMS: 
(unpredicted) chronic mild stress 
 
Main Classes Models Stressor Main Advantages Main Disadvantages Example references 
Acute and sub-
chronic stress-
induced 
FST Inescapable forced swimming Fast induction and drug-screening, cheap 
& easy setting 
Unspecific response to non-
antidepressants, weak validities, 
present single symptom 
(429,452,453) 
TST Tail suspension 
LH Inescapable electric shocks Strong validation, variety of behavior & symptoms 
Comprehensive protocol & 
equipment, strong stressors (429) 
Chronic stress-
induced 
CSI Prolonged-chronic isolation Strong validity, variety of depressive 
symptoms 
Long experimental duration, 
complex setting, anxiety 
symptoms 
(454) 
CSD Repeated bouts of social subordination 
CMS Chronic expose to alternate and variable stressors Strong validity, long lasting symptoms 
Long experimental duration, 
anxiety symptoms 
Models of 
secondary 
depression 
HPA axis 
dysregulation 
Administration of 
corticosterone 
Correlation with pathophysiological and 
molecular mechanisms of depression, 
present various depressive symptoms 
Questionable correlation with 
depression (435,455,456,457) 
Retinoic acid 
model Prolong use of retinoic acid 
Immune system 
dysregulation 
Administration of pro-
inflammatory cytokines 
Immutable 
models 
Olfactory 
bulbectomy 
Surgical removal of 
olfactory bulb Variety of symptoms, specificity in 
studies of particular pathways 
Indistinguishable adaptation 
mechanisms (446,458) Genetically 
modified models 
Genetically selected for 
hypersensitivity to drugs, 
receptor knockouts etc. 
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1.5.2.2 The most frequently used animal models of depression 
The three most popular and widely used pre-clinical models of depression are the FST, the LH 
and the CMS model. Bibliometric data produced from analytical searches using the PubMed 
database between 1980 and 2016 reveal increasing numbers of publications using these models, 
to varying degrees (Figure 7). 
 
Figure 7. Cumulative number of original research articles published from 1/1/1980 to 
31/12/2016 listed in PubMed that used the forced swimming test (FST), the learned 
helplessness (LH) or the chronic mild stress (CMS) as primary models of depression. 
 
The FST model appears to be the most ‘popular’ model in pre-clinical depression research 
(70.9 % of the total published papers using this animal model of depression) and shows the 
steepest increase in published articles among the three models, probably due to its low set-up 
cost, simplicity and short experimental duration. On the other hand, the powerful validity and 
the manifestation of long-lasting symptomatology are probably the strong points of the CMS 
model that make it the second most commonly used model. Finally, the number of published 
articles using the LH model has shown an approximate 5-fold increase compared to the 
published papers in 1996. Clear advantages and disadvantages are inherent to all three models, 
which will be discussed below along with the technical variabilities of these models.  
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Although it generally accepted that the documented variation of face validity in these models 
could be explained by their conceptual and methodological differences, it appears that 
substantial differences in behavioral responses are also observed between studies that use the 
same animal model, as shown in Table 3. For example, the use of specific strains, such as the 
stress-sensitive Flinders rats, can be beneficial to obtain better readouts and reduce variance 
for selected behavioral paradigms. Nevertheless, differing results are also reported for studies 
using the same animal strain. In addition, small alterations of methodological protocols 
contribute to the divergent observed animal responses in different studies. Due to the highly 
technical nature of these behavioral models, research groups tend to base the technical 
parameters of their experiments (such as time length of induction, intensity and duration of 
stressors, types of observational arenas, modes of measurement etc.), on their research needs 
and experimental observations. Thus, there is a huge number of protocols in use, which 
amplifies variations in animal responses. 
                                                                                                                                                                                                                                                
Overview   
54 
 
Table 3: Examples of antidepressant effects in three stress-based models of depression using different animal species and strains. 
The reduction of depressive-like symptoms in experiment groups are presented as percentages of the stressed-saline group. 
 
 Model Recorded behaviours 
Animal 
species & strains 
Tested 
antidepressants Dose (mg/kg/day) 
% reduction of depressive-like 
symptoms in experiment group Reference 
FST 
Immobilization during 
monitoring phase 
Wistar rat imipramine 15, i.p., 22 days -82.4% (459) 
Wistar rat imipramine 15, i.p. -25.0% (460) 
Wistar rat imipramine 15, i.p. n/a (61) phenelzine 10, i.p. -62.5% 
NIH Swiss mouse imipramine 10, i.p. -43.3% (461) 
NIH Swiss mouse desipramine 20, i.p. -60.0% (462) C57/BL6 mouse desipramine 20, i.p. -15.4% 
Swiss mouse tranylcypromine 4, i.p. -13.0% (463) phenelzine 4, i.p. +4.0% 
Immobilization counts 
Sprague Dawley rat fluoxetine 10, i.p. -31.3% (464) 
Sprague Dawley rat desipramine 20, i.p. -45.5% (465) Wistar-Kyoto rat desipramine 20, i.p. -34.9% 
LH 
Escape failures 
Wistar rat imipramine 15, i.p., 22 days -45.5% (466) 
Wistar rat imipramine 32, i.p. n/a (467) 
ICR mouse desipramine 10, p.o. -52.9% (468) 
CD rat fluoxetine 50, p.o. n/a (469,470) imipramine 50, p.o. -68.2% 
Escape latency Sprague Dawley rat 
escitalopram 10, i.p. -40.9% (54) desipramine 10, i.p. -45.5% 
Swiss mouse fluoxetine 30, i.p. -43.5% (471) 
CMS 
Amount of sucrose 
consumption 
Wistar rat imipramine 10, i.p. -46.2% (472) 
Wistar rat imipramine 10, p.o. -54.5% (473) 
SD rat fluoxetine 10, i.p. -60.0% (474) 
Wistar rat imipramine 10, i.p. -57.8% (475) 
Preference of sucrose 
solution to plain water 
Wistar rat imipramine 10, i.p. -24.7% (476) fluoxetine 10, i.p -21.9% 
Wistar rat fluoxetine 10, i.p. -10.8 % (477) 
C57BL/6 mouse imipramine 20, i.p. -12.4% (478) 
C57BL/6 mouse imipramine 30, p.o. -30.0 % (479) 
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1.5.2.2.1 The forced swimming test 
The FST was originally described as “a new method for inducing a behavioral state in rats that 
resembles depression” (480). This model is described to induce a low-mood state in rodents, 
so-called “behavior despair”, in a fairly short period of time. Because only limited time is 
needed to induce depressive-like symptoms in this model, contrary to the development time of 
clinical depression in patients, the FST is now only seen as a quick tool to screen for potential 
antidepressants (481,482). Nevertheless, at present, it has become the most widely used pre-
clinical model to assess antidepressant activity, due to its ease of use and its ability to predict 
a broad range of antidepressant activities (483). In this model, the rodents are placed into an 
inescapable cylinder with cold water and are forced to swim. The time of immobility is used 
to define the floating of the animal when in the water, without active swimming but only 
necessary minor movements required to keep the head above the water. Immobility is used as 
the predominant index of the level of behavioral despair and, therefore, increased duration of 
immobility are characteristics of depressive-like behavior in this model. 
The original description of the rat FST procedure contained two phases (480). Initially, rats 
received a 15 min forced swimming training, followed by a 6 min testing session 24 h after the 
training (Figure 8). A mouse FST model was modified by using only a single 15 min session 
for testing the efficacy of potential antidepressant drugs to reduce immobility levels (484). 
 
 
Figure 8. General protocol of the forced swimming test (FST). 
Animal training (conditioning to the circumstances) is followed by a single day interval before 
re-exposure to the experimental setting, where after habituation behaviour is recorded. Main 
behavioural measurements include immobility times and counts of specific time-blocks of 
continuous activity (i.e. climbing, swimming) 
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Because of its simplicity, this paradigm is considered the most suitable for high-throughput 
screening of antidepressant compounds in rodents. On the other hand, the FST can also be used 
after chronic stress exposure (485,486), as a follow-up method to measure the development of 
depressive-like symptoms in a chronic-stress-based model and to quickly evaluate drug activity 
(487). This feature promotes the use of the FST not only as a model per se to predict 
antidepressants activity, but also as an assessment of depressive-like symptoms that have been 
induced by other depression paradigms. Recent modifications were introduced based on 
different observed activities, as well as differences in the behavioral pharmacology among 
drugs. Active swimming, such as diving, climbing and swimming are now also routinely 
measured individually (488). In addition, serotonergic and noradrenergic antidepressants 
differentially influence the swimming and climbing behavior in this model. The serotonergic 
system mediates the swimming motion, whereas noradrenergic antidepressants enhance the 
climbing behavior (active movements with forepaws in and out of water, usually against the 
cylinder wall) (488), which suggests that it might be important to distinguish these behaviors 
when using this model. Both TCAs (489) and SNRIs (490,491) increase climbing and 
swimming activities. Because increased locomotion can be confused with decreased 
immobility as an index of behavioral despair, most FST studies are combined with the open 
field arena (e.g. open space that records movement) to assess potential hyperactivity. All 
clinically used antidepressants show efficacy in the FST without affecting locomotion in the 
OF test, compared to the immobility scores and locomotion of non-treated controls (492), 
which indicates that the swimming, climbing and diving behaviors in the FST can be increased 
without inducing hyperactivity. Although the FST is used for nearly three decades, its strength 
of validity is still disputed (493). Recent modifications to this model are implemented either to 
increase sensitivity and specificity to the treatment, or to improve the consistency of results 
between studies or research groups. Table 4 summarizes the main differentiating parameters 
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among studies using the FST as a model of depression. Even simple model parameters such as 
the cylinder diameter, the depth of water and the water temperature are sensitive enough to 
lead to variations in measured responses (494). For example, a smaller cylinder diameter has 
been accused of generating more false positive responses due to the animals’ rotatory 
locomotor activity (495), which is another argument for the inter-validation of the FST 
measurements with a locomotion test like the open field. On the other hand, water depth is one 
of the predominant differences among studies. In the rat model of the FST, a water depth of 30 
cm was reported to produce more “behavioral despair” (496), compared to a depth of 15 cm 
that was used in the original protocol (480). The depth of the water should be sufficient to lead 
to non-supporting swimming in relation to the rats’ size and full leg extension. Finally, both 
high and low water temperatures can result in short-lasting immobility and false-positive 
results, suggesting that water temperature should be ambient for optimal results (497,498).
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Table 4: Examples of variability in major methodological parameters in the forced swimming test protocol. 
Studies in mice show a higher degree of variability in the protocol parameters than rat studies. Training session duration and testing duration 
show the largest variability. Up to date, there are no analysis that document an advantage of a particular parameter value over another in terms 
of model validation. Nd: not described in the study 
 
Training duration 
(min) 
Animal 
Species 
Cylinder size Water 
level (cm) 
Water 
temp. 
(˚C) 
Testing duration 
(min) 
Main measurements of 
recorded behavior Example references Height 
(cm) 
Diameter 
(cm) 
0 
CD mouse 
16 - 25 10 6 - 15 21 - 23 6 
Total duration of immobility 
during the last 4 mins 
(484) 
(499) 
(500) 
ddY mouse (501) 
C57/BL6 
mouse (502) 
15 C57BI/6J mouse Nd Nd Nd ~ 30 
4 trials x6 mins + 
7min inter-trial 
interval 
(503) 
2 trials x10min + 24h 
inter-trial interval ICR mouse Nd Nd 15 ~ 23 6 (504) 
15 Swiss mouse 18.5 12.5 13.5 25 ±1 5 Total duration of immobility 
(505) 
(506) 
0 SD rat 46 20 30 25 ±1 15 Counts of immobility, swimming and climbing (507,508,509,510,511) 
15 SD rat 40 - 46 18 - 20 30 25 ±1 5 Total duration of immobility (480) (512) 
15 
Wistar 
Kyoto rat 
46 20 30 24 - 26 5 Total duration of immobility, swimming and climbing 
(513) 
Wistar rat (514) 
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1.5.2.2.2 The learned helplessness model 
One of the core symptoms of clinical depression is the feeling of helplessness, which manifests 
in the form of losing any meaning in life and giving up trying to escape from a stressful 
situation, as a result of exposure to uncontrollable events (515). The features of learned 
helplessness are highly translational from mammals and even non-mammal species to humans 
(516). The first LH paradigm was described in dogs (517), where a series of unconditioned 
stimuli, namely mild electric shocks, were used to induce depressive-like symptoms. 
Clinically, learned helplessness refers to a mental state in patients that 1) fail to control 
unpleasant stimuli, and 2) lose the willingness or ability to avoid future stressful events (518). 
Problem solving is a typical example to explain this behavior. When people fail to fulfill 
specific tasks, they believe that they are not capable to solve similar tasks and consequently 
they generate negative expectations regarding any future attempts in a similar task. This passive 
state of mind contributes to poor performance, and leads to the manifestation of learned 
helplessness (515,519). 
Similarly, rodents exhibit changes in their emotional and cognitive status, as well as significant 
performance deficits in behavioral tests (520). Taking advantage of rodents’ adaptive ability to 
avoid stressors and danger, inescapable shocks (IS) are used in this model to produce the 
“helplessness” symptoms. After learning the uselessness of their positive avoidance response 
to the stimulus, a negative coping strategy, called escape failures, is generated in the following 
test phases (521). The LH protocol as a depression model includes three phases, the induction 
of depressive-like symptoms, the recovery and the test phase (Figure 9). In the induction phase, 
LH symptoms are induced by delivering inescapable electric foot-shocks (429,522) or tail-
shocks (523,524). The induction is typically composed of 60 trials that each includes a stressor-
delivery period and an interval period. After a recovery period of at least 24 hours (to allow 
memory consolidation), the animal enters the final phase (testing) where they are presented 
  Overview 
60 
 
with escapable electric shocks. In this scenario, the animals are allowed to exit through an 
opening to a neighbouring safe chamber. The shocks are delivered acutely (3 s) followed by a 
half-minute interval, with this trial cycle repeated 30 times per day, for 3 consecutive days. 
Non-induced animals will immediately seek the available exit when presented with mild 
electric shocks, in an effort to avert the stressor (active avoidance). Learned helplessness-
induced animals though will not seek to exit but rather accept the “inevitable” stressor (a 
behaviour called “escape failure”). The measurable response in the LH model is the number of 
escape failures during the test phase, in each of the 3 days. In order to differentiate the active 
avoidance responses of the animal (exit during shocks) with passive avoidance responses that 
account for anticipation, the model includes the use of a short unconditioned stimulus 
immediately prior to the shock delivery during the test trials (usually a tone or light). 
Measurement of the number of escape failures, passive avoidance responses and number of 
escapes during the inter-trial interval time, are used by the model as surrogate markers of 
depression, instrumental learning and locomotor activity respectively (525,526).  
 
 
 
Figure 9. Structure of the most frequently used protocol for the learned helplessness model, 
which is divided in three phases. 
Phase 1 (induction) provides repetitive trials of inescapable shock periods intervened by a 
short recovery period. Phase 2 offers a long rest period for memory consolidation, whereas 
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Phase 3 is the testing phase which involves repetitive ES trials intervened by short recovery 
periods. The escape failures of the animals are recorded as surrogate marker of depressive 
like symptoms. 
 
Unlike the FST and the CMS models, only a limited number of studies have looked at the 
impact of protocol variability on the efficiency of the LH model. It was suggested, that the 
parameters that define the electric foot-shocks (i.e. intensity, duration, delivery pattern etc.), 
are most vital for a successful induction phase (527,528). Apart from the definition of the 
electric shocks (intensity and duration), there are a number of numerical parameters that 
describe the number of sessions, the number of trials, the length of intervals, as well as the use 
of conditioned and unconditioned stimuli during the test phase (Table 5). Although there are 
not many studies that focused on the effect of these parameters for the efficiency and validity 
of this model, it is important to note that the nature of the LH model provides the ability to use 
specific internal controls to demonstrate the effect of some parameters in the measurable 
response. For example, an animal group that receives ES during the induction phase, instead 
of IS provides the internal benchmarking for determining the effect of IS on the model 
(529,530). Nevertheless, new studies that can provide more detailed studies on the connection 
between the LH parameters and the manifestation of depressive-like symptoms are urgently 
needed, in order to assess the LH model and improve it further.
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Table 5. Different protocols used in the induction phase and testing phase of learned helplessness model. 
Key influence factors, namely number of sessions of each phase, number of each session, intensity and duration of shocks and the duration of intertribal interval are listed 
as index of per protocol 
 
 Training sessions 
Trials 
per 
session 
Shock 
(mA) 
Shock 
duration 
(s) 
Intertrial 
interval 
(s) 
Interphase 
interval 
Testing 
sessions 
Trials 
per 
session 
Trial 
type 
Trial 
duration 
Shock 
(mA) 
Intertrial 
interval 
(s) 
Reference 
Wistar 
rat 1 60 0.8 15 60 2 3 30 CS/US 
3s light + 3s 
shock 0.8 24 (525,531,532) 
Wistar 
rat 1 60 1.0 2 30 1 1 40 
US 
only 
Maximum 
30s shock 1.0 
Average 
60 (533) 
SD rat 2 90 2.0 9.9 2, 5 or 10 2 2 50 CS/US 
5s light & 
tone + 5s 
shock 
2.0 30 (534) 
SD rat 2 60 0.65 30 20 - 40 1 2 30 CS/US 3s tone + 6s shock 0.65 
Average 
30 (535) 
Swiss-
Webster 
mouse 
1 14 0.28 
10s light 
+ 20s 
shock 
20 1 1 10 US only 2s shock 0.28 60 (536) 
Balb/c 
mouse 2 30 0.3 
10s light 
+ 20s 
shock 
25 - 35 1 3 30 CS/US 10s light + 20s shock 0.3 
Average 
30 (537) 
FVB/N 
mouse 2 180 0.15 1 – 3 1 - 15 1 1 30 CS/US 
5s light + 
max 10s 
shocks 
0.15 30 (538) 
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1.5.5.2.3 The chronic stress model 
The CMS model was developed as a pre-clinical model of depression more than two decades 
ago (539). Since then, different groups have developed different protocols in an effort to 
improve its efficiency and tailor it to the particular needs of their research 
(342,540,541,542,543). The CMS model is mainly designed to produce the characteristic 
anhedonic-like behavior and general loss of interest towards rewards that is seen in most 
patients with depression. In this animal model, the behavioral deficits are induced over a period 
of 3 - 9 weeks by imposing a variety of stressors in a semi-random manner separated by various 
time intervals (Figure 10), which prevents a potential adaptation to the different stressors that 
is usually seen with continuous application of a single stressor (544). 
 
 
Figure 10. General structure of the chronic mild stress model. 
Different stressors (stimuli) are applied weekly and are transiently followed by a test-period 
of monitored sucrose consumption, to quantify the depressive-like symptoms 
 
The natural preference of rodents to sweetened water is considered to parallel human reward 
behavior. At the same time, a loss of interest towards reward is one of the clinical 
characteristics of patients with depression (545). Therefore, the amount of sweetened versus 
plain water consumed before and after exposure to stressors is used as an index of depressive-
like symptoms in the CMS model (546). Different stress stimuli are used between 
measurements, such as water and food deprivation and cage tilting, which reduces the intake 
of sweetened water compared to non-stressed control animals (547). Other behaviors, such as, 
grooming frequency, reduced sexual activity, aggression and reduced locomotion can also be 
measured as indicators of depressive-like behavior (548,549).  
The nature of the protocol allows a combination of a large variety of stressors, with different 
number/length of intervals and the measurement of different behaviors as a response to rewards 
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(Table 6). Grouped housing, overnight illumination, restraint-stress, day-night cycle 
disturbance and flashing lights are only a few stressors in a long list of interchangeable stimuli, 
which are applied to the animal over a certain period, intermitted by a variety of intervals (i.e. 
1 – 2 stressors per day with random intervals, 1 stressor per day with 10 intervals etc.). 
Measurement of sucrose consumption during the experiment and preference of sucrose solution 
over water are examples of recorded behaviors in this model. In addition, the total length of 
these tests, which varies among CMS studies from 3 weeks to 9 weeks, contributes significantly 
to the large diversity in the experimental protocols of the CMS model. At present, no study has 
determined the effect of these variations on the validity or the efficiency of this model. Usually 
research groups choose a particular combination of stressors and timing based on previous 
practical experience and/or the particular needs of their experiments. A thorough analysis of 
these studies is needed to assess the contribution of these variations to the efficiency of the 
model in order to improve it further.
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Table 6. Variability of different protocols exist today in the chronic mild stress model. Variable stressors are applied once or twice a day randomly to induce 
the depressive-like symptoms, which can be measured by a number of different ways, during a variety of experimental length.  
 
Procedure 
(weeks) 
Animal 
Species Stressors applied Stressor intervals Main measurement Example References 
3 Wistar rat 
• food or water deprivation 
• cage tilting 
• intermittent illumination damp sawdust 
• grouped housing 
• low-intensity stroboscopic illumination 
Stressors applied individually and 
continuously with 10 - 14 
intervals 
Amount of 
consumption of 1% 
sucrose solution 
(550,551,552,553) 
3 SD rat 
• food or water deprivation 
• cage titling and wet cage 
• continuous overnight illumination 
• grouped housing 
• low-intensity stroboscopic illumination 
1 or 2 stressors per day and 
randomized intervals (546,554) 
4 SD rat 
• food or water deprivation 
• continuous overnight illumination 
• cage titling 
• grouped housing 
• damp sawdust 
• stroboscopic illumination 
Stressors applied individually and 
continuously 
Test of preference of 
1% sucrose solution to 
plain water 
(555) 
4 C57BL/6 mouse 
• restraint stress 
• cage titling 
• grouped housing 
• white noise 
• day-night cycle disturbance 
Stressor applied individually for 1 
hour per day (556) 
4 Lister hooded rat 
• food or water deprivation 
• cage tilting 
• intermittent or overnight illumination 
• grouped housing 
• low-intensity stroboscopic illumination 
• white noise 
First 2 weeks: two stressors per 
day during daylight 
Last 2 weeks: two stressors per 
day during night 
Amount of 
consumption of 0.7% 
sucrose solution 
(557) 
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Table 6. (Continued) Variability of different protocols exist today in the chronic mild stress model. Variable stressors are applied once or twice a day 
randomly to induce the depressive-like symptoms, which can be measured by a number of different ways, during a variety of experimental length. 
 
Procedure 
(weeks) 
Animal 
Species Stressors Stressor intervals Main measurement Example References 
5 Wistar rat 
• food or water deprivation 
• cage titling 
• intermittent or stroboscopic illumination 
• soiled cage 
• paired housing 
Stressor applied individually and 
continuously with 10 – 14 
intervals 
Amount of 
consumption of 1% 
sucrose solution 
(558) 
5 SD rat 
• grouped housing 
• cage titling and wet cage 
• food or water deprivation 
• stroboscopic illumination 
• white noise 
• continuous overnight illumination 
1 stressor per day, with or 
without repetition 
Amount of 
consumption of 1% 
sucrose solution 
(559) 
6 BALB/c mouse 
• grouped housing 
• noise 
• damp or remove sawdust 
• cage changing & tilting 
• cold water swim 
• low-intensity stroboscopic illumination 
• day-night cycle disturbance 
1 or 2 stressors per day at 
different time each day 
Measured body weight, 
coat state and 
grooming frequency 
(560) 
6 Wistar rat 
• food or water deprivation 
• restraint stress 
• forced swimming 
• flashing light 
• isolation 
One stressor per day at different 
times each day; repeated at 
random 
Sweet food 
consumption (561) 
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Table 6. (Continued) Variability of different protocols exist today in the chronic mild stress model. Variable stressors are applied once or twice a day 
randomly to induce the depressive-like symptoms, which can be measured by a number of different ways, during a variety of experimental length. 
 
Procedure 
(weeks) 
Animal 
Species Stressors Stressor intervals Main measurement Example References 
8 BALB/c mouse 
• cage change & tilting 
• grouped housing 
• damp or remove sawdust 
• restraint stress 
• noise 
• day-night cycle disturbance 
2 stressors per day with 
randomized combinations and 1 – 
2 hrs. interval 
Amount of 
consumption of 1% 
sucrose solution 
(562) 
8 Wistar rat 
• restraint stress 
• cage titling 
• paired housing 
• nip tail 
• day-night cycle disturbance 
1 stressor per day and each 
stressor repeated 6 – 7 times 
across the procedure 
Test of preference of 
20% sucrose solution 
to plain water 
(563) 
9 Wistar rat 
• food or water deprivation 
• cage tilting 
• intermittent illumination 
• soiled cage 
• grouped housing 
• low intensity stroboscopic illumination 
Stressor applied individually and 
continuously with 10 – 14 
intervals 
Amount of 
consumption of 1% 
sucrose solution 
(564) 
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1.5.3 Animal models of anxiety  
1.5.3.1 Light and dark model 
The LD model is based on rodents’ spontaneous exploration behaviour and their innate 
aversion to illuminated areas (565). When the animals are subjected to a novel environment, 
they tend to explore the unfamiliar environment, whereas at the same time try to avoid the 
novelty. Therefore, the exploratory behaviour in the LD model reflects the interplay of these 
two conflicting emotions (566). Generally, a two-compartment chamber is used in the LD 
model but only one compartment is illuminated with white light while the other remains 
darkened. The size of the illuminated compartment can be either equal to or larger than the 
unilluminated one (567). In this model, the time that the animal spends in the darkened versus 
illuminated compartments is used as an index of anxiety-like behaviour (568). Drugs that 
increase the time in the illuminated compartment are considered as anxiolytics or having 
anxiolytic-like properties (569). Four additional parameters are also used to reflect the 
anxiolytic activity of tested drugs: increased transitions between two compartments without 
increased locomotion, the latency for the first passage from the light compartment to the dark 
one, the number of transitions between the two compartments and the movement in each 
compartment (570). Because of the variations in measurements and modifications, discrepant 
findings are reported across different laboratories (571). Therefore, it is important to analysis 
multiple parameters carefully based on the specific experimental setup. 
 
1.5.3.2 Fear conditioning and fear extinction model 
Fear conditioning 
Fear conditioning (FC) or Pavlovian FC is a form of associative learning (572). FC is highly 
transitional across species and behavioral systems (573). The FC model was intensively used 
to study psychophysiological processes and brain circuits that identify danger associated with 
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specific cues or contexts (574). There are two different types of FC, cued conditioning and 
contextual conditioning (575). In a classical cued FC paradigm, a conditioned stimulus (CS, 
e.g., a tone) is repeatedly paired and co-terminated with an aversive unconditioned stimulus 
(US, e.g., a shock), yielding a CS – US association. A conditioned response (CR, e.g., freezing 
behavior) is produced in response to the paired CS. Animals will exhibit CR to the same CS 
signal even when they are subjected to different environment (575). While in the contextual 
FC paradigm, US is presented alone, thus yielding a US-context association. When animals are 
subjected to the same environment, they will express CR even in absence of the US (576).  
 
Fear extinction  
FE is a process used after FC training, where only the CS is presented, leading the CR to decline 
over repeated presentations. Extinction is not to erase the initial CS-US association, but to 
create new learning to overcome the association between CS and US (577). Following 
successful FE, the presentation of CS will only trigger the memory of unpaired CS. Low-level 
of or absent CR expression in the post extinction test at a later stage, which is also known as 
extinction recall, indicates the success of FE training (578) (Figure 11).  
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Figure 11. Schematic representation of the classic fear extinction paradigm. 
Generally, two contexts are employed. In the first context (blue), rodents receive repeated 
pairs of CS and US and learn the CS – US association. After a certain period (memory 
consolidation), the establishment of CS – US association is evaluated in a new context (green). 
Following the post-FC test (retrieval), animals are given repeated CS in absence of US and 
learn to de-associate the CS with US (FE training).The post FE test (retrieval) is carried out in 
the same context that is used in FE training after a certain period (memory re-consolidation) 
to measure the effect of FE training.  
 
It is notable that fear responses may still reappear spontaneously over time (i.e., spontaneous 
recovery), by either subjecting animals back to the initial environment or context where they 
received FC training, or presenting them with the US (579). The interactions between fear 
conditioning and extinction play an important role to understand the underlying brain circuits 
that support cognition, stress and anxiety disorders. In addition, reported differential responses 
to the same stressors that are observed in different strains (580), sex (581) and ages (582) in 
the FC – FE paradigm can be beneficial to investigate individual differences in fear and anxiety, 
and are therefore helpful to develop personalized diagnosis and future treatments. 
 
1.5.4 Animal models of nociception 
Current animal models of nociception are designed to indirectly monitor pain by measuring 
their responses to nociceptive stimuli. Methods to stimulate nociceptive responses can be 
mechanical, chemical, electrical or thermal (167). Measured responses can be mediated by 
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either peripheral or central nerve systems depending on the type of stimuli used and which part 
of the body the stimuli are applied to (583,584). Currently, the hot plate (HP) and tail flick (TF) 
tests are the most commonly used thermal-stimulus based models for acute pain (167).  
 
1.5.4.1 Tail-flick test  
The TF test is a nociceptive essay based on the measurement of the latency of the avoidance 
response to thermal stimulus in rodents (585). It is used to quantify nociception mediated 
primarily by spinal mechanism. This test has proved particularly sensitive for studying the 
analgesic properties of pharmacological substances (586) and is performed in two distinct 
variations. One method induces a nociceptive response by applying radiant heat to a small area 
of the rodent tail (587), while in the other method the animal’s tail is immersed into cold or hot 
water (588). The TF test with radiant heat is a more simplified version to measure nociception. 
The application of thermal radiance (e.g., generated by an infrared lamp) to the animal tail 
provokes a nociceptive response where the tail is vigorously removed from the heat source. A 
timer records the moment the tail is withdrawn and the heat source is switched off 
automatically. The latency from the beginning of the measurement to the removal of the tail 
from the infrared source (called tail flick latency) is interpreted as nociception (585). The time 
to tail withdrawal can vary based on the intensity of the radiant source (589) and the surface 
area stimulated by the heat (590). The higher the heat intensity and the smaller the stimulated 
area, the shorter the TF latency typically is. However, different parts of the rodent tail have 
different sensitivities towards radiant heat. The distal part of the tail is believed to be the most 
sensitive, followed by the middle and proximal sections (591). 
The TF test is widely used because it does not require sophisticated equipment and is easy to 
perform. From a pharmacological point of view, it is sensitive to clinically used analgesics 
(592). For example, it is easy to establish dose- and time-dependencies for morphine-induced 
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analgesia in rodents at clinical equivalent doses (593). It is also effective to predict the potential 
analgesic effect of full opioids agonists in humans, even though it seems to be less reliable to 
detect partial opioid agonists (594). This may be due to the fact that the evaluation of partial 
agonists is more easily impacted by the experimental setup such as cut-off time and intensity 
of radiation heat than when detecting full agonists (594).  . . However, it is still possible that 
opioid-based analgesics do not provide substantial effects in this test under certain conditions 
due to treatment duration and experimental design. Rats, which received morphine for 13 days 
before exposure to foot shocks, failed to exhibit an antinociceptive effect in the TF test 
following re-exposure to shocks when compared to non-treated rats (595). This effect could be 
explained by the release of endogenous opioid ligand β-endorphin in response to a stressful 
stimulus. This endogenous MOP agonist is cross-tolerant with chronically administrated 
morphine (595). On the other hand, individual differences of rodents such as the tail 
temperature may also  introduce bias into nociception measurements (596). Therefore, the 
reliability of this assay relies on several experimental factors, which can contribute to 
misinterpretation of results. .   
 
1.5.4.2 Hot-plate test 
The HP test is designed to measure nociception mediated primarily by a supraspinal mechanism 
(586). The typical equipment that is used in the HP test includes an open-end cylindrical space 
with a metallic floor plate (597). The plate is pre-heated to a consistent and pre-defined 
temperature before placing a rat or mouse into the cylinder. The duration from when the animal 
initially touches the plate to a defined behaviour such as paw licking or jumping is recorded 
manually (597). Both paw licking and jumping behaviours are considered as controlled by 
supraspinal mechanisms (598). Although an early paper claimed that paw licking was only 
observed following administration of opioid analgesics (167), paw-lick latency has been widely 
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used in nociception measurements that did not involve opioid administration (597,599,600). 
.In the HP test, some other behaviours such as sniffing, lifting forepaws and rearing can be 
observed (601), which increase the difficulties to decide the appropriate endpoint of a 
measurement. Therefore, compared to the TF test, the HP creates more variability and produces 
less accurate data. Therefore, to increase the reliability of results, the time until the first 
observed behaviour, regardless of whether it is paw-licking or jumping, was suggested to be a 
better measure (602). In addition, it was suggested that learning is involved in the HP test, since 
shorter pain reaction times were observed after repeated exposure of the test animals to the 
heated plate (601). It was observed that rats immediately jumped as soon as being placed into 
the cylinder in subsequent tests, even when the plate was at room temperature (603). It is also 
worth to notice that a large body area of the test animals (including four paws and the tails) 
typically has contact to the hot plate, which makes results difficult to interpret since the pain 
reactions may be a combination of both peripheral and supraspinal pain perception (167). From 
a pharmacological point of view, the HP test shows good correlative results of drugs that 
produce antinociceptive effects in rodents and are clinically used for the treatment of pain 
(604). Especially, the low intensity hot plate test seems to be more sensitive to analgesic drugs 
(605,606). In addition, this assay is able to evaluate narcotic agonists, antagonists and non-
narcotic analgesics (607). Therefore, compared to the TF test, it appears to be more suitable to 
predict a wider range of compounds with analgesic potential in humans. 
In spite of the vulnerability of the TF and HP assays to different factors such as experimental 
settings and individual differences of animals and their inability to determine pain responses, 
both assays are still required to detect potential analgesics for human use and play an important 
role in the area of pain research. Both assays are important tools for the initial screening phase 
of drug discovery to identify compounds with potential analgesic activity (608)  and are also 
fundamental to understand basic mechanisms of nociception, as well as pain and analgesia. 
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1.5.5 Animal model of cognition 
Cognitive impairment has been reported in patients with depression as one of the depressive 
symptoms (85). Similarly, changes to cognition have also been demonstrated in stress-based 
animal models of depression such as in the learned helplessness model (82). However, if a drug 
is able to improve learning and memory in test animals, potentially false positive results, 
interpreted as antidepressant effects of the tested drug, can be produced. Therefore, in 
preclinical models of depression it is essential to also determine the effects of drugs on 
cognitive function.  
In an integrated model of depression and cognition, it is essential to consider the compatibility 
between two models. For example, it is beneficial to use a model of cognition that does not 
require external averse stimuli, when integrating it with a stress-based depression model. Based 
on this reasoning, the novel object recognition (NOR) model, which is purely based on the 
inquisitiveness of the test animals, has been frequently used. In this model, rodents respond to 
novelty and can learn to recognize previously presented stimuli (609). The NOR model 
assesses the ability of test animals to remember a set of objects and whether they can distinguish 
between a novel and a familiar object. The advantage of the NOR model is that the procedure 
requires no external motivation, rewards and/or punishment but fully relies on the animals’ 
natural propensity to explore novel objects (610). The NOR task has become a widely used 
model for investigating recognition memory. With modifications, it was also reported to test 
working memory, attention and anxiety (611). Yet, it has been used to evaluate the effects of 
various pharmacological treatments and brain circuits that are involved in cognitive function 
(611). A typical NOR procedure consists of three phases, including habituation, familiarization 
and a testing phase. In the habituation phase, each animal is allowed to freely explore the 
experimental chamber. Then in the following object familiarization phase, the animal is placed 
back into the same chamber and is allowed to explore two identical objects (A + A). In the 
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subsequent testing phase, one of the familiar objects is replaced with a novel one (A + B) before 
the individual exploration time for both objects is recorded. In this paradigm, different methods 
are used to quantify memory that include discrimination index (DI), index of global habituation 
and differences in exploration time for both objects (612). This model is based on the 
assumption that a longer exploring time for the novel object indicates that the familiar object 
is present in the animals’ memory. 
The NOR task can be used to study short-term, intermediate-term and long-term memory by 
manipulating the interval between the object familiarization phase and the testing phase (613). 
It has to be noted though that a single testing session is more vulnerable in terms of assessing 
memory function accurately, compared to repeated measurements (614). 
 
1.5.6 Animal model of locomotion 
Reduced physical activity is also observed in patients with MDD and long-term physical 
withdrawal can worsen depressive symptoms (615). To assess drug effects on locomotion in 
pre-clinical depression models can not only give insights into the interaction between physical 
activity and depression, but also helps to determine the interference of a potential stimulating 
effect of a drug on its antidepressant-like effects. The OF model is one of the most frequently 
used animal models to measure exploratory behavior and general physical activity in both rats 
and mice. The simplicity of equipment and clear defined behaviors in this test contributes to 
the popularity of this model (616). Over the past decades, multiple modifications have been 
applied such as different shapes and sizes of the OF chamber, illumination, floor texture and 
odors (617). The most basic outcome of this model is “movement”, which is represented as the 
duration of exploration behavior over the total duration of a testing session. It is believed that 
the longer the exploration is, the more “activity” an animal has (616). However, this outcome 
can be influenced by many factors such as the attractiveness of testing environment, individual 
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differences in exploratory behavior and handling. Apart from time spent moving, other 
parameters, for example, total distance over the testing period have been reported and used as 
index of locomotion (618). Another benefit of using the OF model is that it is easy to be 
integrated with other paradigms (e.g., the LD model) to measure the involvement of locomotion 
and its impact on other behaviors of interest (619). Additionally, physical stimulating, sedative 
and even anxiolytic effects of a wide range of drugs can be tested in this model (619). Thus, 
the OF model is able to measure a number of behaviors beyond simple locomotion, such as 
studying exploratory behavior through measuring the number of rearing events (620). Recently, 
the OF model has also been used to measure anxiety levels in rodents. The major parameters 
that are used for this purpose are freezing time and (a cease of all movement except for 
respiration) time spent staying in central area of testing chamber (621). However, its validity 
to be used as a model of anxiety is still questionable, because drugs that are clinically effective 
for the treatment of anxiety showed little effect in the OF model (622).  
 
1.6 Future perspectives 
Although a large volume of in vivo evidence supports the beneficial use of opioids in depression 
and anxiety, novel opioids have not been clinically developed as viable alternatives for 
conventional antidepressants. It is possible that the addictive properties of opioids as well as 
their tendency to produce tolerance after long-term use are the biggest barriers for the 
development of opioid-based therapies. Therefore, bifunctional opioids that can potentially 
avoid opioid receptor-dependent adverse effects while retaining their therapeutic effects, 
present a promising drug class that should be investigated. At the same time, the complex 
effects of opioids in the regulation of stress circuits via multiple pathways, requires that the 
opioid research community generates a deeper insight into opioid pharmacology, especially 
with regards to the psychological, physiological and neurological activities of opioids. Given 
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that mitochondria, energy metabolism and oxidative stress are described as downstream targets 
and effects of opioids (623,624), a general investigation into the use of targeted mitochondrial 
therapies as antidepressant alternatives also appears warranted. Even more so, since one of the 
most widely used drug targets for the treatment of depression, MAOA is a mitochondrial outer 
membrane enzyme. Considering the role of MAO in the onset of various mental disorders (e.g., 
MDD, anxiety and stress-induced cognitive impairment) and mitochondrial function (e.g., 
ROS-induced lipid peroxidation of mitochondrial membranes), it appears entirely feasible to 
develop novel antidepressant strategies by targeting mitochondrial function.  
 
1.7 Aims of the project 
This project intended to establish an integrated learned helplessness model in a multiple 
conditioning system (MCS) to test antidepressant effects of morphine and 2 novel bifunctional 
opioids synthesized at the University of Tasmania. Validity of the LH model to induce 
depressive-like symptoms and the effects of novel antidepressants in this model will be 
systemically assessed by evaluating 4 interference factors: anxiety, pain, cognition and 
locomotion. Since such a systematic evaluation of the LH model has not been performed 
before, our results can provide significantly improved guidelines for other researchers to use 
and adjust the LH model based on their own laboratory setup. 
In addition, the relationship between oxidative stress, depression and cognitive function will 
be investigated further by testing the mitoprotective antioxidant idebenone.  The results of this 
part of the study will give us better understanding of the role of mitochondrial function and 
oxidative stress in the regulation of cognition under stressful condition.  
Overall, this study allows us to explore opioid-based and mitochondrial therapy-based 
antidepressant alternatives. It is also important that this project can be a cornerstone of 
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investigating the role of opioidergic system and mitochondrial in depression and its-related 
comorbidities. 
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2.1 Materials 
2.1.1 Animals 
2.1.1.1 Strains 
Sprague Dawley rats (SD, 
male), 7 weeks, 200 – 310 g 
at the beginning of 
experiments 
 University of 
Tasmania 
Hobart TAS, 
Australia 
 
2.1.1.2 Animal chow 
Barastoc 20% protein rodent 
diet 102108 
Ridley Agriproducts 
Pty Ltd 
Harristown QLD, 
Australia 
Soy-reduced rodents cubes 
(reformulated), autoclaved SF06-053 Specialty feeds 
Glen Forrest, WA, 
Australia 
Soy-reduced rodents mash, 
autoclaved SF06-052 Specialty feeds 
Glen Forrest, WA, 
Australia 
 
2.1.1.3 Animal facility material 
Clear plastic ventilated 
Techniplast cages 1400U Tecniplast Pty Ltd. 
Rydalmere NSW, 
Australia 
 
2.1.2 Cells 
Human hepatocellular 
carcinoma cell line (HepG2) 85011430  Sigma-Aldrich Castle Hill, NSW, AU 
 
2.1.3 Software 
Leica Application Suite 
Version 3.4.1  Leica Microsystems  Wetzlar, Germany  
Nikon NIS-Elements 
D413.00 (64-bit)  Nikon Instruments Inc. Melville NY, USA  
SoftMax Pro 4.8  Molecular Devices Sunnyvale CA, USA 
GraphPad Prism (version 
6.01)  
FigurePad Software, 
Inc. La Jolla CA, USA 
PhotoShop CS6 (version 
13.0, 64-bit)  Adobe Systems 
Mountain View CA, 
USA 
Fiji ImageJ  NIH Bethesda MD, USA 
VideoMot2  TSE Systems GmbH Bad Homburg, Gemany 
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2.1.4 Instruments 
2.1.4.1 Machines 
Autoclave SX-700E Tomy Tech USA, Inc Fremont CA, USA 
Swing bucket centrifuge CM-6MT ELMI Ltd. laboratory equipment Riga LV, Latvia 
Micro centrifuge 5415D Eppendorf Hamburg, Germany 
Cell Culture Incubator BBD6220  Heraeus  Hanau, Germany  
IKA® MS 1 minishaker 000L001500 H.B.Selby & Co. Pty Ltd Wilmington NC, USA 
PIPETBOY accu 200940 INTEGRA Biosciences Biebertal, Germany 
Magnetic stirring hotplate MR3001K Heidolph Schwabach, Germany 
GFL® Water bath (cell 
culture) 1003 
Faust Laborbedarf 
AG 
Schaffhausen, 
Switzerland 
Inverted biological 
Microscope INV-100 BEL Engineering Monza, Italy 
Vortex mixer VM1 Ratex Instruments Pty Ltd. Boronia VIC, AU 
Multiskan™ GO 
Microplate 
Spectrophotometer 
 ThermoFisher Scientific Scoresby VIC, AU 
Fluoroskan Ascent™ FL 
Microplate Fluorometer 
and Luminometer 
 ThermoFisher Scientific Scoresby VIC, AU 
EuroClone Topsafe Class II 
(Type A2) Biological 
Safety Cabinets 
 LAF Technologies Pty Ltd 
Bayswater North VIC, 
AU 
Stinger Research 
Anaesthesia machine  
Advanced 
Anaesthesia 
Specialists 
Gladesville NSW, AU 
Peristaltic pump Peri-Star
TM 
Pro 
World Precision 
Instruments Sarasota FL, USA 
Safe-Tee Fume Cupboard HC 05/1 Conditionaire International Marrickville NSW, AU 
Raymond Lamb 
Blockmaster Embedding 
centre 
1347624-
W16 Wotol inc. Lyon, France 
Tail flick (TF) unit 37360 Ugo Basile Comerio VA, Italy 
Cold/hot plate unit 35150 Ugo Basile Comerio VA, Italy 
Auto-processor  ASP200 Leica Biosystems Mount Waverley VIC, AU 
Histology water bath HI1210 Leica Microsystems  Wetzlar, Germany  
Microtome RM2255 Leica Microsystems  Wetzlar, Germany  
Coverslipper  CR100 Dako Denmark A/S Glostrud, Denmark 
Light microscope DM 2500 Leica Biosystems VIC, AU 
Orbital Shaker PSU-10i Grant Instruments Royston, UK 
Fluorescence Microscope BX50 Olympus Notting Hill VIC, AU 
                                                                                                                Materials and methods 
82 
 
Fluorescence Microscope 
Excitation Light Source 120Q  Excelitas Technologies Corp. Wheeling IL, USA 
CCD Camera CoolSNAP HQ2 PhotoMetrics Tucson AZ, USA 
Multiple Conditioning 
System 256060-L TSE systems 
Bad Homburg vor der 
Höhe, Germany 
Ultrasonic converter  Misonix Incorporated  Farmingdale NY, USA 
Ultrasonic cell distributor XL Misonix Incorporated  Farmingdale NY, USA 
Microplate reader SpectraMax M2 Molecular Devices Sunnyvale CA, USA 
Centrifuge Z233 MK-2 
HERMLE 
Labortechnik · 
Zentrifugen 
Wehingen, Germany 
Mini Heating Dry Bath 
Incubator MD-mini MS Major Science Saratoga CA, USA 
Vortex VM79 Selby Scientific Ltd Mulgrave North VIC, AU 
Mini-PROTEAN® Tetra 
Vertical Electrophoresis 
Cell for Mini Precast Gels, 
2-gel 
1658005 BioRad San Diego CA, USA 
Mini-PROTEAN® Tetra 
Handcasting Accessory Kit  1653370 BioRad San Diego CA, USA 
PowerPac™ Basic Power 
Supply  1645050 BioRad San Diego CA, USA 
Mini Trans-Blot® Module 1703935 BioRad San Diego CA, USA 
Mini-PROTEAN® system 
Glass Plates 1653308 BioRad San Diego CA, USA 
Mini-PROTEAN® 3 system 
Glass Plates 1653311 BioRad San Diego CA, USA 
Imager A600 GE Healthcare Life Sciences Parramatta NSW, AU 
 
2.1.4.2 Pipettes 
P2.5 Q27350C Eppendorf South Pacific Pty. Ltd., NSW, AU 
LAMBDA P20 358233382 Corning Incorporated Corning NY, USA 
m100 12561335 Biohit Helsinki, Finland 
m200 12574025 Biohit Helsinki, Finland 
Axygen® Axypet® P1000 358162563 Corning Incorporated Corning NY, USA 
Finnpipette®  P10 T19215 ThermoLabsystems Scoresby VIC, AU 
Finnpipette®  P50 S46099 ThermoLabsystems Scoresby VIC, AU 
Finnpipette®  P300 4510 ThermoLabsystems Scoresby VIC, AU 
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2.1.4.3 Miscellaneous 
Quick-Chill Box DS5114- 0012 Nalgene Rochester NY, USA 
 
2.1.5 Recombinant enzymes and antibodies 
Luciferase E1702 Promega Corporation Alexandria NSW, AU 
Anti-MAOA, rabbit, 
monoclonal ab126751 Abcam Melbourne VIC, AU 
Anti-nitrotyrosine, rabbit, 
polyclonal A-21285 Invitrogen Scoresby VIC, AU 
Negative control rabbit 
immunoglobulin fraction 
(normal) 
X0903 Biocompare South San Francisco, USA 
Goat anti-rabbit IgG H&L 
(Alexa Fluor® 594) ab150084 Abcam Melbourne VIC, AU 
Goat pAb to Rb IgG (HRP) ab97051 Abcam Melbourne VIC, AU 
Biotinlated anti-rabbit IgG, 
from Vectastain® ABC kit PK-4001  Biocompare 
South San Francisco, 
USA 
 
2.1.6 Media and cell culture supplements 
2.1.6.1 Cell culture media 
Dulbecco’s Modified 
Eagle’s Medium (DMEM) – 
low glucose 
D5523 Sigma-Aldrich Castle Hill, NSW, AU 
DMEM – without glucose D5030 Sigma-Aldrich Castle Hill, NSW, AU 
 
2.1.6.2 Serum 
Fetal Bovine Serum, sterile 
(FBS, cell culture) SFBS-F 
Bovogen Biologicals Pty 
Ltd. Kellor East Vic, AU 
Bovine Albumin, Fraction 
V, Protease-free, 96.99% 
(histology) 
A-3294 Sigma-Aldrich Castle Hill, NSW, AU 
Horse Serum 26050 Gibco Melbourne VIC, AU 
 
2.1.6.3 Cell culture chemicals 
Penicillin Streptomycin 15140-163 Gibco Melbourne VIC, AU 
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0.25% Trypsin-EDTA (1x) 25200-056 Gibco Melbourne VIC, AU 
Ethylenediaminetetraacetic 
acid (EDTA) solution  03690 Sigma-Aldrich Castle Hill, NSW, AU 
 
2.1.7 Chemicals 
2.1.7.1 Drugs 
1001 10mM (cell culture), 12.5mg/mL (in vivo) University of Tasmania TAS, AU 
1003 10mM (cell culture), 12.5mg/mL (in vivo) University of Tasmania TAS, AU 
Morphine sulphate 
(cell culture) 1mM  
Proprietor Provet Victoria Pty 
Ltd TAS, AU 
Morphine sulphate 
solution, 30mg/mL 
(in vivo) 
2.5 and 5mg/mL Hospira AU Pty Ltd. TAS, AU 
Imipramine 
hydrochloride  25 and 50mg/mL Abcam plc 
Cambridge, 
UK 
Idebenone  200mg/kg Santhera Pharmaceuticals Switzerland 
 
2.1.7.2 Anesthetics  
ISOTHESIA® inhalation 
Anaesthetic 100% Isoflurane 9008931 ProVet Tasmania Tasmania 
Pentobarbital sodium 52356V1 Virbac Animal Health 
Milperra NSW, 
AU 
 
2.1.7.3 Chemicals 
Carboxymethylcellulose 
(CMC), sodium salt  C9481 Sigma-Aldrich Castle Hill, NSW, AU 
EDTA 0.5M 1610729 BioRad Laboratories, Inc. San Diego CA, USA 
L-glutamine  G5792 Sigma-Aldrich Castle Hill, NSW, AU 
Citric acid  C0759 Sigma-Aldrich Castle Hill, NSW, AU 
Sodium bicarbonate  S5761 Sigma-Aldrich Castle Hill, NSW, AU 
Phosphate buffered saline 
(PBS) tablets  18912014 Life technologies Mulgrave VIC, AU 
Sodium dodecyl sulphate 
(SDS) 
10%(
w/v) 1610361 
BioRad 
Laboratories, Inc. San Diego CA, USA 
30% Acrylaminde/Bis 
Solution, 29:1  1610156 
BioRad 
Laboratories, Inc. San Diego CA, USA 
Phenylmethanesulfonyl 
fluoride (PMSF) 
100m
M 78830 Sigma-Aldrich Castle Hill,NSW, AU 
DL-Dithiothreitol (DTT) 1M 43815 Sigma-Aldrich Castle Hill, NSW, AU 
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Glycerol  G7893 Sigma-Aldrich Castle Hill, NSW, AU 
Magnesium chloride 
(MgCl2)  M4880 Sigma-Aldrich Castle Hill, NSW, AU 
HEPES  H4034 Sigma-Aldrich Castle Hill, NSW, AU 
D-(+)-Galactose  G5388 Sigma-Aldrich Castle Hill, NSW, AU 
Bromphenol blue  114391 Sigma-Aldrich Castle Hill, NSW, AU 
Sucrose  S0389 Sigma-Aldrich Castle Hill, NSW, AU 
3,3′-Diaminobenzidine 
(DAB) Enhanced Liquid 
Substrate System 
tetrahydrochloride 
 D3939 Sigma-Aldrich Castle Hill, NSW, AU 
Ammonium persulfate  A3678 Sigma-Aldrich Castle Hill, NSW, AU 
Adenosine 5′-triphosphate 
disodium salt hydrate (ATP)  A2383 Sigma-Aldrich Castle Hill, NSW, AU 
N,N,N′,N′-
Tetramethylethylenediamine 
(TEMED) 
 T9281 Sigma-Aldrich Castle Hill, NSW, AU 
Dimethyl sulfoxide 
(DMSO)  D4540 Sigma-Aldrich Castle Hill, NSW, AU 
Paraformaldehyde (PFA)  158127 Sigma-Aldrich Castle Hill, NSW, AU 
Sodium fluoride  201154 Sigma-Aldrich Castle Hill, NSW, AU 
NP-40   Sigma-Aldrich Castle Hill, NSW, AU 
Sodium deoxycholate  D6750 Sigma-Aldrich Castle Hill, NSW, AU 
Sodium orthovanadate 200mM S6508 Sigma-Aldrich Castle Hill, NSW, AU 
Sodium chloride (NaCl)  27810.295 VWR Chemicals Tingalpa QLD, AU 
Sodium hydroxide (NaOH), 
pellets  221465 Sigma-Aldrich Castle Hill, NSW, AU 
Glycine  G8898 Sigma-Aldrich Castle Hill, NSW, AU 
D-Luciferin  L9594 Sigma-Aldrich Castle Hill, NSW, AU 
Dako Fluorescent Mounting 
Medium  S3023 
Dako North 
America, Inc. Carpinteria CA, USA 
Sodium phosphate dibasic  S5136 Sigma-Aldrich Castle Hill, NSW, AU 
Potassium phosphate 
monobasic  P5655 Sigma-Aldrich Castle Hill, NSW, AU 
Potassium chloride  P5405 Sigma-Aldrich Castle Hill, NSW, AU 
Sodium phosphate dibasic  S5136 Sigma-Aldrich Castle Hill, NSW, AU 
Trizma® base  T1503 Sigma-Aldrich Castle Hill, NSW, AU 
Trizma® hydrochloride  T5941 Sigma-Aldrich Castle Hill, NSW, AU 
Triton® X-100 20%(v/v) T8532 Sigma-Aldrich Castle Hill, NSW, AU 
Tween 20 20%(v/v) 1706531  
BioRad 
Laboratories, Inc. San Diego CA, USA 
Dako Hematoxylin  CS700 Dako Denmark A/S Glostrup, Denmark 
Hydrogen peroxide solution, 
30wt % in H2O  216763 Sigma-Aldrich Castle Hill, NSW, AU 
PageRuler™ prestained 
protein ladder  26616 Life technologies Scoresby VIC, AU 
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Enhanced 
chemiluminescence western 
blotting reagent 1 
 RPN2109D1 
Amersham 
Bioscience UK Pty 
Ltd 
Buckinghamshire, UK 
Enhanced 
chemiluminescence western 
blotting reagent 2 
 RPN2109D2 
Amersham 
Bioscience UK Pty 
Ltd 
Buckinghamshire, UK 
 
2.1.7.4 Fluorescent dyes 
BODIPY-C11 581/591 (4,4-difluoro-
5-(4-phenyl-1,3- butadienyl)-4-bora-
3a,4a-diaza-s-indacene- 3-undecanoic 
acid) 
D3861 Invitrogen Carlsbad CA, USA 
CM-H2DCFDA (5-(and-6)-
chloromethyl- 2’,7’-
dichlorodihydrofluorescein diacetate, 
acetyl ester) 
C6827 Invitrogen Carlsbad CA, USA 
DAPI (4′,6-diamidino-2-phenylindole 
dihydrochloride) D9542 Sigma-Aldrich 
Castle Hill, NSW, 
AU 
 
2.1.7.5 Kits 
DC Protein Assay kit 5000116 BioRad San Diego CA, USA 
Vectastain® Elite ABC-Peroxidase 
Staining Kit PK6100  Biocompare 
South San Francisco, 
USA 
 
2.1.8 Consumables 
2.1.8.1 Cell culture flasks 
25cm2 (T-25) Cell Culture Flask 430639 Sigma-Aldrich Castle Hill, NSW, AU 
75cm2 (T-75) Cell Culture Flask 430641 Sigma-Aldrich Castle Hill, NSW, AU 
 
2.1.8.2 Microplates 
96-well plate, sterile, flat bottom, with 
lid, clear 3596 
Sigma-
Aldrich Castle Hill, NSW, AU 
96-well plate, sterile, flat bottom, with 
lid, black 3916 
Sigma-
Aldrich Castle Hill, NSW, AU 
96-well plate, non-sterile round 
bottom, no lid, white 3789 
Sigma-
Aldrich Castle Hill, NSW, AU 
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2.1.8.4 Filters 
33mm Syringe Driven Filter Unit, 
0.22 µm, sterile SLGP033RS 
Adelab 
Scientific 
Thebarton, South 
AU 
500mL Bottle Top Filter, 0.22 µm, 
PES, sterile 431118 
Sigma-
Aldrich 
Castle Hill, NSW, 
AU 
 
2.1.8.5 Pipette tips 
0.1-10µL 18812000 Corning Incorporated Corning NY, USA 
200µL LAC1702 VWR LabAdvantage Tingalpa QLD, AU 
300µL LAC30804 VWR LabAdvantage Tingalpa QLD, AU 
100 -1250µL 53508-914 VWR LabAdvantage Tingalpa QLD, AU 
 
2.1.8.6 Tubes 
2.0mL Cryotubes 430488 Sigma-Aldrich Castle Hill, NSW, AU 
Corning 15mL Centrifuge 
Tubes 430791 Sigma-Aldrich 
Castle Hill, NSW, 
AU 
Corning 15mL Centrifuge 
Tubes 352070 Sigma-Aldrich 
Castle Hill, NSW, 
AU 
PCR tubes, 0.2mL, with 
attached caps 732-2572 
VWR 
LabAdvantage Tingalpa QLD, AU 
Eppendorf tube 1.5mL 759987 Livingstone International Rosebery NSW, AU 
Eppendorf tube 0.5mL EP0030121023 Livingstone International Rosebery NSW, AU 
 
 
2.1.8.7 Microscope slides and coverslips 
IHC microscope slides K8020 Dako Agilent Pathology Solutions Mulgrave VIC, AU 
Cover glass (24×50mm) CS704 Dako Agilent Pathology Solutions Mulgrave VIC, AU 
 
2.1.8.8 Syringes and needles 
Ultra-Fine Insulin syringe 326103 Becton Dickinson North Ryde NSW, AU 
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1mL disposable syringe 352070 Livingstone International Rosebery NSW, AU 
26G×3/8” 300300 Becton Dickinson North Ryde NSW, AU 
 
2.1.8.9 Miscellaneous 
Tissue-Tek® III Stacked 
Cassette 4154 Sakura 
Alphen aan den Rijn 
Netherlands 
Protein nitrocellulose 
membrane, 0.2µm 
10600001 Whatman Parramatta NSW, 
AU 
 
2.2 In vitro studies 
2.2.1 Cell culture and maintenance 
2.2.1.1 Routine culture of cells 
HepG2 cells were cultivated under standard conditions (37 °C, 5 % CO2 and 95 % relative 
humidity [rH]) in DMEM containing low glucose (1 g/L) and L-glutamine. The media was 
supplemented 1 % (v/v) antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin), 10 
% (v / v) FBS and bicarbonate (3.7 g/L). 
 
2.2.1.2 Passaging of cells 
The routine passaging of HepG2 cells was performed under sterile conditions in a class II 
biosafety cabinet every 3 - 4 days when the cell reached approximately 80 % confluency. The 
cells were seeded in T-25 flasks with 10 mL of low glucose DMEM medium at a density of 2 
million cells / flask. Confluent cells were first washed once with 10 mL PBS without Ca2+ and 
Mg2+, followed by a brief wash with 1 mL of 1 mg/mL EDTA solution for 15 s. Then the cells 
were incubated with 1 mL of 0.05 % Trypsin (0.5 g/l) / EDTA (0.2 g/l) solution for 5 min until 
cells detached from the growth surface. Detached cells were resuspended in culture medium at 
1:9 (trypsin:culture media) dilution and then counted using a haemocytometer. Once 
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thoroughly suspended, cells were seeded at a density of 8x104 cells / cm2 in either T-25 or T-
75 flask.  
 
2.2.1.3 Freezing of cells 
To freeze cells for longer-term storage or as back up, cell suspensions were prepared (detailed 
protocol see 2.2.1.2). Cells were collected by centrifugation (500 x g for 5 min) using a swing 
bucket centrifuge at room temperature. The pellet was resuspended in 1 mL of cryo medium 
(low glucose DMEM, 20 % FBS, 10 % DMSO). The cells were cooled down at a constant rate 
(1 degree / min) in a -80 °C freezer for 24 h using a Quick-Chill unit, followed by transfer into 
the liquid nitrogen gas phase for long-term storage.  
 
2.2.1.4 Thawing of Cells  
After removing the cryotubes from liquid nitrogen storage, cells were rapidly thawed in a water 
bath at 37 °C. The cell suspension was immediately transferred into a T-25 flask with 10mL 
pre-warmed culture medium. The cells were cultivated overnight in CO2 incubator under 
standard conditions. To remove residual DMSO, the culture medium was replaced with fresh 
medium once the cells were fully attached to the bottom of the flask. At least three standard 
passage cycles were conducted before using the cells for any experiments (detailed protocol 
see 2.2.1.2).  
 
2.2.2 Assays 
2.2.2.1 ATP assay 
Glucose-free DMEM medium (1 g/L D-(+)-Galactose, 3.7 g/L bicarbonate, 0.584 mg/L L-
glutamine, 1 % (v/v) of 100 units/mL penicillin and 100 µg/mL streptomycin, 2 % (v/v) FBS) 
was used for the ATP assay. Cells were seeded in this galactose-DMEM medium at 20,000 
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cells/well in 96-well culture plates in a volume of 100 µL/well. After 24 h, the culture medium 
was replaced with 100 µL fresh galactose-DMEM medium with or without test compounds. 
After the treatment period, cells were washed twice with 100 µL room temperature (RT) PBS 
and lysed in 40 μL of lysis solution (4 mM EDTA, 0.2 % Triton X-100) for 10 min on a shaker 
at 200 rpm at RT. For measuring ATP content in the lysate, 10 μL of lysate was transferred 
into a white 96 well culture plate before 100 μL of ATP measurement buffer (25 mM HEPES 
pH 7.25, 300 µM D-luciferin, 5 µg/mL firefly luciferase, 75 µM DTT, 6.25 mM MgCl2, 625 
µM EDTA and 1 mg/mL bovine serum albumin (BSA)) was added. ATP measurement buffer 
was stored as separate substrate (25 mM HEPES pH 7.25, 600 µM D-luciferin, 75 µM DTT, 
6.25 mM MgCl2, 625 µM EDTA and 1 mg/mL BSA) and enzyme solutions (25 mM HEPES 
pH 7.25, 10 µg/mL firefly luciferase, 75 µM DTT, 6.25 mM MgCl2, 625 µM EDTA and 1 
mg/mL BSA) at -80 °C. Luminescence was quantified immediately using a Fluoroskan 
Ascent™ FL plate reader. ATP levels for each individual experiment were averaged from six 
replicate wells/sample for both the control and each drug concentration. ATP levels were 
calculated using a standard curve (0 - 10 µM) for each experiment before values were 
standardised to protein levels determined by BCA assay (protein assay see 2.2.2.2). The result 
of each treatment was calculated as ATP content per mg protein and represented as percentage 
of untreated control. The measurement of cellular ATP levels was performed as three 
independent experiments and presented using the average values (+/- SD). 
The effects of morphine and the novel bifunctional opioids 1001 and 1003 on cellular ATP 
levels were tested in the ATP assay. Morphine sulphate stock (1 mM in PBS) was stored at 4 
ºC and was further diluted to 10 µM using galactose-containing DMEM medium immediately 
before use. Each well treated with morphine contained 10 % PBS (v/v). Similarly, 1001 and 
1003 stocks (10 mM in DMSO, aliquoted and stored at -20 ºC until use) were diluted in 
galactose-containing DMEM medium to a final concentration of 10 µM. This resulted in a final 
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concentration of 0.1 % DMSO (v/v) per well, which on its own did not affect the viability of 
the cells (unpublished observation). 
 
2.2.2.2 Protein assay 
This assay is based on the reaction of protein with alkaline copper tartrate (cuprous ions). 
Initially, aromatic amino acids are oxidized by copper (II), which then reacts as copper (I) with 
Folin reagent, which produces a characteristic blue colour with a maximum absorption at 750 
nm. Protein levels of cell lysates were determined using the BioRad DC protein assay kit 
according to the manufacturer’s instruction with small variations. Briefly, 10 μL of cell lysate 
or protein standards (BSA: 0 - 2 mg/mL) were added into individual wells of a clear 96 well 
plate in triplicate, followed by addition of 25 µL reagent A’, which is a mixture of reagent S 
and reagent A at a ratio of 1:50 respectively. Subsequently, 200 μL of reagent B was added to 
each well. After a 15 min incubation at RT, absorption at 750 nm was measured using a 
Multiskan™ GO Microplate Spectrophotometer. Protein concentrations were calculated using 
a BSA standard curve (0 - 2 mg/mL). The measurement of protein content in lysates was 
presented using average values (+/- SD) from three independent experiments. 
 
2.2.2.3 Reactive oxygen species assay 
2.2.2.3.1 Measurement of cellular ROS levles 
Measurement of cellular ROS levels using an indicator dye can act as an indirect measurement 
of oxidative stress levels. A commonly used fluorescent dye that measures hydroxyl, peroxyl 
and other oxygen radicals is CM-H2DCFDA. After passively diffusing into the cells, its acetate 
groups are de-acetylated by cellular esterases to a non-fluorescent compound, which is later 
oxidized by ROS into 2’,7’-dichlorofluorescin (DCF). DCF is highly fluorescent and can be 
detected with maximum excitation and emission peaks of 495 nm and 529 nm respectively. 
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The presence of cellular ROS is measured as an increase in fluorescence signal. A CM-
H2DCFDA stock solution (1 mM in DMSO) was prepared, aliquoted and stored at -20 ºC until 
use. Upon usage, the dye was further diluted to 10 µM using galactose-containing DMEM 
media.  
To measure cellular ROS levels, HepG2 cells were seeded in galactose-containing DMEM 
medium at a density of 20,000 cells/well in black 96-well culture plates. After 24 h, the wells 
were washed with 100 μL of PBS. Cells were then loaded with 50 μL of 10 µM CM-H2DCFDA 
solution for 30 min, followed by washing with 100 μL PBS to remove excess dye. The cells 
were subsequently treated with 1 mM tyramine and fluorescence was measured every 15 min 
over a 75 min period using a Fluoroskan Ascent™ FL plate reader at Ex/Em 495/529 nm.  
 
2.2.2.3.2 Measurement of lipid peroxidation 
A fluorescent probe for the ratiometric detection of lipid peroxidation in cellular membranes is 
BODIPY-C11 581/591. It is a lipophilic dye that enters the lipid bilayer membrane due to its 
C11 carbon side chain. It is oxidized by oxygen radicals or lipid peroxides inside the membrane, 
which results in a fluorescence emission shift from 590 nm (red) to 510 nm (green). The green 
(oxidized form) and red (non-oxidized form) fluorescence of BODIPY-C11 581/591 was 
quantified using a Fluoroskan Ascent™ FL plate reader (Ex/Em 460/535 nm and 485/600 nm). 
After solubilizing in DMSO, the dye was stored as single use aliquots. The stock solution (1 
mM in DMSO) was aliquoted into 10 μL portions and kept frozen at -20 ºC. Upon usage, one 
aliquot of the BODIPY-C11 581/591 stock was further diluted to a final concentration of 10 
µM using galactose-containing DMEM medium. To measure cellular lipid peroxidation, 
HepG2 cells were seeded in galactose DMEM medium at a density of 20,000 cells/well in black 
96-well culture plates. After 24 h, the wells were washed with 100 μL of PBS. Cells were then 
loaded with 50 μL of 10 µM BODIPY-C11 581/591 solution for 30 min, followed by a wash 
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with 100 μL PBS to remove excess dye. The cells were treated with 1 mM tyramine and 
fluorescence was measured every 15 min over a 75 min period using a Fluoroskan Ascent™ 
FL plate reader. 
 
2.2.2.3.3 Determination of tyramine concentrations 
To determine the optimal working concentration of tyramine, a range of drug concentrations 
(0, 0.1, 1, 10, 100 and 1000 µM) were tested following the method described in 2.2.2.3.1. 
HepG2 cells were incubated with different concentrations of tyramine for 60 min and 
fluorescence was measured using a Fluoroskan Ascent™ FL plate reader at Ex/Em 495/529 
nm. The data was averaged from six replicate wells/sample and was performed as three 
independent experiments. Figures show average values from three independent experiments 
(+/- SD). 
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2.3 In vivo studies 
2.3.1 Drug preparation 
Morphine sulphate stock solution (30 mg/mL) was diluted to 2.5 mg/mL and 5 mg/mL stocks 
in saline (0.90 % w/v of NaCl in MilliQ water, pH 7.4, sterile) and stored (RT) in a locked 
cabinet according to the storage rules for schedule 8 drugs. The tricyclic antidepressant 
imipramine hydrochloride was dissolved in sterile saline as 25 mg/mL and 50 mg/mL stock 
solutions, which were aliquoted and stored at -20 ºC until use.  
Injection solutions of 1001 and 1003 were prepared under sterile conditions. Drug powder (10 
mg) was dissolved in 200 µL of 20 % DMSO in saline, pH 7.4 using a vortex mixer (VM1) at 
maximum speed. The resulting solution was further diluted with a total of 600 µL saline, which 
was added slowly as 4 equal amounts to avoid precipitation. The final 1001- and 1003-solutions 
(12.5 mg/mL in 2.5 % v/v DMSO/saline) were aliquoted and stored at -20 ºC until use. 
Idebenone powder was suspended in 0.5 % (w/v) carboxy methylcellulose (CMC) / MilliQ 
water solution to form a homogeneous suspension by overnight stirring at 4 ºC, before being 
mixed with soy-reduced autoclaved food powder containing 5 % sucrose. The resulting mixture 
was aliquoted into 6.3 g portions on balancing trays to provide 200 mg/kg per administration 
(average daily food consumption amount of 7-week SD rats is 15 - 25g (48)) and stored at -20 
ºC. Similarly, same amount of 0.5 % (w/v) CMC solution without drug was prepared for vehicle 
pellets (6.3 g each). 
 
2.3.2 Drug administration regimes 
2.3.2.1 Opioids 
The daily doses of morphine (5 mg/kg/day) and imipramine (50 mg/kg/day) were injected 
subcutaneously followed previously described injection regime with modifications (525,625)  
Briefly, the first injection at full dose was administrated 1 hour after the 2nd induction session 
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of the LH model on day 2 (See 2.3.4.3 for detailed protocol of the LH model). After 48 h, drugs 
were injected twice a day at half-dose per injection. Animals received the initial half-dose 30 
min before the 1st LH test and the second half dose 4 h after the LH test on day 4. This routine 
was repeated on day 5. The final injection (full dose) was administered 1 h before the last LH 
test on day 6 (Figure 12). The selection of morphine dose in my study was based on a previous 
pharmacokinetic study, where stable plasma concentrations of total morphine  were observed 
up to 6 hours after systemic administration of 5 mg/kg morphine in male SD rats (626). In 
addition, one injection of 2 mg/kg and 5 mg/kg morphine (s.c,) reached peak brain 
concentrations of 0.26 µg/g 1 h and 0.179 µg/g 30 mi n after injection in rats and gave stable  
brain levels for 4 h at the lower dose (627). Since the LH testing procedure in present study 
lasted for approximately 30 mins, a 2.5 mg/kg/injection was able to maintain a stable brain 
concentration of morphine throughout the LH testing session. In addition, the purpose of the 
morphine injection regimen was to avoid the development of morphine tolerance. Repeated 
injections of 2.5 mg/kg twice a day (tid) was shown to produce tolerance from day 3 onwards 
in the TF assay, while this was not observed following doses of 5 mg/kg (tid) or higher in male 
SD rats (628). Therefore, 2.5 mg/kg (tid) was only used for  the first two days before  the dosing 
was changed to single dose injections of 5 mg/kg/day to avoid tolerance as described (628). 
 
Figure 12. Injection regime of opioids and imipramine. 
Male SD rats received 6 injection (s.c.) in total. Both the first and last injection were given as 
a full dose on days 2 and 6, while the dose was split into two half doses per day, 30 min before 
and 4 h after the LH tests respectively on days 4 and 5. 
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Because the pharmacokinetics of UTA1001 and UTA1003 have not been reported or tested so 
far, both bifunctional opioids were administrated following the morphine injection regimen to 
compare the behavioural effects between the novel opioids and morphine.  
 
2.3.2.2 Idebenone 
Idebenone was used at a wide range of doses (10 – 2000 mg/kg per administration) in previous 
studies and no toxicity was reported (384,391). Among those, 200 mg/kg has demonstrated 
neuroprotection of retina in animal study (629). Due to the similarity between the brain retina 
barrier and the brain blood barrier (630), 200 mg/kg/day was selected for my experiment to 
ensure sufficient amount of idebenone would penetrate into the brain. Oral administration of 
idebenone with food mash has also been used (629), thus idebenone (200 mg/kg/day) was 
administrated through the food mash pellets between 17:30 and 18:00 daily according to two 
regimes. In one regime, called pre-learning treatment, idebenone was given for 7 days in total, 
starting from 4 days before the NOR procedure (see 2.3.8.3 for detailed protocol of the NOR 
model) until day 3. In the other regime, called post-learning treatment, the drug was 
administrated from days 4 to 6 (Figure 13). The drug / food mash pellets were fully thawed at 
RT before placing them into the cage of single housed animals. During the experiment, animals 
had always access to normal food pellets ad libitum. Typically, animals preferred the sucrose-
laced food and preferentially ate the drug-containing portions before feeding on the standard 
food pellets. This method allowed exact monitoring of idebenone intake in a way that did not 
affect their behavior. 
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Figure 13. Administration regime of idebenone. 
Idebenone (200 mg/kg/day) was given daily for either 7 days before the learning phase (pre-
learning) or for 3 days after the learning phase (post-learning) via drug-laced food portions.  
 
2.3.3 Animal handling and maintenance 
All procedures were carried out in accordance with the Australian Code for the Care and Use 
of Animals for the Scientific Purposes and incorporated the 3R principles of Replacement, 
Reduction and Refinement. All use of laboratory animals was approved by The University of 
Tasmania Animal Ethics Committee (AEC, #A0013857). All techniques that involved animals 
were competency assessed by the University veterinarian before used for this project. Male SD 
rats that were used in this project were siblings, which minimised the influence of inter-
individual differences on testing the pharmacological effects of the drugs of interest (631). All 
6-week-old animals were delivered weekly to the rat Bio-Bubble pavilion of the Medical 
Science Precinct (MSP, University of Tasmania) animal facility, at a quantity of 3 – 4 rats per 
week until the end of the experiments. All rats were housed under a 12 hour light/dark circle 
(7:00 – 19:00) at 22 ± 0.5 ºC upon arrival. In the LH paradigm, negative emotional states can 
be induced by the use of electric shocks (632), which can be communicated though ultrasonic 
vocalisation by rats within a social group (633). Therefore, all animals in my study were single 
housed to reduce direct communication of negative emotional states. In addition, in the 
                                                                                                                Materials and methods 
98 
 
idebenone experiment, it was necessary to house the animals individually to ensure accurate 
and reproducible dosing of idebenone to each rat through food/drug pellets. In addition, the 
behaviour of rats was closely monitored at least 30 mins before and after the experiments under 
the supervision of the animal technician and the university vet. Those scored behaviours 
included fur/coating condition, level of aggressiveness during handling, routine 
activities/locomotion in the cage, eating behaviour, grooming, various signs for different levels 
of pain and unexpected injuries. Rats were used for experiments only if no abnormalities were 
observed. These measures were implemented to minimise the bias due to housing conditions. 
Rats were allowed to adjust the light-dark cycle and other environmental conditions for 1 week 
before being used in experiments. Clear plastic ventilated cages were used for housing, which 
offered standard housing conditions that also contained a sleeping house, bedding and a plastic 
toy. Rats were able to access standard Barastoc 20 % protein rodent diet and water ad libitum. 
 
2.3.4 Randomisation and allocation 
All animals that were delivered weekly from the university animal breeding facility were 
randomly allocated into different arms of the experiments as previously described (634) with 
the following exception. During the period of establishing the effects of morphine on animal 
behaviour, 6-week-old rats arrived at the MSP animal facility that significantly varied in body 
weight. In batches 1 to 5, rats arrived at the experimental facility with body weights between 
258 to 356 g. Since neither morphine nor imipramine were available during those weeks due 
to import problems into Australia outside my control, animals were allocated into the NS, IS 
and ES groups. By the end of week 5, the experimental procedures of the NS and IS groups 
were fully completed, but not the ES group. From week 6 to 11, rats arrived the MSP animal 
facility in weekly batches with significantly lower body weights between 178 to 258 g. Those 
smaller animals were used in the treatment groups (morphine and imipramine) and the ES 
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group. Because of the differences in rat body weights upon arrival from the breeding facility at 
different weeks, at the end of the morphine-imipramine experiment, a discrepancy in average 
body weights between the NS, IS and two treatment groups was seen. Furthermore, due to the 
unavailability of testing compounds during the initial 5 weeks, it was impossible to perform 
controls and the treatment groups simultaneously between weeks 1 to 5. Detailed information 
have been listed in the Appendix (A4) to illustrate animal allocations and body weights for 
each animal and treatment group (Table 10 and 11). 
 In contrast, for the experiment that aimed to establish idebenone effects, all animals supplied 
weekly were of similar weight. Hence, rats were randomly allocated into both control and 
treatment groups throughout the experiment following a complete randomization method 
(634). For the experiment that aimed to establish the effects of the novel opioids, no additional 
contemporaneous controls were employed due to the robustness of the LH model. Therefore, 
weekly delivered rats were only allocated into either the 1001 or 1003 treatment groups. 
 
2.3.5 The multiple conditioning system 
The MCS provides a platform for a range of diverse tests and consists of paradigms for anxiety, 
locomotion, cognition, addiction and depression. It consists of a sound-attenuated box with a 
light barrier frame that contains three infrared light-beam systems with sensors. Each infrared 
beam system includes 31 light barriers with 14 mm distance between each barrier. Two of the 
systems were detecting movement in horizontal X-Y plane, allowing to measure the moving 
distance, the transfer counts from one compartment to the other in a two-compartment chamber 
and the number and duration of freezing episodes. The last sensor system was assembled on 
the top of the Y system and was designed to detect the movement in the vertical (Z) plane such 
as the number of rearings (XYZ bipedal standing), jumps (Z only), climbs (XYZ bipedal) and 
leaning/upward movements against chamber walls. The light-barrier frame had a push-pull 
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style and supported different experimental chambers. In addition, two additional observation 
LED lights were installed outside of the MCS box to indicate individual foot shock events. 
A grid floor for delivering foot shocks was placed underneath the experimental chambers. It 
measured 30 × 30 cm and was composed of 25 stainless steel rods (ø = 6 mm) that were 18 mm 
apart from each other. On the ceiling of the MCS housing box, 4 lights (10 W) were assembled 
as a house light, which were covered with removable red Plexiglas boards, to provide a 
maximum of 15 Lux red-light and 250 Lux white-light illumination. Two additional lamps 
were installed between each two house lights that were covered by a sliding blue board to 
provide stimulus illumination. The intensities of both housing lights and stimulus lights were 
controlled by the central control unit. A camera was installed 30 cm above the X-Y infrared 
frame to take the real-time recordings. A speaker was installed on the side of the camera that 
delivered tone and white noise. The activities of animals in the dark experimental chamber 
were observed through an infrared-light/camera setup (Figure 14). The experimental data was 
automatically recorded by the associated control software packages (MCS Two-CP PA-PP-
LA, MCS ActiMot-OF and MCS Fear Conditioning) for the different paradigms. 
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Figure 14. Major components of the multiple conditioning system.  
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2.3.6 The learned helplessness model 
2.3.6.1 Apparatus 
The LH procedure is performed in a two-compartment conditioning chamber (458 × 458 × 403 
mm) in the MCS system, which is divided by a removable black Plexiglas board with opened 
arch way in the middle. This chamber is composed of 2 black walls on the side and another 2 
clear walls in the front and rear respectively. It has no fixed bottom, which allows the passage 
of electric foot shocks from the stainless steel grid. A transparent lid is placed on the top to 
stop the escape of animals during shock trials (Figure 15). 
Figure 15. The learned helplessness chamber of the MCS system. 
 
2.3.6.2 Optimization of the LH model 
Number of induction sessions 
There are two phases in the LH model, including induction (to induce depressive-like 
symptoms using IS) and testing (the effects of treatment and IS are evaluated using escape 
shocks) phases. In previous studies, the induction phase was set as either one or two sessions. 
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In order to induce depressive-like symptoms successfully in male SD rats, different numbers 
of induction sessions were tested.  
In one experiment, a single induction session was used, which contained 60 repeats of 
inescapable foot shocks (IS, 15 s, 0.8 mA) with a fixed 60 s interval between two shocks. The 
depressive-like symptoms were assessed in a single test conducted 24 h after the induction 
phase. In this test, 30 trials of a combination of light (3 s) and ES (3 s, 0.8 mA) was used with 
a fixed 30 s interval between two trials. The trials were terminated if the animal transferred 
from one compartment to the other during either light or shock period (Figure 5A). The number 
of trials in which the rats failed to transfer during a 6 s period (= escape failures) was used as 
an indicator of depressive-like symptoms. 
In the other experiment, 2 induction sessions were used on consecutive days. In each induction 
session, 60 repeats of IS (15 s, 0.8 mA) were combined with a fixed 60 s interval between two 
shocks. After 24 h, the effects of induction sessions on inducing depressive-like symptoms 
were measured using 2 testing sessions that were conducted on 2 consecutive days (Figure 
16B). The same parameters as above were applied in the testing phase of the experiment. The 
number of escape failures was calculated as indicator of depressive-like symptoms. Three male 
SD rats were used in each experiment. 
 
Figure 16. Protocols of comparing different number of induction sessions in the learned 
helplessness (LH) model. 
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Number of inescapable foot shocks in the induction phase 
In this experiment, the number of IS was increased, in order to enhance the effect of IS to 
induce long-lasting depressive-like symptoms. Two induction sessions were applied with 
minor modifications. Male SD rats (n = 3) received 90 IS (15 s, 0.6 mA) with a fixed 60 s 
interval. The testing phase was carried out 24 h after the 2nd induction session on two 
consecutive days. In each testing session 30 trials were used, which contained 3 s light, 3 s ES 
(0.6 mA) and 30 s between two trials (Figure 17).   
 
Figure 17. Protocol of comparing different number of inescapable foot shocks in the 
induction phase of the LH model. 
 
Length of interphase interval 
In order to determine the influence of interphase interval on escape performance of rats in the 
testing phase, the effect of a 48 h interphase interval was tested. Animals (n = 3) were subjected 
to 2 induction sessions, which contained 90 repeats of IS (15 s, 0.6 mA) with scrambled 
intervals of 45 – 75 s between two shocks. Three testing sessions were conducted on 3 
consecutive days, 48 h after the 2nd induction session. In each test, a combination of 30 trials 
of 3 s light and 3 s ES was used. Scrambled intertrial intervals of 23 – 37 s was used between 
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two trials (Figure 18). The number of escape failures was calculated as indicator of depressive-
like symptoms. 
 
Figure 18. Protocol of comparing the effects of different length interphase intervals in the 
learned helplessness (LH) model. 
 
2.3.6.3 Application 
The modified 6-day LH paradigm included 2 induction sessions and 3 testing sessions with a 
48 h interphase interval. The average body weight of male SD rats (n = 5 - 8) was 200 - 310 g 
at the beginning of the experiments. After being transferred from the Bio-Bubble pavilion to 
the behavioral room, rats habituated for 60 min to the new environment under 30 Lux 
illumination every day. Then animals were allowed to explore the LH chamber over a 5 min 
period before the conduction of the 1st induction session, followed by exposure to 90 IS (15 s, 
0.6 mA) with 45 – 75 s intervals between two shocks. This session was carried out without 
chamber illumination. After 24 h, animals were subjected to another induction session without 
further habituation in the same chamber with 50 Lux white light illumination. The testing phase 
was conducted 48 h after the 2nd induction phase. Rats were habituated for 3 min at the 
beginning of the 1st session, which subsequently consisted of 30 trials of 3 s light and 3 s shock 
(0.6 mA) with scrambled 23 – 37 s intertrial interval length. The test was repeated two times 
on consecutive days without further habituation and the same parameters were applied to all 
animals.  Animals were excluded based on their behavioral stress response before and during 
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the IS paradigm of the LH model in line with previously published report (635). Specifically,  
in non-stressed rats (NS-group) were excluded if they showed LH symptoms with more than 
20 EFs in 30 trials (636). On the other hand, animals of the IS group were excluded if they 
failed to show LH symptoms and produced less than 10 EFs in 30 trials in the initial LH testing 
session as previously published (636). Since all measurements were performed in an integrated 
model, data of excluded rats were removed for all models. The chamber was wiped with F10Sc 
(1:250 dilution in distilled water) to avoid sensory distraction and cross-contamination between 
animals. All LH experiments were conducted between 9:00 am and 5:00 pm. Body weight and 
food consumption were measured daily for the idebenone study. 
To illustrate the effects of IS, additional induction sessions with NS and ES were used for two 
groups of rats. In the NS group, animals were placed in the LH chamber for 20 min without 
exposure to shocks in the induction phase. In contrast, in the ES group the rats received 90 
repeated ES (15 s, 0.6 mA) and shock delivery was terminated if the animal transferred to the 
other compartment. A further 6 groups of rats that received opioids, imipramine and idebenone 
treatments based on specific administration regimes (see 2.3.2 for details) after exposure to the 
IS regimen. 
In the LH model, 5 parameters were measured in the testing phase: the number of avoidance 
events (= number of transfers made during the 3s light), the number of escape failures (= 
number of trials that rats failed to make any transfers), the number of intertrial interval transfers 
(= number of transfers made during intertrial intervals), the freezing duration during intertrial 
intervals and the mean escape latency (= the time taken by the animal to transfer from one 
compartment to the other from of beginning of trial). These parameters were used as indicators 
of avoidance learning, depressive-like symptoms, physical activity, anxiety-like symptoms and 
escape learning respectively. 
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2.3.7 The light and dark model 
2.3.7.1 Apparatus 
A two-compartment chamber was used in this LD model. This model consisted of one darkened 
compartment and a second compartment that was illuminated with 15 Lux white light. The 
entire chamber was rectangular (450 × 300 × 250 mm) and was partitioned into two equal-
sized compartments by a software-controlled automatic door (65 × 70 mm). Exchangeable 
black walls and a lid surrounded the dark compartment of this chamber, while the other 
compartment consisted of transparent Plexiglas boards, which allowed white light to penetrate. 
A square black insert with matte finish was placed underneath the chamber to create an 
enclosed environment (Figure 19).  
 
Figure 19. The light and dark apparatus.  
 
2.3.7.2 Model optimization 
A wide range if illumination intensities have been used across different laboratories (637). In 
order to establish the optimal light intensity for our experimental conditions, a variety of light 
intensities (0, 5, 15, 30, 50 and 100 Lux) were tested on 6 consecutive days by testing one 
intensity per day. Male SD rats (n = 3, 7 weeks) were repeatedly used in the experiment. After 
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habituating to the behavioural room (30 Lux) for 60 min, animals were placed in the centre of 
the light compartment with the connecting door closed for each session. The animals were 
allowed to explore the illuminated compartment for 5 min, followed by another 5 min test. 
During the testing period, the connecting door was opened and rats were able to freely transfer 
between the two compartments. The percentage of time spent in the dark compartment was 
used an indicator of anxiety-like symptoms, which was determined as follows: 
% time = 100 × (time in seconds spent in dark compartment ÷ 300 s). 
The light intensity that did not induce anxiety-like symptoms in naïve rats was selected for 
subsequent tests. The chamber was wiped with F10Sc (1:250 dilution in distilled water) to 
avoid sensory distraction and cross-contamination between animals. All tests were conducted 
between 9:00 and 11:00.  
 
2.3.7.3 Model application 
Male SD rats (7 weeks) were habituated for 60 min to the behavioral room (30 Lux) for each 
session. The rat was placed in the central area of the bright compartment (15 Lux) and was 
habituated for 5 min with the connecting door closed. Following the habituation, a 5 min test 
was performed and the door opened automatically. The time spent in the dark compartment 
was measured over a 5 min testing period. The LD tests were conducted on days 1, 2, and 6, 5 
min before the LH procedure (Figure 20). The chamber was wiped with F10Sc (1:250 dilution 
in distilled water) to avoid sensory distraction and cross-contamination between animals. 
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Figure 20. Protocol of the light and dark paradigm (LD). 
The LD model was conducted in combination with the LH model. It was performed on days 1, 
2 and 6 to measure the anxiety levels of animals. 
 
2.3.8 The open field model 
The OF model uses a square open chamber (456 × 456 × 400 mm) with a solid floor plate. It 
is surrounded by 4 clear Plexiglas walls (Figure 21A). The central area of the chamber was 
defined as a square area representing 50 % of the total chamber size in the center of the arena. 
In the initial test, after habituating to the behavioral room for 60 min, male SD rats (n = 5 - 8, 
7 weeks) were allowed to explore the chamber for 5 min, followed by a 5 min test. Several 
behaviors were recorded automatically by the software over 5 min testing period: 1) % of time 
spend in the central area, 2) % of distance travelled in the central area, 3) time spent moving 
and exploring in the whole chamber, and 4) rearing duration. In addition, the pattern of 
movement was tracked automatically by the system (Figure 21B). The chamber was wiped 
with F10Sc (1:250 dilution in distilled water) to avoid sensory distraction and cross-
contamination between animals. 
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Figure 21. The open field chamber and 
the movement tracking function of the 
MCS. 
(A) The OF chamber is an open square 
box with 4 clear walls with a fixed floor 
plate. (B) The software used in the open 
field model automatically tracked the 
moving path of animals. The thin red 
lines marks their movement and the 
bold blue line show rearing behavior. 
The green lines label the corner and 
central areas of the chamber.    
 
 
 
 
 
 
 
 
 
 
The OF tests were performed 10 min before the LH procedure. In IS, NS (200 µL saline, s.c.) 
and imipramine (50 mg/kg/day, s.c.) groups, the OF tests were carried out on days 1, 2 and day 
6, while for the morphine (5 mg/kg/day, s.c.) group the OF tests were conducted on days 1, 2, 
4 to 6 (Figure 22A). For the 1001, 1003 (5 mg/kg/day, s.c.) and idebenone (200 mg/kg/day, 
oral) groups, the OF performance was tested from days 2 to 7 (Figure 22B) (see 2.3.2 for 
treatment administration regimes). 
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Figure 22. Protocols of the open field paradigm for different groups.  
 
2.3.9 Pain perception 
Potential changes to pain thresholds after shock exposure and drug treatment in the IS and IS 
+ morphine groups were measured using the tail-flick and hot plate tests, which are designed 
to assess heat-induced spinal and supraspinal responses respectively (638) . 
 
2.3.9.1 The tail-flick test 
The tail flick (TF) tests were performed parallel to the LH procedure. The intensity of infrared 
radiation was set to 30 mV / cm2 to give control times of approximate 4 – 6 sec in male SD 
rats. Measurement were only performed on a specific part of the tail as sensitivity to radiant 
heat differs at different parts of the rat tail. Therefore, a distal area of the tail 2 – 4 cm away 
from of the tip was selected based on previous studies (596,639,640,641). In order to minimise 
the variance induced by individual tail size, three testing points (i.e., at 2, 3 and 4 cm away 
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from the tip respectively) were marked within the targeted area.. The rat tail was placed on an 
infrared beam of the TF equipment as the heat source of the apparatus (Figure 23), while the 
rat’s head was covered by a soft black towel. The TF test was only  started after sufficient 
habituation and handling when the animals’ tail was completely relaxed on the infrared beam  
area. After feeling the heat, the animals flicked their tail away from the detector and thus 
terminated the test. The time to the termination (= tail flick latency) was recorded automatically 
and was used as an indicator of pain perception. To avoid tissue damage, the maximum cut-off 
time was set as 15 s. Each rat was measured 3 times for each test at 3 different points on the 
tails. There was a 1 min interval between each measurement. If a rat failed to cut off the test 
within 15 s, no further measurement was conducted for the following 5 min. 
 
Figure 23. The instrument used in the tail flick (TF) test. 
Tail-flick unit (model 37360) was used in the experiments. Image was copied from the 
manufacturer’s website (http://www.ugobasile.com/products/catalogue/pain-and-
inflammation/item/14-37360-tail-flick-unit.html). 
 
2.3.9.2 The hot-plate (HP) test 
The cold/hot equipment consisted of a metal plate, which was pre-heated to 54 ºC before 
experiments. A Plexiglas cylinder surrounding the plate prevented the escape of the animal 
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(Figure 24). Male SD rats were placed into the cylinder 15 min after receiving an injection 
(see 2.3.2 for drug administration regimes). The timer was started manually once the rat was 
placed on the plate. The test was terminated manually by the operator when the first nociceptive 
response of licking or shaking a hind paw was observed (= hot plate latency). Each rat was 
measured 3 times with a 1 min interval between each measurement. A maximum cut-off time 
of 30 s was set up to avoid tissue damage. If the animal failed to show responses to the heat 
within 30 s, a 10 min period was allowed before the next measurement was started.  
 
Figure 24. The equipment used in the hot plate (HP) test. 
Hot/cold plate unit (Ugo Basile S.R.L. model 37360) was used in the experiments. Image was 
copied from the distributor’s website (https://www.somatco.com/hotplateforanimal.htm). 
 
 
2.3.10 The novel object recognition model 
Novel object recognition is a highly validated test for recognition memory. It has been widely 
used to test the effects of compounds on both memory enhancement and impairment as well 
as the influence of genetics or age on memory function (642). 
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2.3.10.1 Apparatus 
The NOR model employs the same chamber as the LH model, where the removable black 
Plexiglas board is removed to form an open compartment. A black insert is placed underneath 
the chamber to cover the stainless steel rods (Figure 25). There are two phases in this model: 
the object learning phase (rats learn 2 identical objects) and the memory testing phase (rats are 
exposed to novel objects). The NOR paradigm was used parallel to the LH procedure. 
 
Figure 25. Arena for the novel object recognition model. 
The chamber is an open compartment with black floor insert. The objects are evenly spaced 
and placed in the middle of the chamber. 
 
2.3.10.2 Model optimization 
Selection of objects 
In this paradigm, object characteristics such as shape, color and size can per se influence the 
outcome of NOR experiments. The detected object exploration time will be reduced if the 
tested objects induce stress or fail to attract the attention of the animals (642). Therefore, to 
ensure the reliability of measurements, these objects should be selected carefully. Preferably, 
objects should be made from materials that can be easily cleaned and deodorized. In addition, 
they should be of a size that allows the rats to climb on top, so that they can fully explore the 
objects. Another important rule for object selection is that the objects should catch the animal’s 
attention and motivate them to explore. For this purpose, 11 different objects were tested 
(Figure 26).  
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Figure 26. Tested objects for the novel object recognition model. 
Eleven plastic objects were chosen and 3 of them (marked with red ticks) were selected for 
following experiments. 
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The experiment was conducted between 9:00 - 10:00 am and 4:00 - 5:00 pm on 3 days. In both 
morning and evening sessions, 2 objects were tested. Selected objects were placed in the middle 
of the chamber (measured as 22 cm from the top and 14 cm from the side) and their bottoms 
were attached to the black insert using Blu-tack. Objects were evenly spaced (around 17 cm 
between two objects) every time (Figure 27).  
 
Figure 27. Location of objects in the NOR chamber.  
 
Animals (n = 4) were allowed to explore the objects for 10 min in each session. Time spent 
sniffing, touching with nose tip or forepaws whilst sniffing and climbing was recorded 
manually using a stopwatch and considered as exploration time. However, time spent turning 
around, leaning against and standing on the objects was excluded (643). At the end of these 
trial experiments, three objects (marked by red ticks in Figure 26) where the rats spent the 
most time exploring were selected for the following experiments. F10Sc was used to clean the 
objects between each rat to avoid sensory distraction and cross contamination, followed by 70 
% ethanol to remove the odor. 
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Persistence of the natural memory of rats 
Because IS can induce memory loss in rodents (644), the natural memory of rats (n = 3) was 
tested without exposing them to the foot shocks. This experiment contained two learning 
sessions and four testing sessions with a 24 h interval between two sessions.  In the learning 
session, 2 identical objects were used. Rats were allowed to explore the objects for 20 min in 
each learning session on days 1 and 2. Over days 3 to 6, the memory of the animals was 
assessed 24, 48, 72 and 96 h after the 2nd learning session respectively. In each testing session, 
one of the familiar objects was replaced with a novel object. Rats were exposed to both objects 
for 5 min. The experiment was recorded to DVD disk, which was subsequently analysed using 
VideoMot 2 software. The actual time spent exploring both novel and familiar objects was 
calculated and the exploration time for the novel object was used an indicator of memory 
function. 
 
Effect of stress exposure on learning and memory 
Cognitive dysfunction has been frequently reported in patients with depression and has been 
replicated in depressed rodents in the LH model (87,644). However, stress exposure can either 
enhance or impair memory dependent on the interval between stress exposure and object 
learning (645). Therefore, to produce symptoms of memory loss in our LH model, 2 
experimental designs were tested in which the learning sessions were conducted at different 
time points after exposing the rats to stress. In the first experiment (Figure 28A), rats (n = 3) 
habituated to the NOR chamber for 30 min before on day 1 before they were subjected to 90 
IS on day 2. Ten min after the shock exposure, a 20 min object learning session was carried 
out using 2 identical objects. On day 3, rats were given another 90 IS, followed 10 min later by 
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the 2nd 20 min learning session. The memory of animals was assessed on day 4 in a 5 min 
testing session using a novel object.  
In the second experiment (Figure 28B), rats (n = 3) were habituated to the NOR chamber on 
day 1, before exposing them to 90 IS on days 2 and 3. Two object learning sessions were 
conducted 24 h after the 2nd IS session using the identical objects used in experiment 1 on day 
4 with a 7 h interval between two sessions. The memory of rats was initially measured 30 min 
after the 2nd object learning session over a 5 min period. Another two 5 min memory testing 
sessions were conducted on days 5 and 6. Different novel objects were used in different testing 
sessions. Both experiments were recorded automatically to DVD and subsequently analysed 
using VideoMot 2 software. 
Figure 28. Two post-stress learning paradigms of the novel object recognition test. 
 
2.3.10.3 Model application 
The modified NOR model was performed over 7 days in parallel to the LH paradigm (Figure 
29). The NOR chamber was illuminated with 15 Lux white light during the procedure. On day 
1, rats were habituated to the NOR chamber for 30 min before they were transferred back to 
Bio-bubble pavilion. Approximately 24 h after the habituation, animals received the 1st LH 
induction session in an unilluminated chamber, which contained either 90 trials of IS (15 s, 0.6 
mA) with an average of 60 s scrambled intertrial intervals or 20 min non-shock exploration 
time. The foot-shock exposure was repeated on day 3 and on this day, the chamber was 
illuminated with 50 Lux white light. On day 4, rats were subjected to 2 x 20 min learning 
sessions using two identical objects (object #1 was used in the learning phase see Figure 26), 
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with a 7 h interval between two sessions. On day 5, the 1st NOR test was performed over a 5 
min period by replacing one of the familiar objects with object #10 (see Figure 26), 15 min 
after the injection of 1001 and 1003. On the evening of day 5, the post-learning idebenone 
group received the first dose of 200 mg/kg/day idebenone through their food (see 2.3.2 for drug 
administration regimes). On day 7, long-term memory was assessed 15 min after the drug 
injection in a 5 min test using object #11 (see Figure 26). The experiments were recorded and 
then analysed using VideoMot 2, to determine the exploration time for the different objects. 
 
 Figure 29. Protocol of the novel object recognition model .  
 
2.3.10.4 Discrimination index 
To assess differences in exploring time for the familiar and the novel objects in a memory 
testing session, the commonly used DI was determined using the following formula: 
DI = (TN – TF) / (TN + TF)  
(TN: exploration time on novel object, TF: exploration time on familiar object). 
A value below zero indicates that the animals explored the familiar object more than the novel 
object. A value above zero indicates that the animals explored the novel object more than the 
familiar object. The use of the DI allows to identify differential exploration behaviors for both 
objects (642). 
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2.3.11 The fear extinction model 
The FE model was developed to investigate the neural circuits of extinction of FC in both 
animals and humans (646). In the current study, this model consisted of 4 phases: habituation, 
FC training, FE training and a post-extinction (PE) test. Different chambers were used at 
different phases of this model, in order to minimize the fear that associated with specific 
experimental environments.  
 
2.3.11.1 Model optimization 
In this preliminary experiment, the most commonly used parameters described in previous 
studies were tested. Similarly, 2 different chambers were used for the different phases of the 
FE model. For the habituation and FC phases, the chamber used in the LH model without the 
black board in the middle was employed (Figure 30A). On day 1, rats (n = 4) were placed 
inside this chamber and allowed to explore the chamber for 20 min. After 24 h, animals were 
placed back to the same box and were given 20 min for habituation before being subjected to 
six stimuli pairs of tone (20 s, 68 db, 10 kHz) and shock (0.5 s, 0.8 mA), which co-terminated 
with the tone. The trials were separated by an intertrial interval of 100 ± 20 s. After exposure 
to the tone and foot shock, rats were kept in the chamber for a further 2 min before returned to 
their housing cages. No illumination was provided during the habituation and FC phases. 
Chamber 1 was wiped with F10Sc after each rat. On days 3 and 4, rats received FE training in 
chamber 2, which was illuminated with 15 Lux white light (Figure 30B). To create a different 
experimental environment, chamber characteristics were changed based on odour, visual and 
tactile cues. The chamber was changed to a shorter rectangular size (450 × 300 × 250 mm) with 
black/white stripes on the front wall and 15 Lux white light illumination. On the floor of the 
chamber, a layer of paper towels and bedding materials was provided and sprayed with 70% 
ethanol to offer a distinct smell. Chamber 2 was wiped with F10Sc followed by 70 % ethanol 
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after each rat. In the first FE session, rats were placed into the new chamber, where they were 
exposed to 30 trials of the same tone signal (68 db, 10 kHz, 20 s) with 100 ± 20 s intervals. 
After 24 h, animals were exposed to a FE session of 15 trials using identical settings. On the 
last day, a PE testing phase was conducted by exposing the animals to 6 trials of the same tone 
signals in chamber 2 without illumination. The freezing duration during the tone signal was 
recorded and used as an indicator of fear. 
 
Figure 30. Two chambers that used in the optimization experiment of the fear extinction 
(FE) model.  
 
2.3.11.2 Model application 
In this experiment, chamber 1 was used (Figure 31A). However, in order to increase the 
discrimination between 2 chambers and to reduce the fear of rats towards the grids, a grey insert 
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with a smooth surface was placed underneath the chamber to cover the steel grids (Figure 
31B). 
 
Figure 31. The changes made to chamber 2 of the fear extinction (FE) model.  
 
Rats were given a daily dose of idebenone (200 mg/kg/day, see 2.4.1.2 for details of idebenone 
preparation) between 5:30 and 6:00 pm for 7 days prior to the conduction of the FE procedure. 
The drug was continuously administrated until the end of day 3. To minimize the stress 
associated with the transfer from the Bio-Bubble pavilion to the behavioral room, the animals 
were transferred once a day for 3 days prior to the experiment. Each day animals were 
habituated to the behavioral room for 30 min under 30 Lux illumination before being returned 
to the Bio-Bubble pavilion. 
Minor changes were made to the protocol used in the preliminary study, in order to enhance 
the effect of FC training to generate fear towards the tone. Briefly, on day 1 rats were habituated 
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to chamber 1 for 30 min before returned to their home cages. On day 2, after another 2 min 
habituation period, they were exposed to six pairs of tone (30 s, 75 db, 4 kHz) and shock (1 s, 
0.8 mA, co-terminated with the tone) with a scrambled intertrial interval of 100 ± 50 s between 
pairs. Chamber 1 was cleaned with F10Sc between rats. For FE training, rats were presented 
with 8 trials of the same tone signals with the same duration of intertrial interval in chamber 2, 
followed by another 2 min delay before placing them back to their home cages on day 3. 
Chamber 2 was wiped with 70 % ethanol between animals. The PE test was performed 
approximately 24 h after the FE training (Figure 32). Red light illumination (15 Lux) was used 
throughout the experiment. 
 
Figure 32. Protocol of the fear extinction (FE) model. 
 
2.3.11.3 Data collection and analysis 
Freezing behaviour is defined as the lack of movement except movement required for 
respiration. In the experiment, ‘freezing duration’ was recorded when the freezing behaviour 
of rats was greater than 3 s and encompassed the total length of time the rat kept still (647). 
Freezing response is represented as percentage of freezing duration in response to a 30 s tone. 
The freezing response is automatically recorded by the FC software of the MCS in seconds, 
while the freezing (% time) of each rat is calculated manually by adding up all recorded 
freezing times during a tone signal and then divided by 30.  
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2.3.12 Transcardiac perfusion fixation 
2.3.12.1 Equipment and preparation of anesthetics  
2.3.12.1.1 Isoflurane stinger 
A mobile isoflurane stinger contains isoflurane vaporizer, oxygen supply, gas supply regulator 
and flowmeter (0 – 1000 mL/min). The system was checked before each use to ensure adequate 
amounts of supply gas and isoflurane were available for the following procedure. Then the 
connection between induction chamber and the stinger was checked to ensure adequate flow 
of anesthetic gas into the chamber. After this system check, both oxygen supply and isoflurane 
vaporizer were turned on. 
  
2.3.12.1.2 Perfusion bench and peristaltic pump 
The perfusion fixation procedure was performed in a fume cupboard. A plastic box with steel 
net on the top was used to support the rat body and to collect blood. Bottles of ice cold sterilized 
PBS and 4 % PFA in PBS were placed on the side of the peristaltic pump. The tubes of the 
perfusion pump were flushed with PBS to remove residual bubbles before use.  The flow rate 
for PBS and PFA was set as 20 mL/min. In addition, 50 mL centrifuge tubes with ice cold 4 % 
PFA solution was placed inside the fume cupboard for brain tissue collection.  
 
2.3.12.1.3 Pentobarbital sodium 
 Stock solution of pentobarbital sodium (325 mg/mL) was diluted with sterilized saline to 60 
mg/mL and used at a dose of 200 mg/kg. 
 
2.3.12.2 Perfusion fixation 
Rats were placed in the induction chamber and anesthetized using 5 % isoflurane delivered at 
a rate of 800 mL/min. Once the animal was anesthetized, pentobarbital sodium (200 mg/kg at 
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60 mg/mL) was injected (i.p., 29G ½” needle). After the absence of pedal reflex was confirmed, 
a wide incision was made with a scalpel through the abdomen. With sharp scissors, the 
connective tissue at the bottom of diaphragm was cut to allow access to the rib cage. Then the 
thoracic cavity was opened up with larger scissors along the sidelines of the rib cage and 
clamped open to expose the heart and to provide drainage for blood and fluids. While holding 
the beating heart steady with forceps, the perfusion needle was inserted vertically directly into 
protrusion of the left ventricle and secured in this position by clamping near the point of entry. 
As soon as an incision was made in the atrium with sharp scissors to allow circulation, PBS 
was pumped through the rat’s body. Then 4 % PFA was delivered to fix the brain tissue. Both 
PBS and PFA were delivered at a rate of 20 mL/min. The perfusion fixation was terminated 
when pale eyes and a stiff body were observed. At the end of the perfusion fixation, brain tissue 
was collected into 50 mL centrifuge tubes. The brain samples were kept at 4 ºC overnight for 
immersion-fixation, before proceeding to dehydration and embedding. 
 
2.3.13 Blood collection 
2.3.13.1 Preparation of EDTA-coated tubes 
Blood was extracted from the rat’s heart immediately prior to perfusion fixation and collected 
using 0.5 M EDTA (pH 8.0) -coated 1.5 mL Eppendorf safe-lock tubes. EDTA powder was 
dissolved in MilliQ water to prepare a 0.5 M stock and adjusted to pH 8.0 before autoclaving. 
The final solution was stored at room temperature. This 0.5 M EDTA solution was used as 
anticoagulant. EDTA-coated 1.5 mL Eppendorf tubes were prepared fresh by adding 1.5 mL 
EDTA into the tubes. After 1 min, EDTA was transferred into other tubes in sequence. In the 
last, 0.5 M EDTA was loaded into the coated tubes at an EDTA/blood ratio of 1:100. All tubes 
and pipette tips were pre-cooled to 4ºC.  
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2.3.13.2 Plasma collection 
In present study, plasma was collected to quantify the levels of stress hormones such as cortisol 
as indicator of HPA axis function. Before inserting the perfusion needle into the heart, blood 
was extracted and transferred into the EDTA-coated 1.5 mL Eppendorf tubes. Then the blood 
sample was centrifuged immediately at 10,000 × g for 90 s at room temperature. Supernatants 
were stored at -80 ºC for further analysis. 
 
2.3.14 Statistical analysis 
The data of all behavioural tests were automatically recorded by the MCS software. Recorded 
videos from the novel object recognition model were analysed using VideoMot 2. The in vitro 
and in vivo data were expressed as mean ± standard deviation (SD) and mean ± standard error 
(SEM) respectively, as indicated in the figure legends. Determination of statistical significance 
was performed using Student t test, (repeated) one-way or (repeated) two-way Analysis Of 
Variance (ANOVA) followed by Tukey’s or Dunnett’s multiple comparison tests where 
appropriate using GraphPad Prism. Images obtained from histological analysis were analysed 
using Fiji ImageJ. In all assays, p<0.05 was considered as statistically significant and the results 
were represented as mean ± SEM, in presence of the value of degrees of freedom DFn (= a – 
1, where a is the number of groups) and DFd (= N - a, where N is the total number of subjects 
in all groups). All figures were assembled using Photoshop CS6.  
 
2.4 Ex vivo study 
2.4.1 Western blot 
2.4.1.1 Materials 
Rats that were used in the morphine and imipramine study were decapitated straight after 
isoflurane anesthesia (see 2.3.10.1.1 for isoflurane vaporizer setup). The brain was removed 
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immediately into a cryotube and snap-frozen in liquid nitrogen, before stored at -80 ºC for 
western blot (WB) analysis. To determine the impact of the snap-freezing procedure on protein 
stability, fresh tissue was also tested as in parallel. Snap-frozen rat liver microsomes were 
donated by another group and used as positive control for the analysis. 
 
2.4.1.2 Protein extraction and sample preparation 
Both hemispheres of the brain were cut into 3 sections in coronal direction, including anterior 
(½) cerebrum, posterior (the other ½) cerebrum and cerebellum. Ice cold protein lysis buffer 
(50 mM Tris-HCl, pH 7.4, 1 % NP-40, 0.5 % Na-deoxycholate, 0.1 % SDS, 150 mM NaCl, 2 
mM EDTA, 50 mM NaF, 10 µM DTT, 100 µM PMSF and 10 µM Na3VO4) was added to the 
weighed tissue at a ratio of 8 µL/mg tissue. The tissues were homogenized manually on ice 
using a pestle method, before being transferred into 1.5 mL Eppendorf tube for vortexing over 
a 15 min period at 4 ºC. Then the lysate was homogenized further using an ultrasonic 
homogenizer (3 x 10 s, with 1-2 min intervals).  The resulting lysate was centrifuged at 22,000 
× g for 20 min at 4 ºC. The protein content in the supernatant was determined as described in 
2.2.2.2. The supernatant was diluted with protein lysis buffer and 4x Laemmli buffer (40 % 
glycerol, 240 mM pH 6.8 Tris-HCl, 8 % SDS, 0.04 % bromophenol blue, 5 % beta-
mercaptoethanol) to a concentration of 5 µg/µL and stored at -20 ºC until use. 
 
2.4.1.3 Gel electrophoresis 
Eight percentage of gels were cast (375 µM Tris pH 8.8, 7.8 % acrylamide, 0.1 % SDS, freshly 
added 0.1 % APS and 0.1 % TEMED) in a commercial mini-gel apparatus. 1 mL of isopropanol 
was layered on top of the separating gel to smooth the border and avoid exposing the top of gel 
to oxygen. After 20 min, isopropanol was removed and the top of the gel was cleaned with 
milliQ water. The stacking gel (126 µM Tris pH 6.8, 3.9 % acrylamide, 0.1 % SDS and freshly 
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added 0.15 % APS and 0.14 % TEMED) was poured on the top of the separating gel after the 
inside of the glass plates was dried with filter paper. A comb was positioned into the stacking 
gel. After 10 min, the comb was slowly removed and the wells were rinsed thoroughly with 
MilliQ water to remove non-polymerized acrylamide. Running buffer (25 mM Tris base, 192 
mM glycine, 10 % SDS) was partially loaded into the wells for the ease of loading samples. 10 
µL of 5 µg/µL protein samples were denatured for 5 min at 95 °C and loaded into each well. 
The gel cassette was then placed into the electrophoresis chamber, which was filled with 
running buffer (7 mM SDS, 50 mM Tris and 38.4 mM glycine, pH 8.3). The proteins were 
separated at a constant 25 mA per gel.  Protein transfer from separating gel onto a nitrocellulose 
membrane was carried out by assembling a sandwich of gel, membrane and Whatmann filter 
paper cut to 5.3 × 8.1 cm. The sandwich was placed inside a holder and submerged in the 
apparatus with transfer buffer (25 mM Tris base, 192 mM glycine, 10 % SDS, 20 % methanol) 
with the gel facing the anode. The transfer was performed at a constant voltage (100 V) for one 
hour at 4 °C. Subsequently, the membrane was briefly washed in MilliQ water and then blocked 
using 5 % skimmed milk powder in Tris-buffered saline with 0.1 % Tween-20 (TBS-T) for 1 
h, before incubation with anti-MAOA antibody solution (ab126751, 1:1000 in blocking buffer) 
overnight at 4 °C. The next day, the membrane was washed 3x 10 min with TBS-T and then 
incubated with anti-rabbit horseradish peroxidase-conjugated secondary antibody (ab97051, 
1:5000) in blocking buffer for 1 hour at RT. The membrane was washed 4x 10 min with TBS-
T. Antibody binding was visualized using an Amersham Imager with enhanced 
chemiluminescence western blotting reagent according to the manufacturer’s instructions. 
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2.4.2 Histology 
2.4.2.1 Tissue fixation and dehydration 
All brain tissues were dehydrated in 70 % ice cold ethanol for 7 days at 4 ºC, after being 
immersed in 4 % PFA (in PBS, pH 7.4) overnight.  
 
 2.4.2.2 Tissue processing 
 Table 5. Processing steps of rat brain tissue for histology. 
 
The rat cerebellum was removed before briefly dissecting the remaining tissue into four 
portions at 10 mm, 12 mm, 14 mm and 16 mm respectively away from the top of the olfactory 
bulb. Among these portions, the ones containing the hippocampus were kept for further 
processing. In such way, the hippocampus was divided into 2 parts, which separately contained 
the anterior and the posterior areas of the hippocampus. The dissection points were selected 
based on the online Rat Atlas tool (http://labs.gaidi.ca/rat-brain-atlas/). Tissue was processed 
using a Leica ASP200 auto-processor. To ensure the success of paraffin wax infiltration, water 
was completely removed following a series of dehydration steps using increasing concentration 
of ethanol. The tissue was infiltrated with paraffin wax after being cleared in xylene (Table 5).  
 
 
Solution Duration (Min) 
Temperature 
(˚C) 
Ethanol 70 % 60 37 
Ethanol 95 % 60 37 
Ethanol absolute 60 37 
Ethanol absolute 90 37 
Ethanol absolute 90 37 
Ethanol absolute 120 37 
Xylene 60 37 
Xylene 60 37 
Paraplast wax 60 60 
Paraplast wax 60 60 
Paraplast wax 60 60 
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2.4.2.3 Embedding and sectioning 
Two parts of the hippocampal rat brain were  embedded into a single paraffin wax block using 
a metal mould. A Leica 2250 microtome was initially adjusted to 10 μM for coarse sections 
followed by 5 μM sections when the anterior hippocampus was reached (Figure 33). Every 
100 sections was considered as a group and labelled in alphabetical order, thus approximately 
400 sections were produced. Due to limited availability of antibody, only the 50th section of 
the second group was collected for analysis. Therefore, 5 - 8 slides were stained for each group 
(one slide per rat). 
 
 
Figure 33. Brain area of interest. 
Both anterior and posterior hippocampal sections were collected and the dentate gyrus 
region was focused on for the histological analysis (as marked by red lines). 
 
2.4.2.4 Immunohistochemistry 
Paraffin sections were placed in a heater at 60 ˚C for 20 min to melt the wax and help specimen 
attachment to the Dako IHC slides. Then sections were dewaxed and rehydrated in fresh xylene 
twice for 10 min each, 100 % ethanol, 95 % ethanol, 70 % ethanol, MilliQ water and RT PBS 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, pH 7.4) for 5 min each. Then 
antigen retrieval was achieved by heat (pressure cooker method in 10 mM citrate buffer pH 6.0 
for 20 min), followed by 3 washes with PBS for 10 min each. 
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2.4.2.4.1 Fluorescent IHC staining 
After PBS washing,  sections were blocked with 10 % horse serum and 0.2 % Triton X-100 in 
PBS for 1 h at RT, before incubation with either primary antibodies against MAO-A 
(ab126751, 1:200) in antibody diluent (1 % horse serum, 0.2 % Triton X-100 in PBS) or 
blocking solution (200 µL per slide) overnight at 4 ˚C. After the sections were rinsed three 
times with PBS-T (0.1 % Tween-20 in PBS) for 10 min each, they were allowed to react with 
goat anti-rabbit Alexa Fluor® 594 (ab150084, 1:2000) for 2 h at RT, followed by another 3 
washes with PBS-T. The sections were subsequently incubated with DAPI solution (1:5000 in 
PBS) before being mounted with Dako florescent mounting medium and left to dry overnight. 
Nikon NIS-Elements D413 (64-bit) suite was used to acquire fluorescence images. Digital 
images were mounted into panels and labelled with Adobe Photoshop Software CS6. 
 
2.4.2.4.2 DAB immunohistochemistry 
After PBS washing, sections were incubated with 1 % hydrogen peroxide for 5 min at RT to 
block endogenous peroxidase activity, followed by three washes with PBS for 5 min each. To 
block non-specific background staining, the sections were blocked (4 % milk, 10 % horse 
serum, 5 % BSA, 0.2 % Triton X-100 in PBS) for 1 h at RT before incubating with primary 
antibody against nitrotyrosine (A21285, 1:300) in antibody diluent (2 % milk, 1 % horse serum, 
0.2 % Triton X-100 in PBS) overnight at 4 ˚C. Then sections were reacted with biotinylated 
anti-rabbit IgG (PK-4001, 1:200) for 1 hr at RT before incubated with ABC solution (PK-6100) 
for 30 min. The histological signal was developed by incubating the sections with DAB 
solution (3:100) for 5 min, followed by counterstaining with hematoxylin (protocol see 
2.4.2.4.3). The sections were dehydrated (fresh 90 % ethanol, absolute ethanol twice and xylene 
1 and 2 for 5 min each) and mounted using an auto-coverslipper. Finally, the mounted sections 
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were examined using light microscopy (Leica DM 2500). Digital images were assembled into 
panels and labelled with Adobe Photoshop Software CS6. 
 
2.4.2.4.3 Hematoxylin staining 
The sections were incubated with Dako hematoxylin solution for 5 min and washed in running 
water until the tissue turned pink (color change was monitored using light microscopy). Then 
the sections were exposed to 0.2 % ammonia water for 30 s before washed in running water 
until a blue color developed.  
 
2.4.3 Imaging analysis 
DAB immunohistochemistry and fluorescent IHC images were acquired using light and 
fluorescence microscopy respectively at 20 x magnification. Images were analysed using Fiji 
ImageJ. Briefly, the color of all images was changed to greyscale as the initial step. Then the 
region of interest (ROI) was manually selected on the acquired images based on the anatomic 
structure of the HPC, by outlining the granular cell layer of the hippocampal DG. Threshold 
adjustment is an essential step in imageJ analysis to segment grayscale images into features of 
interest and background. To obtain uniform threshold values for all images, initially the 
staining intensity of the negative control was examined using imageJ. For this, both lower and 
upper thresholds were adjusted to identify the threshold values that would not pick up any 
staining signals from the image of negative control. Subsequently, individual lower and upper 
threshold values of the samples stained with the primary antibody were adjusted based on the 
identified threshold values of the negative control. Using this approach, the lower and upper 
threshold values were set to 48 and 116 respectively for all analyzed images. This procedure 
ensured that only intense staining in dark grey to black color was detected, while pale signals 
of comparable intensity to the negative control were excluded (Figure 34). Any images that 
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would have required different thresholds were excluded from the analysis. In the last step, the 
ratio of positive staining in relation to the ROI was determined and the results were presented 
as % area.  For immunohistochemical quantification, blinding to the treatment groups was not 
performed because ROI selection was fully based on anatomical structure, which was clearly 
visible in the images with very little scope for investigatot bias. In addition, oxidative damage 
was scored using the image analysis method described above with little potential for 
investigator bias.The data was further analysed using GraphPad Prism (Version 6) and the 
average values calculated from 5-8 slides per group was used to represent the data. 
Figure 34. Quantification of IHC images using Fiji ImageJ. 
Three basic stages to analyze histological staining images were used that included changing 
image color, setting contrast and threshold and selecting an area of interest.  
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Chapter 3   Optimisation of Behavioural Animal Models  
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Based on the reported antidepressant-like effects of both clinical used and experimental opioids 
(288,332), we aimed to test the effects of novel UTAS-synthesized bifunctional opioids on 
depression and depression-associated comorbidities such as stress-induced analgesia, anxiety 
and cognitive dysfunction. To ensure the validity of the results, all behavioural models needed 
to be optimised before drug-induced effects on animal behaviours could be determined.  
 
3.1 Optimising the light and dark model 
Anxiety-like symptoms were assessed in the LD model (648). This model uses a two-
compartment chamber, of which one compartment is illuminated with white light while the 
other is darkened. To optimise the experimental settings, different light intensities were tested 
in this model using male Sprague Dawley (SD) rats (n=3) over a period of 5 min. With 
increasing light intensities between 0 and 100 Lux, the animal spent an increasing amount of 
time in the darkened compartment, indicative of increased levels of anxiety-like symptoms. 
From 30 Lux onwards, animals spent significantly more time in the darkened chamber 
compared to basal levels at 0 Lux (repeated 1-way ANOVA, 30 Lux: (70.79 ± 6.156) s,  
p=0.00028; 50 Lux: (97.45 ± 4.827) s, p<0.0001 and 100 Lux: (99.30 ± 2.476) s p<0.0001) 
(Figure 35). 
Figure 35. Optimisation of the light and 
dark (LD) model.  
The impact of light intensity on anxiety-
like behaviour of rats was investigated in 
the LD model using a two-compartment 
chamber. The experiment was conducted 
on 6 consecutive days with the same 
animals (n=3) by testing one light intensity 
per day. The data represents as 
percentage of time spent in the dark 
compartment over a 5-minute period. 
***p<0.001 and ****p<0.0001 versus basal 
level at 0 Lux using repeated one-way 
analysis of variance (ANOVA) followed by 
Dunnett comparison tests. Error bar=SEM. 
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3.2 Optimising the learned helplessness model 
Depressive-like symptoms of rats were assessed using the LH model, which exposes animals 
to IS. Three crucial parameters, the number of induction sessions, the number of shocks and 
the length of the interphase interval were optimised using an automated MCS. Learned 
helplessness occurs when an animal is repeatedly subjected to an aversive stimulus that it 
cannot escape. As a consequence, the animal will stop trying to avoid the stimulus even when 
they are allowed to escape. This unwillingness to escape is indicative of depressive-like 
symptoms and is quantified as the number of escape failures (EF). In the first experimental 
design, rats were only subjected to one induction session, containing 60 trials of 0.8 mA 
inescapable foot shocks with average 60 s intertrial interval (Figure 36A). No significant 
differences between the stressed (IS) and non-stressed (NS) animals after a 24 h interphase 
interval was detected (Figure 36A). Therefore, one more induction session was included in the 
second experimental design, which showed a trend towards increased number of escape 
failures in the 1st test that, however, did not reach significance. No differences between IS 
group (7.14 ± 1.461 attempts) and NS group (5.62 ± 1.500 attempts) could be detected in the 
2nd test (Figure 36B). To increase the number of escape failures in the stressed animals, 180 
instead of 120 inescapable foot shocks were delivered during the induction phase. Under these 
conditions, rats now showed significantly (repeated 2-way ANOVA, p=0.0342) increased 
escape failures in the 1st test (NS: 8.635 ± 2.490 attempts, IS: 18.901 ± 1.872 attempts) 
(repeated two-way ANOVA: time: F (1, 4) = 4.787, p=0.0939, treatment: F (1, 4) = 26.06, 
p=0.0070, time × treatment: F (1, 4) = 0.1915, p=0.6843), while no significant increases in the 
2nd test (NS: 5.520 ± 1.500 attempts, IS: 13.426 ± 1.361 attempts) (Figure 36C). Finally, to 
assess the impact of the interphase interval on the development of depressive-like symptoms, 
a 48 h interval was introduced between the induction phase and testing phase. This change 
resulted in significantly increased escape failures in the IS group in 3 consecutive testing 
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sessions (T1: NS: (6.124 ± 1.861 attempts), IS: (22.500 ± 2.453 attempts), p=0.0180; T2: NS: 
(7.346 ± 3.114 attempts), IS: (23.450 ± 5.861 attempts), p=0.0207; T3: NS: (6.983 ± 2.104 
attempts), p=0.0105) (repeated 2-way ANOVA: time: F (1, 6) = 0.06842, p=0.9346; treatment: 
F (1, 6) = 54.76, p=0.0003; time × treatment: F (2, 6)=0.1105, p=0.8971) (Figure 36D).  
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3.2.1 Number of induction sections, intertribal interval and number of shocks 
 
Figure 36. Optimisation of the learned helplessness (LH) model. 
Three important parameters of the learned helplessness model: 1) numbers of induction 
sessions, 2) number of foot shocks and 3) the length of interphase interval were optimised in 
rats. Rats received either no foot shocks (NS, n=3) or inescapable foot shocks (IS, n=3) during 
the induction phase(s). Number of escape failures was measured in consecutive test sessions 
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(T) with 30 trials per session, after a variable length of interphase interval. The effect of one 
induction session on inducing depressive-like symptom was assessed (A), followed by 
assessment on two induction sessions (B). Different number of inescapable foot shocks were 
tested (C), prior to the optimisation on the length of interphase interval (D). *p<0.05 versus 
the NS group using repeated two-way Analysis of variance (ANOVA) followed by Sidak 
comparison tests. Error bar=SEM. 
 
3.2.2 Different types of foot-shocks 
To ensure the validity of IS in inducing depressive-like symptoms, ES were used as control to 
demonstrate that resulting symptoms were due to the inescapability of shocks rather than 
shocks per se. Rats exposed to IS exhibited significantly increased EFs in 3 consecutive tests 
(T1: (26.000 ± 1.000 attempts), T2: (24.200 ± 1.467 attempts), T3: (23.571 ± 1.131 attempts)), 
compared to NS group (T1: (7.000 ± 2.345 attempts), T2: (3.750 ± 1.436 attempts), T3: (6.750 
± 3.838 attempts)) (repeated 2-way ANOVA, time: F (2, 47) = 0.03207, p=0.9685, treatment: 
F (2, 47) = 44.50, p<0.0001, time × treatment: F (4, 47) = 0.8136, p=0.5229). As expected, no 
significant increases in the ES group were observed, compared to the NS group, it did not reach 
significance in comparison with NS group (Figure 37B). 
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Figure 37. Effects of inescapable foot shocks on inducing depressive-like symptoms. 
Rats exposed to either inescapable shocks (IS, n=8), escapable shocks (ES, n=6) and no shocks 
(NS, n=5) in the learned helplessness model with 2 induction training sessions. During the 
tests, the intervals between testing trials were set as 30 s ± 25 % (scrambled ITI) (A). The data 
is represented as the number of escape failures from three consecutive testing (T) sessions 
with a 24 h interval between sessions (B). ****p<0.0001 using repeated two-way analysis of 
variance (ANOVA) followed by Tukey multiple comparison tests. Error bar=SEM, ns=no 
significance. 
 
3.3 Optimising the novel object recognition model 
Memory loss has been frequently reported in the patients with depression (649). To investigate 
the effects of IS and novel drugs on depression-associated cognitive deficits, the NOR model 
was used, which is based on the tendency of rodents to spend more time exploring novel objects 
than familiar ones (650), while stressful situations usually impair object recognition (651). 
Briefly, the NOR model contains two phases: object learning and memory testing. In the 
learning phase, two identical objects are used while in the testing phase, one of the familiar 
objects is replaced with a novel object.  
 
3.3.1 Persistence of natural memory in rats 
To establish how long the animals memorize familiar objects in our laboratory setting, their 
natural memory was measured without stress exposure. In the first experiment, the animals 
spent (85.49 ± 6.300) % total object exploring time with the novel object after learning the 
familiar objects on 2 consecutive days, compared to the last day of test(repeated one-way 
ANOVA, time: F (3, 6) = 4.043, p=0.0156) (Figure 38). 
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Figure 38. Persistence of natural 
recognition memory in rats. 
The natural recognition memory of 
rats was measured in the novel 
object recognition (NOR) model. Rats 
received 2 learning (L) sessions on 
days 1 and 2, followed by assessment 
of memory on 4 consecutive days (A). 
The data is represented as the 
percentage of time spent exploring 
novel objects to the total exploring 
time on both objects over a 5-minute 
period (B). **p<0.01 versus day 3 
using repeated one-way analysis of 
variance (ANOVA) followed by Tukey 
multiple comparisons test. Error bar=SEM, n=3.  
 
3.3.2 Effect of stress exposure on learning and memory 
To evaluate effect of inescapable foot shocks on recognition memory in rats, in a second 
experiment, animals were exposed to 2 sessions of IS inductions (I) in the LH model, prior to 
memory learning session. Each IS induction session contained 90 trials of 0.8 mA inescapable 
foot shocks (Figure 39A). Object learning was conducted over a 15 min period, 10 min after 
the stress exposure. In the following memory test (24 h after the 2nd learning session), rats spent 
significantly more time exploring the novel object (familiar object: 28.60 ± 10.75 s, novel 
object: 82.4 ± 12.48 s, p=0.0309) (unpaired Student t test, t (4) = 3.266) (Figure 39B), 
suggesting that the foot shocks did not affect memory if the learning is conducted shortly after 
the stress exposure. This finding is in conflict with current clinical observations, where memory 
loss is reported in depressed patients (649).  
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Figure 39. Effect of stress exposure on 
instant learning. 
Rats received 2 inescapable-shock (IS) 
induction sessions in the learned 
helplessness (LH) model, 10 min before the 
object-learning (L) sessions in the novel 
object recognition (NOR) model on days 1 
and 2. Memory of rats was measured in a 
single memory test over a 5 min period on 
day 3 (A). The data is represented as the 
percentage of time spent exploring familiar 
and novel objects respectively to total 
exploration time during test (B). *p<0.05 
was calculated using unpaired Student t 
test. Error bar=SEM, n=3.  
 
 
In a third experiment, object-learning sessions were carried out 24 h after the stress exposure. 
To parallel the LH and NOR tests, both learning sessions were conducted on the same day, 
during the interphase interval of the LH model. To ensure that rats learn familiar objects 
successfully, they received the 1st memory test 30 min after the 2nd object-learning session. In 
this scenario, no significant changes on % time spent on novel object exploration were 
observed in all testing sessions over a 5 min period (T1:73.64 ± 9.629 %, T2: 47.16 ± 22.484 
%, T3: 44.16 ± 10.574 %) (multiple t test, T1: t (4) = 1.082, T2: t (4) = 0.1207, T3: t (4) = 
2.061)(Figure 40).  
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Figure 40. Effect of shock exposure on 
object learning and memory. 
Rats were given 2 inescapable shock (IS) 
sessions in the learned helplessness (LH) 
model on days 1 and 2. Two object-
learning (L) sessions of the novel object 
recognition (NOR) model were 
conducted 24 hours after IS exposure on 
day 3. There were 7 h interval between 
these two learning sessions. The 1st 
memory test (T1) was carried out 30 
minutes after L2. T2 and T3 were 
conducted on days 4 and 5 respectively 
(A). The data represents the percentage 
of time spent exploring novel object to 
total object exploration time over a 5 
min period (B). Statistical analysis was 
performed using multiple t tests with Holm-Sidak correction. Error bar=SEM, n=3, ns=no 
significance.  
 
3.4 Optimising the fear extinction model 
To further investigate the effects of stress and drug treatment on learning and memory of rats, 
the FE model was used, which requires active learning to dissociate a stress-induced fear from 
a stimulus (646). There are four phases in this model: habituation, FC or fear acquisition, FE 
learning and PE testing. In this experimental design, 2 different chambers were used. One was 
used for the habituation and FC phases, and the other was used for the FE training and PE tests. 
Illumination was only applied for the FE phase. In the FC phase, animals acquired fears to a 
sound signal through pairing the sound with a foot shock. Overall, no significant changes were 
observed across all phases (Figure 41B-E).  
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Figure 41. Optimisation of the fear extinction (FE) model. 
The fear conditioning and extinction of rats were tested in the fear extinction (FE) model (A). 
Rats received fear conditioning (FC) training without illumination in the experimental arena 
on day 2 (B), followed by 2 sessions of FE training on days 3 and 4 respectively, where a 
different experimental chamber was used. In the FE phase, the chamber was illuminated with 
15 Lux white light (C,D). The effect of extinction training was tested on day 5 (E). Duration of 
freezing during the sound signal was measured as an index of fear. The data is analysed using 
one-way analysis of variance (ANOVA) followed by Tukey multiple comparison tests, Error 
bar=SEM, n=4. 
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In the present study, multiple parameters of different pre-clinical behavioural models were 
measured as index of depression, stress perception, anxiety and cognitive dysfunction. The 
following content describes the effects of drugs in those models, which will be discussed based 
on the parameters of interest (Table 6). 
Table 6. Parameters of interest in different behavioural models.  
(LH: learned helplessness; EFs: escape failures; ITTs: intertrial interval transfers; ITI: intertrial 
interval; NOR: novel object recognition; OF: open field; TF: tail flick; HP: hot plate; FE: fear 
extinction) 
Models Measured parameters Indication  
LH 
EFs Depressive-like symptoms 
Number of avoidance Avoidance behaviour 
Mean escape latency Escape behaviour 
ITTs Physical activity 
Freezing duration during ITI Anxiety-like symptoms 
NOR Time spent on exploring objects Recognition memory 
OF 
Moving duration Physical activity 
%time spent in central area 
of OF chamber 
Anxiety-like symptoms %distance travelled in 
central area of OF chamber 
Rearing duration 
TF Tail flick latency Pain perception HP Hot plate latency 
FE Freezing duration Anxiety and learning 
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Chapter 4   The Psychopharmacological Effects of 
Morphine 
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4.1 Psychopharmacological effects of morphine in the learned helplessness model 
4.1.1 Effect of morphine on depressive-like symptoms 
After optimising the behavioural models to a stage where they produced reliable readouts, we 
evaluated the antidepressant-like effects of morphine in the LH model. Rats that were supplied 
by the UTAS animal breeding facility each week were allocated into control and/or treatment 
groups based on approach that was described in the section 2.3.4 of Chapter 2. The LH model 
was conducted in a two-compartment chamber, which was divided by a central door. Animals 
were allowed to transit between the two compartments freely. This model contained induction 
and testing phases. The induction phase was carried out with male SD rats on two consecutive 
days and included 180 trials of IS. After a 48 h interphase interval, the depressive-like 
symptoms of rats were assessed from days 4 to 6 by measuring the number of escape failures 
in each session (30 trials/session) (Figure 42A). Previously, morphine was reported to induce 
antidepressant-like effects in different pre-clinical models of depression (472,625,652). 
However, inconsistent results have been reported from different laboratories (525,653). 
Therefore, to exanimate the hypothesis of using opioids as antidepressants, and also to confirm 
the validity of the optimised LH model, morphine and the tricyclic antidepressant imipramine 
were tested. Drug treatment of rats started one hour after the 2nd IS induction training and 
subsequent injections were given from days 4 to 6 before the conduction of LH tests. The 
stressed saline-treated rats showed a significant increase in the number of escape failures across 
all tests (T1: 25.875 ± 1.125 attempts; T2: 24.250 ± 1.601 attempts; T3: 22.500 ± 1.452 
attempts), compared to the NS group (T1: 9.200 ±  2.853 attempts; T2: 5.400 ± 1.990 attempts; 
T3: 5.400 ±  3.265 attempts) (repeated 2-way ANOVA, time: F (2, 47) = 0.03207, p=0.9685; 
treatment: F (2, 47) = 44.50, p<0.0001; time × treatment: F (4, 47) = 0.8136, p=0.5229), 
whereas both morphine (T1: 10.143 ± 2.098 attempts; T2: 5.857 ± 1.668 attempts; T3: 1.143 
± 0.986 attempts) and imipramine (T1: 8.500 ± 2.262 attempts; T2: 7.167 ± 2.725 attempts; 
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T3: 5.000 ± 1.789 attempts) significantly decreased IS-induced escape failures, compared to 
the IS group (repeated 2-way ANOVA, treatment: F (2, 57) = 104.3, p<0.0001) (Figure 42B). 
 
Figure 42. Effect of stress exposure and drug treatment on depressive-like symptoms. 
Saline-treated rats received either no stress (NS, n=5) or inescapable stress (IS, n=6) induction 
training on day 1 and day 2. Stressed rats were treated with morphine (MOR, 5 mg/kg/day, 
n=7) or imipramine (IMI, 50 mg/kg/day, n=6) on day 2 and from days 4 to 6. The 
antidepressant-like effects of drugs were evaluated over 3 consecutive testing sessions from 
days 4 to 6, after a 48 h interphase interval between induction- and testing-phases (A). The 
data represents the number of escape failures over three consecutive testing sessions (T1-T3) 
(B). ****p<0.0001 using repeated two-way analysis of variance (ANOVA) followed by Tukey 
comparison tests. Error bar=SEM.  
 
4.1.2 Effect of morphine on avoidance learning 
In the induction phase of the LH model, animals learn that the outcome of foot-shocks is 
independent of their escape response. Therefore, the component of cognition is believed to be 
highly involved in the induction phase (654). In the testing phase, the animals’ ability to learn 
could also enhance their escape performance. To investigate the involvement and potential 
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interference of cognition in our LH model, two different forms of learning: avoidance and 
escape learning, were assessed. 
In the testing phase of the LH model, 30 pairs of signalled foot shocks were used. In each trial, 
a 3 s light signal was followed by a 3 s escapable foot shock. If rats transferred during the light 
signal to avoid the foot shock, the action was called avoidance. Even through exposure to IS 
can induce memory loss (Figure 40), the repeated testing pattern may still be learned by rats 
to avoid subsequent shocks, which eventually could result in false positive results in the 
treatment groups. Therefore, to evaluate if avoidance learning interfered the antidepressant-
like effects of morphine and imipramine in our LH model, the number of avoidance events 
were measured. There were no significant differences in the 1st test between the groups. In the 
2nd test, higher numbers of avoidance events were observed in all groups (Figure 43). 
Imipramine-treated rats exhibited significantly more avoidance behaviour (8.667 ± 2.728 
attempts) in comparison with the IS group (3.125 ± 1.008 attempts) (repeated 2-way ANOVA, 
p=0.0321). In the 3rd test, no significant changes were observed between the NS (3.6000 ± 
1.503 attempts), IS (3.250 ± 1.013 attempts) and imipramine-treated (7.333 ± 1.801 attempts) 
groups, whereas morphine-treated rats showed significantly more avoidance events (18.000 ± 
2.526 attempts), compared to the IS groups (repeated 2-way ANOVA, time: F (2, 54) = 16.01, 
p<0.0001; treatment: F (2, 54) = 14.07, p<0.0001; time × treatment: F (4, 54) = 6.646, p = 
0.0002). 
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Figure 43. Effects of stress exposure 
and drug treatment on avoidance 
learning. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress 
(IS, n=6) training on days 1 and 2. 
Stressed rats were treated with 
morphine (MOR, 5 mg/kg/day, n=7) or 
imipramine (IMI, 50 mg/kg/day, n=6) on 
day 2 and from days 4 to 6 (for timeline 
see Figure 8A).  The data represents the 
number of avoidance transitions over 
three consecutive testing sessions from 
days 4 to 6. *p<0.05 and ****p<0.0001 
using repeated two-way analysis of 
variance (ANOVA) followed by Tukey 
comparison tests. Error bar=SEM. 
 
4.1.3 Effect of morphine on escape learning 
In the LH model, mean escape latency is measured as the time period from the start of a trial 
to the occurrence of transfer behavior. This parameter is used to quantify the level of escape 
learning involved during the testing trials. In essence, the faster the rats stop the trial, the better 
their memory is. Similar to avoidance learning, learning the escape pattern may also lead to 
false positive results in the treatment groups. In the 1st test, IS rats showed a significantly 
shorter mean escape latency 2.520 s (± 0.557) compared to the NS group 4.032 s (± 0.109) 
(repeated 2-way ANOVA, treatment: F (2, 54) = 11.31, p=0.0072), while no significance was 
observed in the morphine 3.453 s (± 0.069), p=0.5938 and imipramine 3.457 s (± 0.101), 
p=0.4409 groups. In the 2nd and 3rd test, no significant changes were observed between all 
groups. (Figure 44). 
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Figure 44. Effects of shock exposure 
and drug treatment on escape 
learning. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress 
(IS, n=6) training on days 1 and 2. 
Stressed rats were treated with 
morphine (MOR, 5 mg/kg/day, n=7) 
or imipramine (IMI, 50 mg/kg/day, 
n=6) on day 2 and from days 4 to 6 
(for timeline see Figure 42A). The 
data represents the mean escape 
latency measured over three 
consecutive testing sessions from 
days 4 to 6. **p<0.01 using repeated 
two-way analysis of variance 
(ANOVA) followed by Tukey 
comparison tests. Error bar=SEM. 
 
4.1.4 Effect of morphine on physical activity 
Because the number of escape failures are counted only when there are no transfers between 
two compartments of the LH chamber in each trial, the measurements highly rely on the 
physical activity of animals. In essence, the more active a rat behaves during the LH test, the 
higher its chance to randomly perform an escape behaviour. In the LH model, physical activity 
is represented as the number of transitions made during the intertrial intervals (ITTs) (429). 
Since morphine was reported to increase the locomotion in rats (655), it was important to assess 
if morphine-induced increased physical activity could be involved in its antidepressant-like 
effect. Generally, no significant changes were observed in the 1st and 2nd test. While in the 3rd 
test, morphine-treated rats showed significantly increased number of ITTs (15.286 ± 1.886), 
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compared to the IS group (7.125 ± 0.915) (repeated 2-way ANOVA, time: F (2, 54) = 5.219; 
treatment: F (2, 54) = 4.025; time × treatment: F (4, 54) = 5.219, p=0.0002) (Figure 45). 
Figure 45. Effects of shock exposure 
and drug treatment on escape 
learning. 
Saline-treated rats received either 
no stress (NS, n=5) or inescapable 
stress (IS, n=6) training on days 1 and 
2. Stressed rats were treated with 
morphine (MOR, 5 mg/kg/day, n=7) 
or imipramine (IMI, 50 mg/kg/day, 
n=6) on day 2 and from days 4 to 6 
(for timeline see Figure 42A). The 
data represents the number of 
intertrial interval transfers (ITT) 
measured over three consecutive 
testing sessions from days 4 to 6. 
***p<0.001 using repeated two-way 
analysis of variance (ANOVA) 
followed by Tukey comparison tests. 
Error bar=SEM.  
 
 
4.1.5 Effect of avoidance learning, escape learning and physical activity on the 
antidepressant-like effect of morphine 
Our previous results showed that morphine-treated animals showed significantly increased 
numbers of avoidance events (Figure 43) and ITTs (Figure 44). Based on the results, we 
hypothesised that the increased avoidance counts and ITTs may contribute to the observed 
escape events in morphine-treated rats. Therefore, in order to determine whether 
avoidance/escape learning and physical activity were at least partially responsible for the 
observed antidepressant-like effect of morphine, these parameters were correlated with the 
number of escape failures using residual plots. For regression analysis, residuals represent the 
difference between the observed value of the dependent variable and the predicted value (656). 
In my case, the dependent variables include the number of avoidance events, mean escape 
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latency and ITTs. The values of residuals in this study were calculated based on the line 
regression equations of those three factors against the escape failures in the morphine-treated 
group. Randomly scatted residuals in a residual plot indicate a linear relationship between two 
variables of interest. This would suggest that the change of one variable is likely to directly 
result in changes to the other variable. Thus the two variables of interest are highly correlated 
to each other. In my study, residuals randomly scattered in all plots (Figure 46). Hence, in 
supportive of the hypothesis, the avoidance/escape learning and physical activity of morphine-
treated rats may partially be involved in or interfere with the observed escape performance of 
rats. 
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Figure 46. Correlation between avoidance 
learning, escape learning, physical activity 
and the antidepressant-like effect of 
morphine. 
Correlations were generated using residual 
plots. The values used in the plots were 
calculated from all three LH tests of the 
morphine group (n=7). Residuals randomly 
scattered in all plots indicate some 
interference of learning and locomotion 
effects on the antidepressant-like effects of 
morphine in the LH model.  
 
 
4.1.6 Effect of morphine on anxiety-like behaviour 
It is well known that exposure to stress can result in the development of anxiety symptoms 
(657,658,659). Approximately 85 % of patients with depression also experience significant 
symptoms of anxiety. Similarly, comorbid depression occurs in up to 90 % of patients with 
anxiety disorders (660). Parallel to the clinical observations, exposure to IS over a short period 
can also induce anxiety-like symptom in animals (661). To access if the IS used in our LH 
model could produce anxiety-like symptoms as that observed in previous studies, freezing 
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duration, as surrogate marker for anxiety was measured during intertrial intervals in each 
testing session. In the NS and imipramine group, no significant changes were observed across 
3 testing sessions. In the IS group, the freezing duration was significantly higher in the 2nd test 
(262.225 ± 41.548 s, p=0.0044), compared to the non-stressed rats (82.820 ± 21.387 s) (Figure 
47). In contrast, significantly decreased freezing duration was observed in the morphine-treated 
group in the 2nd (and 3rd tests compared to the IS group (T2: 108.229 ± 36.004 s, p=0.0056, T3: 
IS + MOR: 17.714 ± 17.714 s, IS: 233.250 ± 29.620 s, p<0.0001) (repeated 2-way ANOVA, 
time: F (3, 66) = 2.954, p=0.0591, treatment: F (3, 66) = 12.12, p<0.0001, time × treatment: F 
(6, 66) = 1.978, p=0.0813),.  
Figure 47. Effects of prior shock 
exposure and morphine on 
anxiety-like behaviour. 
Saline-treated rats were either 
unstressed (NS, n=5) or exposed 
to inescapable stress (IS, n=6) 
training on days 1 and 2. Stressed 
rats were treated with morphine 
(MOR, 5 mg/kg/day, n=7) or 
imipramine (IMI, 50 mg/kg/day, 
n=6) on day 2 and from days 4 to 
6 (for timeline see Figure 42A). 
The data represents the freezing 
duration measured over 3 
consecutive testing sessions 
from days 4 to 6. **p<0.01 and 
****p<0.0001 using repeated 
two-way analysis of variance 
(ANOVA) followed by Tukey comparison tests. Error bar=SEM.  
 
4.1.7 Effect of shocks and morphine on body weight 
Weight loss after exposure to shocks in the LH model has been reported previously (662). 
However, both weight loss (663) and weight gain (664) were observed in depressed patient 
resulting from personal eating habit and attitudes, suggesting a complex relationship between 
depression and weight changes in clinic. Therefore, to evaluate the influence of stress and 
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helpless emotional status on body weight in my experiment, animals were weighed over the 
entire duration of the LH procedure (Figure 48A). In all groups, no body weight changes were 
detected in all groups (Figure 48B-E). Due to the significant body weight differences of the 
animals and the attempt to use a weight based randomization scheme, the groups nevertheless 
showed different average body weights.  
 
Figure 48. Effects of shocks and treatment on body weight changes. 
Body weight changes of rats were measured throughout the experiment except on day 3 (A). 
Saline-treated rats received either no stress (B, NS, n=5) or inescapable stress (C, IS, n=6) 
training on days 1 and 2. Stressed rats were treated with morphine (D, MOR, 5 mg/kg/day, 
n=7) or imipramine (E, IMI, 50 mg/kg/day, n=6) on day 2 and days 4-6. Statistics were 
performed versus day 1 within same groups using repeated two-way analysis of variance 
(ANOVA) followed by Dunnett comparison tests, Error bar=SEM. 
 
To compare the influence of foot-shocks and treatments on body weight, the percentage 
changes in body weight were calculated (Figure 49). In both control groups, no significant % 
                                                                                                                                          Results 
157 
 
changes against the starting body weight on day 1 were detected (Figure 49A, B). However, 
in the morphine-treated group, significantly increased body weights were detected on day 5 
and day 6 (Day 1: -2.189 ± 0.796; Day 5: 1.927 ± 0.526, p=0.0062; Day 6: 1.057 ± 0.989, 
p=0.043) (repeated 2-way ANOVA, time: F (12, 100) = 2.157, p=0.0195, treatment: F (4, 100) 
= 15.06, p<0.0001, time × treatment: F (3, 100) = 10.05, p<0.0001) (Figure 49C). In the 
imipramine-treated group, a significant decrease in body weight on day 2 was observed 
(repeated 2-way ANOVA, Day 1: -1.353 ± 0.624; Day 2: -8.499 ± 1.302, p=0.00006) (Figure 
49D).  
 
Figure 49. Percentage changes in rat body weight. 
The body weights of rats were measured throughout the experiment except on day 3 (Figure 
48A). Saline-treated rats received either no stress (B, NS, n=5) or inescapable stress (C, IS, 
n=6) training on days 1 and 2. Stressed rats were treated with morphine (D, MOR, 5 
mg/kg/day, n=7) or imipramine (E, IMI, 50 mg/kg/day, n=6) on day 2 and days 4-6. The 
percentage changes of body weight in each group were calculated based on the starting body 
weight measured on day 1. Statistics were performed versus day 1 within same groups. 
*p<0.05, **p<0.01 and ***p<0.001 using repeated two-way analysis of variance (ANOVA) 
followed by Dunnett comparison tests. 
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4.2 Psychopharmacological effects of morphine in the open field test 
4.2.1 Effect of morphine on physical activity 
The OF test is widely used to measure general physical activity and anxiety in rodents (617). 
To investigate the impact of IS and treatment on physical activity and anxiety-like symptoms 
in more detail, several parameters (1. time spent on moving in the OF chamber over 5 min test 
(=moving duration), 2. percentage time spent and distance travelled in the centre of the OF 
chamber, and 3. the number of rearing) were measured. In our model, the OF test was carried 
out on the same days as the LH procedure. OF tests of controls were measured on days 1, 2 
and 6, while OF tests of the morphine group were also performed on days 4 and 5 (Figure 50A). 
Generally, no changes on total moving duration were detected between IS and NS groups 
across 3 testing sessions (Figure 50B). In the imipramine-treated group, a significant decrease 
in moving duration was observed on day 6, compared to the IS groups (IS: 161.667 ± 18.828 
s, IS+IMI: 156.400 ± 13.670 s, p=0.0041) (repeated 2-way ANOVA, time: F (2, 36) = 0.8038, 
p=0.4555, treatment: F (2, 18) = 5.736, p=0.0118, time × treatment: F (4, 36) = 7.731, 
p=0.0001) (Figure 50B). Morphine-treated rats, on the other hand, showed significant 
increased moving duration from day 4 onwards, compared to the basal levels measured on day 
1 (basal: 147.200 ± 5.416 s, day 4: 198.800 ± 14.491 s, p=0.00054, day 5: 199.667 ± 19.989 s, 
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p=0.0034, day 6: 189.700 ± 6.756 s, p=0.043) (repeated 1-way ANOVA, treatment: F (4, 25) 
= 7.515, p=0.0004) (Figure 50C). 
Figure 50. Effect of drug treatment on physical activity. 
The physical activity of rats was measured in the open field model. Saline-treated rats 
received either no stress (NS, n=5) or inescapable stress (IS, n=6) training on days 1 and 2. 
Stressed rats were treated with morphine (MOR, 5 mg/kg/day, n=7) or imipramine (IMI, 50 
mg/kg/day, n=6) on day 2 and days 4-6 (A). Time spent on moving of MOR group was 
measured throughout the experiment except day 3 (C), while moving duration of reminding 
groups was measured on days 1, 2 and 6 (B). The data represents total moving time over a 5 
min period. **p<0.01 using repeated two-way Analysis of variance (ANOVA) followed by Tukey 
comparison tests. +p<0.05, ++p<0.01 and +++p<0.001 versus basal level in the MOR group using 
repeated one-way analysis of variance (ANOVA) followed by Dunnett comparison tests. Error 
bar=SEM.  
 
4.2.2 Effect of morphine on anxiety-like symptoms 
The OF test was originally described as “a test of emotionality” (665). In this test, animals are 
subjected to an inescapable open chamber and their activities including rearing, moving, 
jumping and resting are recorded (665). When compared to naïve animals, anxious rats tend to 
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avoid entering into the central area of the testing chamber (666). In addition, activity of rearing 
has been used as an index of exploratory behavior in the OF test and reported to be reliable to 
indicate stress levels of animals (617). Three parameters, 1) percentage time spent in the central 
area of the OF chamber, 2) percentage of distance the rats travelled in the centre and 3) the 
duration of rearing are used as indicators of anxiety-like behaviour. In our study, no significant 
changes for time (Figure 51A, D), distance travelled in the central area of the OF chamber 
(Figure 51B, E) or rearing behaviour (Figure 51C, F) were observed for all groups overall.  
 
Figure 51. Effects of drug treatment on anxiety-like behaviour. 
Saline-treated rats received either no stress (NS, n=5) or inescapable stress (IS, n=6) training 
on days 1 and 2. Stressed rats were treated with morphine (E-F; MOR, 5 mg/kg/day, n=7) or 
imipramine (A-C; IMI, 50 mg/kg/day, n=6) on day 2 and days 4-6 (for timeline see Figure 49A). 
The percentage of time (A, D), percentage of distance (B, E) and duration of rearing (C, F) were 
                                                                                                                                          Results 
161 
 
measured over 5-minute period in the open field model. Statistical analysis used repeated 
two-way analysis of variance (ANOVA) followed by Tukey comparison tests; Error bar=SEM.  
 
 
4.3 Psychopharmacological effect of morphine in the light and dark model 
As above stated, exposure to stress can induces anxiety or anxiety-like symptoms in both 
humans and rodents (667). In order to evaluate the specificity of our LH model to induce 
depressive-like symptoms, the LD model for anxiety was used. The measurement of anxiety-
like symptoms was carried out on days 1, 2 and 6 before the LH procedure. The time spent in 
the dark compartment of the LD chamber over a 5-min test was measured as an indicator of 
anxiety-like symptoms. No significant changes on time spent in the dark compartment was 
observed in the IS group. On contrast, a significant decrease was detected in the 3rd LD test in 
the morphine group, compared to the 1st test (repeated 2-way ANOVA, p=0.0333) (Figure 
52B). 
Figure 52. Effects of stress exposure and morphine on the induction of anxiety-like 
behaviour. 
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Anxiety-like symptoms of rats were measured in the light and dark (LD) model. Saline-treated 
rats were exposed to inescapable stress (IS, n=6) on days 1 and 2. Stressed rats were treated 
with morphine (MOR, 5 mg/kg/day, n=7) on day 2 and days 4-6 (A). The data presents the 
percentage of time that rats spent in the dark compartment of the LD chamber and measured 
on days 1, 2 and 6 (B). *p<0.05 using repeated two-way analysis of variance (ANOVA) followed 
by Tukey comparison tests, Error bar=SEM. 
 
4.4 Effects of shocks and morphine on nociception 
Stress-induced analgesia (SIA) is a natural pain suppression response when mammals are 
exposed to aversive stressful events (668). Exposure to IS in the LH model was reported to 
induce opioidergic system-mediated SIA (669). A physiological decrease in pain perception 
could conceivably decrease the animals’ sensation and fear to the foot shocks, which would 
reduce escape failures in the LH testing sessions. To determine if the analgesic effect of 
morphine could interfere with its antidepressant-like effects, the tail-flick (TF) test and hot-
plate (HP) test were used. Both tests were performed before the LH procedure. In the TF test, 
the tail flick latency of stressed saline-treated rats significantly increased on day 2 after 
exposure to 90 IS (basal: 4.367 ± 0.170 s, day 2: 5.206 ± 0.449 s, p=0.0398), while the TF 
latency returned to basal levels on day 6 (3.128 ± 0.339 s, p=0.0006) (repeated 2-way ANOVA, 
time: F (2, 22) = 4.628, p=0.0210; treatment: F (1, 11) = 0.4875, p=0.4995; time × treatment: 
F (2, 22) = 6.026, p=0.0082). In this test, pain perception of morphine-treated rats remained 
the same in all tests (Figure 53B). In the HP test, no significant differences were detected either 
between or within groups across the three tests (Figure 53C). 
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Figure 53. Effects of stress exposure and morphine on pain perception. 
Saline-treated rats were exposed to inescapable stress (IS, n=6) on days 1 and 2. Stressed rats 
were treated with morphine (MOR, 5 mg/kg/day, n=7) on day 2 and days 4-6. Pain perception 
was measured on days 1, 2 and 6 (A) in the tail flick (TF) test (B) and the hot plate (HP) test 
(C). *p<0.05 and ***p<0.001 using repeated two-way analysis of variance (ANOVA) followed 
by Tukey comparison tests, Error bar=SEM. 
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Chapter 5   The Psychopharmacological Effects of 
Bifunctional Opioids 
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5.1 Toxicity of 1001 and 1003 in vitro 
Activation on a single receptor often produces insufficient biological activity in medical 
practice or is associated with adverse effects (670,671,672). Therefore, recent research focused 
on ligands that display multiple specificities and/or activities (673). Bi- or multifunctional 
drugs promise to display significantly improved potency due to synergistic effects and might 
produce less side effects than compounds acting at a single target (368). So far, novel DOP 
agonists have demonstrated both anxiolytic- and antidepressant-like effects in animal models. 
For example, UFP-512 decreased immobilization duration in the FST (a model of depression), 
as well as evoked more open arm visits in the elevated plus maze (a model of anxiety), which 
could be fully blocked by the selective DOP antagonists naltrindole (512). Similarly, another 
full DOP agonist SCN80 exhibited positive therapeutical effects in multiple pre-clinical models 
of anxiety and depression (674). In addition, there is some evidence that the DOP receptor can 
modulate the function of the MOP receptor. Pharmacological inhibition of DOP receptor 
activity was reported to enhance the binding and signaling of MOP receptor agonist in vitro 
(675,676). This functional interaction of both receptors is also supported by in vivo results that 
described that the DOP receptor agonists DPDPE was able to induce mild analgesic effects, 
partially by activating the MOP receptor (677). On the other hand, chronic morphine 
administration increased the expression of DOP receptors in the rat spinal cord (678). Finally, 
morphine tolerance was not observed in DOP knockout mice (355), which strongly suggests a 
possible role for the DOP receptor in regulating morphine-mediated tolerance. . Therefore, the 
rationale to develop bifunctional opioid agonists for MOP and DOP receptors is to develop 
novel drugs that can produce both antidepressant and analgesic effects at same time, while 
harbouring fewer adverse effects. 
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Both novel bifunctional opioids 1001 (also called UFP505) and 1003 were synthesised in 
cooperated with the School of Chemistry. Both purity of 1001 and 1003 was assessed by our 
collaborators (Department of Chemistry, University of Tasmania) using standard analytical 
techniques (LC-MS/MS, NMR) and the compounds used in this study always showed a purity 
of above 98%. Based on a previous report (679) and so far unpublished data (manuscript in 
preparation) derived from another PhD student at UTAS  (A. Paul), the bifunctional opioid 
1001 (Figure 54A) simultaneously activates the MOP receptor and blocks the DOP receptor. 
In contrast, the closely related compound 1003 (Figure 54B) simultaneously activates both 
MOP and DOP receptors. 
Figure 54. Chemical structures of 1001 and 1003. 
Both novel bifunctional opioids show selectivity for both mu-opioid (MOP) and delta-opioid 
(DOP) receptors but display different activities. 
 
Since morphine is a potent MOP agonist with a range of behavioural effects in our models, we 
hypothesized that 1001 and 1003 could also show potential behavioural effects in the same 
model. However, before testing this possibility in vivo we assessed the safety profiles of 1001 
and 1003 in vitro. The toxicity of both novel opioids was tested with regards to cellular 
bioenergetics and proliferation. For this purpose, we assessed cellular ATP levels and protein 
content in the hepatocarcinoma cell line (HepG2) in the absence and presence of these novel 
compounds. Typically for small molecular drugs, the highest concentrations are observed in 
the liver. Therefore HepG2 cells were selected as a commonly used cell culture test system to 
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predict potential liver toxicity in vivo. The cells are well characterized and highly sensitive to 
different kinds of xenobiotics and cytotoxic compounds and are therefore routinely used in 
drug discovery (680,681). In addition, cellular ATP levels were also standardised on protein 
content and drug effects were expressed as a percentage of untreated control. Significantly 
increased ATP levels/mg protein were observed in morphine-treated cells after 6 hours 
(untreated cells: 105.21 ± 7.36 %, morphine-treated cells: 120.90 ± 9.87 %; p=0.0170), 
compared to untreated cells (Figure 55A). After both 12 and 24 hour incubations, 1003-treated 
cells showed significant increased ATP levels (12-hour: untreated cells: 115.64 ± 6.82 %, 
1003-treated cells: 138.79 ± 10.86 %, p=0.0001; 24-hour: untreated cells: 131.22 ± 11.51 %, 
1003-treated cells: 173.96 ± 7.06 %, p<0.0001). In contrast, after 24 hour incubation a 
significant drop of ATP/mg protein content was detected in the 1001-treated cells (1001-treated 
cells: 81.36 ± 9.55 %) (2-way ANOVA, time: F (4, 80) = 49.97, p<0.0001; treatment: F (3, 80) 
= 30.54, p<0.0001; time × treatment: F (12, 80) = 19.59, p<0.0001) (Figure 55A). A significant 
increased protein content was observed after 24 hours of incubation in the 1003-treated cells, 
compared to the untreated cells (untreated cells: 106.23 %, 1001-treated cells: 62.14 %, 1003-
treated cells: 127.86 %). However, the opposite was seen in the 1001-treated cells (2-way 
ANOVA, time: F (4, 80) = 4.789, p=0.0243; treatment: F (3, 80) = 9.375, p=0.00626; time × 
treatment: F (12, 80) = 3.549, p=0.0361) (Figure 55B).  
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Figure 55. Effects of 1001 and 1003 
on cell viability. 
Cell variability was measured using 
liver hepatocellular carcinoma 
(HepG2) cells. Cells were incubated 
with 0.01 mM of morphine (MOR), 
1001 and 1003 respectively for 
different period (0 – 24 h). Toxicity 
was assessed as ATP/mg protein (A) 
and protein content (B) in the lysate 
(mg/ml). The data represents the 
average of three independent 
experiments and is expressed as 
percentage of the untreated control. 
*p<0.05, ***p<0.001 and ****p<0.0001 
using two-way analysis of variance 
(ANOVA) followed by Tukey multiple 
comparison test. Error bar=SD, n=6. 
 
 
 
 
 
5.2 Psychopharmacological effects of 1001 and 1003 
5.2.1 Psychopharmacological effects of novel opioids in the learned helplessness model 
5.2.1.1 Effects of 1001 and 1003 on depressive-like symptoms 
UFP505 (1001) exhibits antinociceptive effects in rats only after intrathecal injection which 
suggests that brain penetration of subcutaneous injected drug is poor (682). Therefore, one of 
the major aims of the present research program was to improve on the limited uptake of 1001 
into the brain. To achieve this goal, several analogues were synthesized by the Department of 
Chemistry (UTAS) that were modified to improve brain penetration. One of those 1001 
analogues, termed 1003, surprisingly showed DOP receptor agonist activity (PhD thesis A. 
Paul, see Appendix 2 for details) in contrast to 1001, which is a DOP receptor antagonist. Since 
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there is some evidence that DOP receptor agonists can be effective in treating mood disorders 
(289), it was hypothesized that 1003 might also provide beneficial antidepressant-like effects 
in our model. In addition, functional antinociceptive experiments suggested that 1003 had 
improved brain permeability compared to 1001 (PhD thesis A. Paul, see Appendix 3 for 
details). This study, evaluated the differential behavioural effects of 1001 and its analogue 
1003, where 1001 was employed as a control compound that was expected to be inactive. 
Overall, my results provide some evidence that the structure of 1001 can be successfully 
modified to improve its pharmacological properties. 
Our in vitro results suggest that 1003 is safe to be used in animal studies. Even though 1001 
reduced the ATP/mg protein levels of cells over 24 h incubation period, its in vivo safety in 
rats has been evaluated in a previous study (671). To compare the effects of 1001 and 1003 on 
animal behaviour against morphine treatment, both bifunctional opioids were tested in the same 
animal models as described above. In the experiment, rats that were supplied by the UTAS 
animal breeding facility each week were allocated into the different treatment groups using a 
completely radomised method as previously described (634). 
For this purpose, identical dose and injection regimes to the ones used with morphine were also 
employed for 1001 and 1003. In this experiment, no contemporaneous controls were used in 
parallel with the treatment groups for three reasons. Firstly, the LH paradigm is a very robust 
model, since consistent control and treatement results were even obtained from experiments 
that were performed in different calendar years (Table 8 and 9 in Appendix). Secondly, due 
to the technically difficult nature of the integrated testing paradigm, it was impossible to test 
more than 4 rats per day without added interfering factors such as circadian effects and added 
environmental stress. Thus, to add simultaneous testing of control animals to the testing 
paradigm would have seriously jeopardized the overall quality of the data due to time 
constraints of the testing paradigm. Thirdly, additional controls were not tested due to the 
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project budget. Therefore, the data set for the NS and IS groups that was obtained when 
establishing the effects of morphine was employed to demonstrate the behavioural effects of 
1001 and 1003. Similarly, both drugs were given at the end of 2nd LH induction session on day 
2 and before the conduction of each depression test on days 4 to 6 (Figure 56A). As expected, 
exposure to IS significantly increased number of escape failures in stressed rats (T1: NS: 9.200 
± 2.853 attempts, IS: 25.875 ± 1.125 attempts; T2: NS: 5.400 ± 1.990 attempts, IS: 24.250 ± 
1.601 attempts; T3: NS: 5.400 ± 3.265 attempts, IS: 22.500 ± 1.452 attempts) (repeated 2-way 
ANOVA, time: F (2, 47) = 0.03207, p=0.9685; treatment: F (2, 47) = 44.50, p<0.0001; time × 
treatment: F (4, 47) = 0.8136, p=0.5229). However, in contrast to the previous results with 
morphine (Figure 42B), no significant changes to the number of escape failures were observed 
in 1001 or 1003-treated animals compared to the IS group (Figure 55B).  
 
Figure 56. Effects of novel opioids on depressive-like symptoms. 
Saline-treated rats received either no stress (NS, n=5) or were exposed to inescapable stress 
(IS, n=6) on days 1 and 2. Stressed rats were treated with 1001 (5 mg/kg/day, n=8) or 1003 (5 
mg/kg/day, n=7) at the end of day 2 and from days 4 to 6 (A). The data represents the number 
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of escape failures measured over 3 consecutive testing (T) sessions in the learned 
helplessness (LH) model (B). ****p<0.0001 using repeated two-way analysis of variance 
(ANOVA) followed by Tukey comparison tests. Error bar=SEM. The data set for the NS and IS 
groups was also used for Figure 42B. 
 
5.2.1.2 Effects of 1001 and 1003 on avoidance learning 
Based on previous results, morphine enhancing avoidance learning in rats subjected to the LH 
paradigm. Because 1001 and 1003 display affinity for the MOP receptor similar to morphine, 
we hypothesized that our bifunctional opioids could also influence learning and memory of the 
treated animals. It is important to stress that cognition is expected to significantly affect the 
performance of animals in the LH model (82). Since exposure to IS can lead to memory loss 
(683), it was essential to confirm that the increased escape failures observed in 1001 and 1003-
treated rats was not a consequence of drug-induced impairment of learning and memory.  
Therefore, the number of avoidance events was measured as indicator of avoidance learning. 
In the 1st test, a trend towards reduced avoidance events was detected in the stressed animals 
and novel opioids-treated rats (Figure 57). In the 2nd test, the novel opioids (IS: 3.125 ± 1.008 
attempts; 1001: 0.625 ± 0.263 attempts, p=0.0445; 1003: 0.571 ± 0.202 attempts, p=0.0485) 
significantly reduced the number of avoidance events compared to IS group (repeated 2-way 
ANOVA, time: F (2, 72) = 4.089, p=0.0208; treatment: F (3, 72) = 8.156, p<0.0001; time × 
treatment: F (6, 72) = 0.9319, p=0.4776) (Figure 57). The same pattern was observed in the 
3rd test, but the differences did not reach statistical significance. Overall, no significant changes 
on the number of avoidance events were seen between IS and NS groups (Figure 57). 
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Figure 57. Effects of novel opioids on 
avoidance learning. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress 
training (IS, n=6) on days 1 and 2. 
Stressed rats were treated with 1001 (5 
mg/kg/day, n=8) or 1003 (5 mg/kg/day, 
n=7) on day 2 and days 4-6 (for timeline 
see Figure 55A). The data represents 
the number of escape failures that 
were measured over 3 consecutive 
testing (T) sessions on days 4 to 6. 
*p<0.05 using repeated two-way 
analysis of variance (ANOVA) followed 
by Tukey comparison tests. Error 
bar=SEM. The data set for the NS and 
IS groups was also used for Figure 43. 
 
5.2.1.3 Effects of 1001 and 1003 on escape learning 
Other than avoidance learning, escape learning is also one important factor in the LH model. 
This type of learning indicates how quickly the animals respond to the shocks and how well 
they remember the escape pattern in the testing trials. To investigate the effects of 1001 and 
1003 on escape learning, mean escape latency was measured. In the 1st test, a significantly 
decreased mean escape latency in the IS group (2.520 ± 0.557 attempts) was observed 
compared to the NS group (4.032 ± 0.109 attempts) (repeated 2-way ANOVA, time: F (2, 54) 
= 1.336, p=0.2716; treatment: F (2, 54) = 11.31, p<0.0001; time × treatment: F (4, 54) = 1.219, 
p=0.3135). While in the 2nd and 3rd tests, no significant changes were observed in all groups. 
(Figure 58). 
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Figure 58. Effects of novel opioids on 
escape learning. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress 
(IS, n=6) training on days 1 and 2. 
Stressed rats were treated with 1001 (5 
mg/kg/day, n=8) or 1003 (5 mg/kg/day, 
n=7) on day 2 and days 4-6 (for timeline 
see Figure 55A). The data represents 
the mean escape latency measured 
over 3 consecutive testing (T) sessions 
from days 4 to 6. **p<0.01 using 
repeated two-way analysis of variance 
(ANOVA) followed by Tukey comparison 
tests. Error bar=SEM. The data set for 
the NS and IS groups was also used in 
Figure 44. 
 
5.2.1.4 Effects of 1001 and 1003 on physical activity 
In the LH model, transitions between two compartments of the LH chamber during intertrial 
intervals (i.e., intertrial interval transfers, ITTs) can be used as an index of physical activity, 
which is known to affect the results of the LH model. It was conceivable that exposure to IS 
might reduce physical activity of 1001- and 1003-treated rats. Therefore, those animals could 
present with more escape failures in the LH paradigm. In order to evaluate the influence of the 
novel bifunctional opioids on the physical activity of the treated rats, the number of ITTs was 
measured. Between the NS and IS groups, no significant changes of ITTs were detected over 
three testing sessions. In contrast to morphine (Figure 45), 1001-treated animals exhibited a 
significant decrease in the number of ITTs in the 3rd test (IS: 7.125 ± 0.915 attempts, 1001: 
2.625 ± 1.068 attempts, p=0.0317) (repeated 2-way ANOVA, time: F (2, 48) = 9.071, 
p=0.0005; treatment: F (3, 24) = 3.933, p=0.0205; time × treatment: F (6, 48) = 0.8804, 
p=0.5165), compared to IS group, but no significance was observed in 1003-treated rats across 
all testing sessions (Figure 59). 
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Figure 59. Effects of novel opioids on 
physical activity. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress (IS, 
n=6) training on days 1 and 2. Stressed 
rats were treated with 1001 (5 
mg/kg/day, n=8) or 1003 (5 mg/kg/day, 
n=7) on day 2 and days 4-6 (for detailed 
timeline see Figure 55A). The data 
presents the number of intertrial interval 
transfers (ITT) measured over 3 
consecutive testing (T) sessions from 
days 4-6. *p<0.05 using repeated two-
way analysis of variance (ANOVA) 
followed by Tukey comparison tests. 
Error bar=SEM. The data set for the NS 
and IS groups was also used for Figure 45. 
 
5.2.1.5 Effects of 1001 and 1003 on anxiety-like symptoms 
Another confounding factor of the LH model is anxiety, which is known to be potentially 
induced by exposure to stress (657). Given that 1001 and 1003 did not affect stress-induced 
escape failures (Figure 56) compared to morphine treatment (Figure 42B) we investigated if 
this effect could be due to increased drug-induced anxiety-like symptoms. We therefore 
measured the freezing time during the intertrial intervals as an index of anxiety in our LH 
model. Overall, stressed-rats showed increased freezing times compared to the non-stressed 
rats. A significant increase in freezing time was observed in the IS group (262.225 ± 41.548 s) 
in the 2nd testing session compared to the NS group (82.820 ± 21.387 s) (repeated 2-way 
ANOVA, time: F (2, 48) = 9.071, p=0.0005; treatment: F (3, 24) = 3.933, p=0.0205; time × 
treatment: F (6, 48) = 0.8804, p=0.5156). In both the 1001- and 1003-treated groups, no 
significant drug-dependent changes to freezing times were observed compared to the IS group 
(Figure 60).  
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Figure 60. Effects of novel opioids on 
anxiety-like behaviour. 
Saline-treated rats received either no 
stress (NS, n=5) or inescapable stress 
(IS, n=6) training on days 1 and 2. 
Stressed rats were treated with 1001 
(5 mg/kg/day, n=8) or 1003 (5 
mg/kg/day, n=7) on day 2 and days 4-
6 (for timeline see Figure 55A).  The 
data represents the freezing duration 
during the intertrial intervals 
measured over 3 consecutive testing 
(T) sessions from days 4 to 6. *p<0.05 
using repeated two-way analysis of 
variance (ANOVA) followed by Tukey 
comparison tests. Error bar=SEM. 
The data set for the NS and IS groups was also used for Figure 46. 
 
5.2.2 Psychopharmacological effects of 1001 and 1003 in the novel object recognition model 
My previous results demonstrated that morphine-treated rats showed an increased number of 
avoidance events compared to the stressed saline-treated rats (Figure 43), indicating a possible 
morphine-induced enhancement of learning. Because 1001 and 1003 can activate MOP 
receptors as morphine does, we assumed that our bifunctional opioids might also improve the 
learning and memory abilities of our rats. In order to assess the cognitive effects of 1001 and 
1003, the NOR model, was used as a widely established learning/memory model. The NOR 
model is particularly attractive because it requires no external motivation, reward, or 
punishment and only little habituation. Furthermore, this model can be completed in a 
relatively short time (684). Briefly, the NOR model contains 3 phases, a habituation phase (the 
animals familiarize the experimental environment), an induction phase (2 identical objects are 
used) and a testing phase (one of the familiar objects is replaced with a novel one). In our 
model, the object learning phase of the NOR model was conducted 24 hours after the 2nd shock 
induction of the LH model on day 4. The learning phase contained two sessions with an 
approximate 7 h interval. The short-term and long-term memory of animals were measured 24 
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and 72 h after the 1st object learning session respectively (Figure 61A). In this model, DI was 
used to display the difference of exploration time between familiar and novel objects.  
In both object-learning sessions, all groups of rats spent similar amounts of time exploring both 
identical objects (Figure 61B, 60C). In both the short-term test, non-stressed rats spent 
significant more time exploring the novel object (novel object: 51.848 ± 12.499 s, familiar 
object: 12.316 ± 3.678 s, p<0.0001) (repeated 2-way ANOVA, time: F (3, 44) = 8.401, 
p=0.0002; treatment: F (1, 44) = 15.39, p=0.0003; time × treatment: F (3, 44) = 8.726, 
p=0.0001) (Figure 61D). However, no significant changes to exploration time between 
familiar and novel objects were observed in the IS, 1001- and 1003-treated groups (Figure 
61D). In the long-term memory test, the non-stressed rats still spent significantly more time 
with the novel object as expected (novel object: 20.132 ± 6.743 s, familiar object: 5.494 ± 1.381 
s) (repeated 2-way ANOVA, repeated 2-way ANOVA, time: F (3, 44) = 8.401, p=0.0002; 
treatment: F (1, 44) = 15.390, p=0.0003; time × treatment: F (3, 44) = 8.726, p=0.0001) (Figure 
61E). In the NOR model, the DI was used to quantify how performance of the rats on 
exploration novel and familiar objects. A negative value of DI indicates memory loss. The DI 
values in the IS group were significantly lower than that of the NS group in the short-term (IS: 
-0.154 ± 0.139, NS: 0.568 ± 0.115) (unpaired t test, t (10) = 3.762, p=0.0100) (Figure 61F) 
and long-term (IS: -0.186 ± 0.112, NS: 0.526 ± 0.142) (unpaired t test, t (10) = 3.989, p=0.0026) 
(Figure 61G) memory tests. No significant changes on the DI values were observed between 
1001-, 1003-treated rats and stressed rats in both memory tests.  
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Figure 61. Effects of bifunctional opioids on recognition memory. 
Vehicle-treated Sprague Dawley rats received either no stress (NS, n=5) or inescapable stress 
(IS, n=6) training on days 2 and 3. Stressed rats were treated with 1001 (5 mg/kg/day, n=8) or 
1003 (5 mg/kg/day, n=7) on day 2 and days 4-6. The novel object recognition (NOR) model 
was conducted in parallel to the LH procedure (A). Two object learning sessions were 
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conducted on day 4 using 2 identical objects, which were placed in either the left (L) or right 
(R) position of the arena. There was 7-hour interval between two sessions (B, C). Basal 
preference to selected objects were assessed in 15-min learning sessions. Twenty four hours 
after the first learning session, the short-term memory of rats was tested in a 5 min retention 
test on day 5 and one of the familiar objects was replaced with a novel object (D). On day 7 
the long-term memory was assessed 72 h after the first learning session using a different 
novel object over 5 min period (E). **p<0.01 and ****p<0.0001 using two-way analysis of 
variance (ANOVA) followed by Tukey comparison tests. Error bar=SEM, ns=no significance. 
The DI was calculated to illustrate the difference of exploration time between familiar and 
novel objects in the different groups in the short-term (F) and long-term (G) memory tests. 
+P<0.01 and ++p<0.01 using two-sided unpaired t test.  
 
5.2.3 Psychopharmacological effects of 1001 and 1003 in the open field model 
5.2.3.1 Effects of 1001 and 1003 on physical activity 
Our results showed overall decreased numbers of intertrial interval transfers in both 
bifunctional opioids-treated groups (Figure 59), which indicates decreased physical activity. 
Therefore, the OF model as a model of locomotion was used to confirm these effects. The 
locomotion tests of the OF model were carried out in parallel to the LH procedure. The physical 
activities of rats were represented as moving duration over a 5-min OF testing period. The 
physical activity of 1001- and 1003-treated rats were assessed daily from days 2 to 7 (Figure 
62A). Overall, however, treatment with 1001 or 1003 did not affect moving duration in the 
stressed animals. (Figure 62B). 
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Figure 62. Effects of novel bifunctional opioids on physical activity. 
UTA1001 and 1003-treated rats received inescapable stress training on days 2 and 3. Animals 
were treated with 1001 (5 mg/kg/day, n=8) or 1003 (5 mg/kg/day, n=7) on day 2 and days 4-
6. The open field tests were performed prior to the conduction of the LH procedure (A). The 
physical activity of 1001 and 1003 groups was measured from days 3-7 (B).The data 
represents time spent moving in the OF arena over a 5-min observation period. Data was 
analysed using repeated two-way analysis of variance (ANOVA) followed by Tukey 
comparison tests.  
 
 
5.2.3.2 Effects of 1001 and 1003 on anxiety-like symptoms 
Percentage of time spent in the central area of the OF chamber can be used as an index of 
anxiety-like behaviour. No significant changes to the percentage of time spent in the central 
area of the OF chamber were observed between groups over six testing sessions (Figure 63). 
However, a significant but transient decrease of % time spent in the central area was found for 
day 4 in the 1003-treated group (6.125 ± 1.080 %), compared to its basal level (20.740 ± 7.414 
%) (repeated 2-way ANOVA, time: F (5, 70) = 3.265, p=0.0105; treatment: F (1, 14) = 7.222, 
p=0.0177; time × treatment: F (5, 70) = 1.010, p=0.4185) (Figure 63). 
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Figure 63. Effects of novel opioids on anxiety-like symptoms. 
The anxiety-like behaviour of rats was measured using the open field model and was 
represented as the percentage of time spent in staying at the central area of the OF arena in 
a 5 min test (for timeline see Figure 61A). The anxiety-like behaviours of 1001 and 1003-
treated groups were measured from days 2-7 (B). *p<0.05 compared between basal and day 
4 in the 1003-treated group using repeated two-way analysis of variance (ANOVA) followed 
by Dunnett comparison tests; Error bar=SEM.  
 
5.2.4 Effects of 1001 and 1003 on nociception 
Activation of both MOP and DOP receptors can produce analgesic effects (685). Since 
bifunctional opioids 1001 and 1003 showed agonistic activity towards the MOP receptor, we 
hypothesized that both drugs could have pain-killing effects. Previously, the analgesic effects 
of 1001 (also called UFP505) were been demonstrated using the tail flick (TF) test (682). To 
confirm the analgesic effect of 1001 and 1003 in our model, pain perception of 1001- and 1003-
treated rats were measured using the TF test, which was performed daily before the conduction 
of the LH procedure. However, no significant changes were observed within either the 1001- 
or 1003-treated groups over all testing sessions, compared to the basal pain perception levels 
(Figure 64B).   
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Figure 64. Effects of novel opioids on the pain perception. 
Saline-treated rats received inescapable stress (IS, n=6) training on days 2 and 3.Stressed 
rats were treated with 1001 (5 mg/kg/day, n=8) or 1003 (5 mg/kg/day, n=7) on day 2 and 
days 4-6. The pain perception of rats was measured in the tail flick (TF) test (A). The TF 
latency of the 1001- and 1003-treated groups were measured from days 2 to 7 prior to the 
conduction of the LH procedure (B). The data was analysed using repeated two-way analysis 
of variance (ANOVA) followed by Dunnett comparison tests; Error bar=SEM.  
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Table 7. Overview of the effects of morphine, imipramine and novel bifunctional opioids in different behavioural models. 
(NS: non-stressed, IS: inescapable stress, MOR: morphine, IMI: imipramine; n/a: not measured, EFs: escape failures, ITTs: intertrial interval 
transfers, ITI: intertrial interval, LD: light and dark, NOR: novel object recognition, TF: tail flick, HP: hot plate, —: no effects, three arrows: 
significant changes, one arrow: a trend) 
Groups 
and 
parameters 
Depression model (LH) Locomotion model (OF) 
Anxiety 
model 
(LD) 
Learning 
and 
memory 
model 
(NOR) 
Pain 
models 
EFs Avoidance events 
Mean 
escape 
latency 
(s) 
ITTs 
Freezing 
duration 
during ITI 
Moving 
duration 
(s) 
%time 
spent 
in 
centre 
%travel 
distance 
in 
centre 
Rearing 
duration 
(s) 
TF 
test 
HP 
test 
Measured 
behaviours 
Depressive-
like 
symptom 
Avoidance 
learning 
Escape 
behaviour 
Physical 
activity 
Anxiety-like 
symptom/fear 
Physical 
activity Anxiety-like symptoms 
Anxiety-
like 
symptoms 
Recognition 
memory 
Pain 
perception 
IS  — 
  
—    
 
— — — 
   — 
IMI 
 
   
— — — 
 
— — — n/a n/a n/a 
MOR 
   —  
    — — — 
 
n/a n/a 
1001 —  — 
 
— — — n/a n/a n/a  — n/a 
1003 — 
 
— — — — — n/a n/a n/a  — n/a 
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Chapter 6   Preliminary Investigation of The Relationship 
Between Monoamine Oxidase, Oxygen Reactive Species 
and Depression
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6.1 In vitro investigation of the relationship between MAO and ROS production 
MAO produces cytotoxic ligand hydrogen peroxide (H2O2) during the metabolism processes 
of catecholamines. Hydrogen peroxide as a form of oxidative stress can further lead to 
mitochondrial dysfunction (686). In order to evaluate the relationship between MAO and 
mitochondria, we measured the amount of MAO-produced ROS using the nonselective MAO 
substrate tyramine. Since there were no clearly defined protocols to measure MAO-induced 
ROS, at a first stage, we selected a suitable oxidative stress-responsive probe, optimized 
exposure time to drugs and established the optimal concentration of tyramine. 
 
6.1.1 ROS production and monoamine oxidase enzyme 
The choice of oxidative stress probes 
A general ROS indicator (CM-H2DCFDA) and a lipid peroxidation sensor (BODIPY-C11 
581/591) were used to detect MAO-produced ROS. No lipid peroxidation was detected by 
BODIPY 581/591, whereas significantly increased amount of ROS were detected by the CM-
H2DCFDA from 15-min onwards (0 min: 100.000 ± 7.076 %; 15 min: 155.751 ± 4.139 %; 30 
min: 189.807 ± 4.823 %; 45 min: 215.987 ± 8.638 %; 60 min: 232.307 ± 11.246 %; 75 min: 
252.945 ± 13.856 %) (2-way ANOVA, time: F (5, 36) = 35.27, treatment: F (1, 36) = 600.1, 
time × treatment: F (5, 36) = 36.98, p<0.0001) (Figure 65).  
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Figure 65. Suitability of different 
dyes for the detection of MAO-
induced reactive oxygen species. 
Hepatocarcinoma (HepG2) cells were 
incubated with 1 mM tyramine for up 
to 75 min and the brief amount of 
monoamine oxidase (MAO)-produced 
reactive oxygen species was detected 
using either CM-H2DCFDA or BODIPY-
C11 581/591. Data represents the 
percentage of fluorescence intensity 
relative to the 0 min time point. 
Statistical significance was 
determined against the 0 min time 
point using two-way analysis of 
variance (ANOVA) followed by Tukey 
comparison tests; ****p<0.0001; Error 
bar=SD; n=6 for each time point. 
 
Optimal exposure time to tyramine 
To determine the optimal incubation time, HepG2 cells were exposed to 1 mM tyramine for 
different time periods up to 75 min and CM-H2DCFDA fluorescence was detected every 15 
min. Overall, tyramine-treated cells produced more ROS compared to the untreated cells. 
Significant increases in ROS production were observed from 30 min onwards (30 min: control: 
133.309 ± 36.366 %, tyramine: 198.787 ± 12.980 %, p=0.0176; 45 min: control: 181.547 ± 
65.491 %, tyramine: 262.790 ± 24.978 %, p=0.001; 60 min: control: 227.777 ± 72.547 %, 
tyramine: 304.929 ± 29.425 %; 75 min: control: 244.333 ± 76.998 %, tyramine: 330.976 ± 
33.942 %, p<0.0001). (2-way ANOVA, time: F (5, 27) = 23.16, p<0.0001; treatment: F (1, 27) 
= 20.75, p=0.0001; time × treatment: F (5, 27) = 0.7546, p=0.5901). However, the changes to 
ROS levels seen over time in the untreated cells did not reach significance (Figure 66).  
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Figure 66. Time-dependent ROS 
production by tyramine. 
HepG2 cells were exposed to 1mM 
tyramine for up to 75 min. Time-
dependent ROS production is 
displayed as percentage of CM-
H2DCFDA fluorescence intensity 
relative to the 0 min time point. 
Statistical significance was 
determined against the 0 min time 
point using two-way analysis of 
variance (ANOVA) followed by 
Dunnett comparison tests; 
*p<0.05, ***p<0.001 and 
****p<0.0001; Error bar=SD, n=6 for 
each time point. 
 
 
Optimal working concentration of tyramine 
The optimal working concentration of tyramine was determined after a 60 min incubation 
period with HepG2 cells using CM-H2DCFDA. A range of concentrations of tyramine (0.1 – 
1000 µM) were tested in this experiment. Significantly increased amounts of MAO-dependent 
ROS were observed in a concentration-dependent manner from 1 µM onwards with a 
maximum at 1000 µM (1 µM: 157.065 ± 12.782 %, p=0.0132; 10 µM: 178.323 ± 17.694 %, 
p=0.0005; 100 µM: 190.301 ± 13.096 %, p=0.0003; 1000 µM: 191.524 ± 18.482 %, p=0.0003) 
(1-way ANOVA, treatment: F (5, 12) = 12.53, p=0.0002) (Figure 67).  
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Figure 67. Concentration-
dependent ROS production by 
tyramine. 
HepG2 cells were incubated with 
different concentrations of 
tyramine (0.1 – 1000 µM) over 60 
min incubation period.  ROS 
production is displayed as 
percentage of fluorescence 
intensity relative to untreated 
cells. Statistical significance was 
determined against the untreated 
control using one-way analysis of 
variance (ANOVA) followed by 
Dunnett multiple comparisons 
tests with *p<0.05 and 
***p<0.001; Error bar=SD. 
 
6.2 Western blot 
MAOA is one of the major targets of the conventional antidepressants and this enzyme plays 
vital role in metabolizing  monoaminergic neurotransmitters (687). Increased activity and 
expression levels of MAOA have been reported in patients with depression (74). Therefore, it 
was of interest to evaluate potential changes to MAOA expression in rats after exposing them 
to IS and drugs.  For this purpose, western blot (WB) analysis was employed to quantify the 
expression levels of MAOA in brain homogenates. The homogenates were generated from snap 
frozen and fresh rat brains. Both hemispheres were used to detect possible differences of 
MAOA expression in different brain areas. In the present study, an anti-MAOA antibody 
detected a single band of 68 kDa in rat liver microsomes that were used as positive control 
(Figure 68A), while multiple bands between about 53 to 175 kDa were detected in all brain 
homogenates (Figure 68B), suggesting nonspecific binding of the antibody to brain 
homogenates. A major band was consistently detected in brain homogenates at around 110 kDa 
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that did however not correlate to any of the described or expected molecular weights for the 
MAOA enzyme (Figure 68B). 
Figure 68. Evaluation of anti-MAOA antibody western blotting. 
An anti-MAOA antibody was tested for its ability to detect monoamine oxidase A in rat brain 
homogenates. Rat liver microsomes (15 µg/lane) were used as a positive control (A). Rat brain 
homogenates (50 µg/lane) were generated from different regions of both hemispheres (B).  
 
 
6.3 Histology 
6.3.1 MAOA expression 
Based on the western blotting results, the selected anti-MAO antibody appeared to be not 
suitable for quantifying MAOA expression in total brain homogenates. According to the Allen 
Brain Atlas (http://mouse.brain-map.org/experiment/show?id=74750015), the expression of 
MAOA mRNA is only observed in very few specialized neuronal cells in the adult mouse brain 
and it can be expected that this also applies to the situation in rat brain. The present study used 
total brain extracts since the regions containing MAOA-expressing neurons cannot be dissected 
from mouse brain. Thus, it was very likely that the quantity of MAOA protein in total brain 
extract was simply too low to be detectable by western blotting. Therefore, histological analysis 
was used to investigate the effects of IS and drug treatment on MAO expression using the same 
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antibody, aiming to specifically stain the MAOA-expressing neurons in brain sections. Since 
the HPC plays a central role in regulating mood and cognitive function (644), this brain area 
was selected for histological analysis. MAOA staining appeared as punctuate staining in trails 
as would be expected for the axonal localisation of a mitochondrial protein (Figure 69A,B). In 
this study, no significant changes in expression levels of MAOA were detected in the HPC of 
rats after IS exposure, compared to the non-stressed group (Figure 69C). 
 
Figure 69. Effect of inescapable foot shocks on MAOA enzyme expression in the 
hippocampus. 
An anti-MAOA antibody was used to detect the expression levels of MAOA in in the 
hippocampus. Rat brain sections were obtained from the non-stressed (NS, n=5) and the 
inescapable shock group (IS, n=6). Scale bar indicates 50µM for all images. Images were taken 
at 20x magnification. Statistics was calculated using Student’s t test, ns=no significance. 
 
 
6.3.2 Oxidative stress  
Oxidative stress is associated with the development of depressive symptoms (688). 
Nitrotyrosine, a product of tyrosine nitration mediated by reactive nitrogen species, can be 
used as an indicator of oxidative cell damage. To evaluate the effects of IS exposure on 
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inducing oxidative stress damage in anterior and posterior HPC, anti-nitrotyrosine antibody 
was used. In the anterior HPC, a significant increase in the area of nitrotyrosine staining was 
observed in the IS group (5.169 ± 1.227 % area), compared to the non-stressed rats (1.248 ± 
0.250 % area) (1-way ANOVA, F (3, 19) = 3.715, p=0.0295). Even though decreased 
nitrotyrosine stain was detected in the 1001- and 1003-treated groups, this change was not 
significant (Figure 36). Significantly increased staining was also detected in the posterior HPC 
of the stressed rats (5.333 ± 1.659 % area) compared to the NS group (1.287 ± 0.374 % area) 
(1-way ANOVA, F (3, 16) = 2.730, p=0.0783), while only a trend towards decreased 
nitrotyrosine staining was observed in the stressed rats that were treated with the bifunctional 
opioids compared to the stressed animals (Figure 70).  
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Figure 70. Effect of novel bifunctional opioids on stress-induced oxidative cell damage in rat 
hippocampus. 
Oxidative cell damage in the dentate gyrus (DG) areas of the anterior hippocampus (HPC) (left 
column) and the posterior HPC (right column) was detected using anti-nitrotyrosine antibody. 
Brain sections were obtained from non-stressed (NS, n=5), inescapable stress (IS, n=5), 1001- 
(5 mg/kg/day, n=8) and 1003-treated (5 mg/kg/day, n=7) rats respectively. Non-specific rabbit 
IgG was used as negative control (-Ve). The density of oxidative cell damage was quantified 
as percentage of stained granule cells (dark brown) in selected DG areas (% area). Scale 
bar=50µM for 20x magnification. *p<0.05 using one-way analysis of variance (ANOVA) 
followed by Tukey comparison tests; Error bar=SEM, ns=no significance
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Chapter 7   The Psychopharmacological Effects of 
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7.1 Histology 
The previous results of the 1001- and 1003-treated animals, despite not reaching statistical 
significance, indicated that stress-induced oxidative damage to the HPC (Figure 70) might be 
related to memory loss (Figure 61). Therefore, we hypothesized that prevention of oxidative 
cell damage might improve depression-related memory loss and possibly also decrease 
depressive-like symptoms in rats. To test this hypothesis, we used the potent antioxidant 
idebenone (IDE) in our behavioural models. The antioxidative effect of IDE was confirmed by 
detecting nitrotyrosine in the HPC of stressed rats. As expected, compared to NS group 
(anterior: 1.248 ± 0.250 % area; posterior: 1.287 ± 0.374 % area), exposure to IS (anterior: 
5.169 ± 1.227 % area; posterior: 5.333 ± 1.659 % area) lead to a significant increase in 
nitrotyrosine staining in the granule cell layers of hippocampal DG (1-way ANOVA, anterior: 
F (3, 18) = 6.944, p=0.0027; posterior: F (3, 20) = 3.488, p=0.0349) indicative of elevated 
oxidative stress-induced protein damage. In the anterior HPC, both pre-learning (7-day) and 
post-learning (3-day) IDE treatment significantly decreased nitrotyrosine staining (% area), 
compared to the stressed rats (pre-learning IDE: p=0.0163; post-learning IDE: p=0.0022). 
However, IDE-induced reduction in nitrotyrosine levels in both treatment groups did not reach 
statistical significance in the posterior HPC, compared to the stressed rats (Figure 71). 
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Figure 71. Effects of idebenone (IDE) on stress-induced oxidative cell damage in rat 
hippocampus. 
Oxidative cell damage in the dentate gyrus (DG) area of the anterior hippocampus (HPC) (left 
column) and the posterior HPC (right column) was detected using anti-nitrotyrosine antibody 
staining. Brain sections were obtained from non-stressed (NS, n=5), inescapable stress (IS, 
n=5), 7-day IDE-treated (pre-learning, n=7) and 3-day IDE-treated (post-learning, n=8) rats 
respectively. Non-specific rabbit IgG was used as negative control (-Ve). The density of 
oxidative cell damage was quantified as percentage of dark brown granule cells in selected 
DG areas (% area). Scale bar=50µM. *p<0.05 and **p< 0.01 using one-way Analysis of 
variance (ANOVA) followed by Tukey comparison tests; Error bar=SEM, ns=no significance. 
The data set of the NS and IS groups was also used for Figure 34.
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7.2 Psychopharmacological effects of idebenone (IDE) in the learned helplessness 
model 
7.2.1 Effect of IDE on depressive-like symptoms 
It was proposed that oxidative stress is causally involved in the pathogenesis of depression 
(408). Therefore not surprising, antioxidants have recently been used as a co-treatment in 
combination with conventional antidepressants (689). However, this antioxidant approach has 
led to controversial findings with regards to the treatment of depression (690). We investigated 
the antidepressant-like effects of IDE, as well as the possible use of antioxidants as 
antidepressants. Rats that were supplied weekly by the UTAS animal breeding facility were 
allocated into the control and treatment groups in parallel using a completely randomised 
method as previously described (634). The antidepressant-like effects of IDE were tested in 
our LH model in two paradigms, either as a pre-learning treatment (days -3 to 3) or as a post-
learning treatment (days 4 to 6) (Figure 72A). As shown previously, exposure to IS 
significantly increased the number of EFs, compared to the non-stressed rats (T1: NS: 6.000 ± 
1.844 attempts, IS: 23.000 ± 2.671 attempts; T2: NS: 3.000 ± 1.0488 attempts, IS: 24.833 ± 
1.721 attempts; T3: NS: 8.000 ± 3.507 attempts, IS: 23.667 ± 1.256 attempts) (repeated 2-way 
ANOVA, time: F (2, 69) = 0.05162, p=0.9497; treatment: F (3, 69) = 68.93, p<0.0001; time × 
treatment: F (6, 69) = 0.7398, p=0.6194). However, despite potent anti-oxidative activity in the 
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HPC (Figure 71), no significant reduction in escape failures were observed in both IDE 
treatment groups compared to the IS group (Figure 72B).  
Figure 72. Effects of idebenone (IDE) on depressive-like symptom. 
Vehicle-treated rats received either no stress (NS, n=5) or inescapable stress (IS, n=6) training 
on days 2 and 3. Stressed rats were treated with IDE (200 mg/kg/day) for 7 days from days -3 
to 3 (pre-learning, n=7) or for 3 days from days 4 to 6 (post-learning, n=8) (A). The data 
represents the number of escape failures that measured over 3 consecutive testing (T) 
sessions in the learned helplessness (LH) model (B). ****p<0.0001 using repeated two-way 
analysis of variance (ANOVA) followed by Tukey comparison tests, Error bar=SEM. 
 
 7.2.2 Effect of IDE on avoidance learning 
In the testing phase of the LH model, any changes to the rodents’ ability for avoidance learning 
could conceivably change their escape performance, thus leading to false-positive or false-
negative outcomes of drug treatment. IDE has been investigated as a therapeutical approach 
for AD due to its activity as a cognitive enhancer (691). Therefore, it was important to evaluate 
the effect of IDE on avoidance learning. In our model, stressed rats (T1: 0.500 ± 0.224 attempts, 
p=0.0328; T2: 1.333 ± 0.494 attempts, p<0.0001; T3: 0.500 ± 0.342 attempts, p<0.0001) 
showed significantly less avoidance events compared to the non-stressed rats (T1: 2.600 ± 
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0.900 attempts, T2: 8.800 ± 2.200 attempts, T3: 10.400 ± 3.900 attempts) over three testing 
session (repeated 2-way ANOVA, time: F (2, 66) = 4.592, p=0.0136; treatment: F (3, 66) = 
27.82, p<0.0001; time × treatment: F (6, 66) = 3.451, p=0.0050).  However, no significant 
changes were observed in both IDE-treated groups compared to the stressed group (Figure 73).   
 
Figure 73. Effects of idebenone 
(IDE) on avoidance learning. 
Vehicle-treated rats received either 
no stress (NS, n=5) or inescapable 
stress (IS, n=6) training on days 2 
and 3. Stressed rats were treated 
with IDE (200 mg/kg/day) for 7 days 
from days -3 to 3 (pre-learning, n=7) 
or for 3 days from days 4 to 6 (post-
learning, n=8) (for timeline see 
Figure 71A). The data represents 
the number of avoidance events 
measured over three consecutive 
testing (T) sessions with 24 h 
interval between sessions. *p<0.05 
and ****p<0.0001 using repeated 
two-way analysis of variance 
(ANOVA) followed by Dunnett 
comparison tests. Error bar=SEM. 
 
7.2.3 Effect of IDE on escape learning 
Escape learning is another form of learning that could affect the experimental outcomes of the 
LH model. Similar to avoidance learning, escape learning can also enhance the escape 
performance of test animals and could result in reduced escape failures. Therefore, we assessed 
the effect of IDE on escape learning by measuring the mean escape latency in the LH model, 
but no significant changes were observed in the treated or untreated groups over three testing 
sessions (Figure 74). 
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Figure 74. Effects of idebenone 
(IDE) on escape learning. 
Vehicle-treated rats received 
either no stress (NS, n=5) or 
inescapable stress (IS, n=6) training 
on days 2 and 3. Stressed rats were 
treated with IDE (200 mg/kg/day) 
for 7 days from days -3 to 3 (pre-
learning, n=7) or for 3 days from 
days 4 to 6 (post-learning, n=8) (for 
timeline see Figure 71A). The data 
represents the average escape 
latency of each testing trial 
measured over three consecutive 
testing (T) sessions with a 24-hour 
interval between sessions. 
Statistical analysis was calculated 
using repeated two-way analysis of variance (ANOVA) followed by Tukey comparison tests. 
Error bar=SEM.  
 
 
7.2.4 Effect of IDE on physical activity 
Less physical activity has been observed in patients with depression (692). Similarly, exposure 
to stress can also induce reduced physical activity in animals (693). Therefore, it was important 
to confirm that the observed escape failures in the IDE-treated groups were not a result of 
reduced locomotion in our rats after exposure to foot shocks in my own study. In the LH model, 
the number of intertrial interval transfers (ITTs) was measured as an index of physical activity.  
Overall, no significant changes were observed in any of the groups across all testing sessions 
(Figure 75).  
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Figure 75. Effect of idebenone (IDE) 
on locomotion. 
Vehicle-treated rats received either 
no stress (NS, n=5) or inescapable 
stress (IS, n=6) training on days 2 and 
3. Stressed rats were treated with 
IDE (200 mg/kg/day) for 7 days from 
days -3 to 3 (pre-learning, n=7) or for 
3 days from days 4 to 6 (post-
learning, n=8) (for timeline see 
Figure 71A). The data represents the 
number of intertrial interval 
transfers measured over three 
consecutive testing (T) sessions with 
a 24-hour interval between sessions. 
Statistical analysis was calculated 
using repeated two-way analysis of variance (ANOVA) followed by Tukey comparison tests. 
Error bar=SEM. 
 
7.2.5 Effect of IDE on anxiety-like behaviour 
Exposure to inescapable foot shocks can induce anxiety-like symptoms (657). To evaluate if 
the observed escape failures in the IDE-treated groups (Figure 72) were a result of anxiety-
like symptoms, we measured the freezing time during intertrial intervals in the LH model as an 
indicator of anxiety. Overall, no significant changes were observed between groups over three 
testing sessions (Figure 76).  
Figure 76. Effects of idebenone 
(IDE) on anxiety-like behaviour. 
Vehicle-treated rats received 
either no stress (NS, n=5) or 
inescapable stress (IS, n=6) 
training on days 2 and 3. Stressed 
rats were treated with IDE (200 
mg/kg/day) for 7 days from days 
-3 to 3 (pre-learning, n=7) or for 
3 days from days 4 to 6 (post-
learning, n=8). (for timeline see 
Figure 71A). The data represents 
the freezing duration during 
intertrial interval measured over 
three consecutive testing (T) 
sessions with a 24 h interval 
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between sessions. Statistical analysis was calculated using repeated two-way analysis of 
variance (ANOVA) followed by Tukey comparison tests. Error bar=SEM. 
 
7.3 Psychopharmacological effects of IDE in the novel object recognition model 
IDE has been used to treat cognitive deficits in patients with dementia, demonstrating potent 
clinical effects by enhancing learning and memory (694). There is also some limited evidence 
that oxidative stress is involved in the pathogenesis of memory impairment in depression (695). 
Since IDE is a much more potent antioxidant compared to our bifunctional opioids, we 
hypothesized that this drug may more effectively reverse depression-associated memory loss 
via reducing oxidative damage in the brain. Even though no significant changes were observed 
in the IDE-treated animals with regards to avoidance (Figure 73) and escape (Figure 74) 
learning in the LH model, it was still of interest to confirm the effects of IDE in a model of 
depression-induced cognitive deficits. The memory abilities of rats were accessed in the NOR 
model. In both object-learning sessions of our model, rats from all groups spent similar 
amounts of time exploring identical objects (Figure 77B, 77C). In the short-term memory test, 
non-stressed rats spent significantly longer time exploring a novel object than a familiar object 
(novel object: 51.848 ± 12.499 s, familiar object: 12.316 ± 3.678 s) (repeated 2-way ANOVA, 
time: F (3, 46) = 11.00, p<0.0001; treatment: F (1, 46) = 17.38, p=0.0001; time × treatment: F 
(3, 46) = 10.64, p<0.0001). However, no significant changes in exploration time between 
familiar and novel objects were detected in the IS and IDE-treated groups (Figure 77D). In the 
long-term memory test, significantly less time was spent exploring a familiar object in both the 
NS and pre-learning IDE-treated groups (novel object: 20.132 ± 6.743 s, familiar object: 5.494 
± 1.381 s) (repeated 2-way ANOVA, repeated 2-way ANOVA, time: F (3, 46) = 0.7326, 
p=0.5379; treatment: F (1, 46) = 4.808, p=0.0334; time × treatment: F (3, 46) = 6.386, 
p=0.0010) (Figure 77E). In the NOR model, the DI was used to quantify the performance of 
the rats regarding the exploration of novel and familiar objects. A negative value of DI typically 
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indicates memory loss, while a positive value indicates memory of the familiar (learned) object. 
In the short-term memory test, the DI value of the IS group was negative (-0.154 ± 0.139) and 
was significantly lower than the NS group (0.568 ± 0.115) (unpaired student t test, t (10) = 
3.989, p=0.0037) (Figure 77F). In contrast, a significantly higher, positive DI value was 
detected in the pre-learning IDE-treated (0.405 ± 0.049) group compared to the IS group 
(unpaired student t test, t (12) = 1.270, p=0.0015) (Figure 77F). In the long-term memory test, 
stressed rats showed a significantly smaller, negative DI value than the NS group (IS: -0.186 ± 
0.112, NS: 0.526 ± 0.142) (unpaired student t test, t (10) = 3.989, p=0.0026). Similarly, in this 
test, a significant DI increase was observed in the pre-learning IDE-treated group (0.334 ± 
0.146) compared to the IS group (unpaired student t test, t (12) = 2.828, p=0.0152), while no 
significant changes were observed in the post-learning IDE-treated groups for both short- and 
long-term memory (Figure 77F, 77G).  
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Figure 77. Effects of idebenone (IDE) on recognition memory. 
The learning and memory of Sprague Dawley rats was measured in the novel object 
recognition (NOR) model from days 2 to 7. Vehicle-treated rats received either no stress (NS, 
n=5) or inescapable stress (IS, n=6) training on days 2 and 3. Stressed rats were treated with 
IDE (200 mg/kg/day) for 7 days from days -3 to 3 (pre-learning, n=7) or for 3 days from days 
4 to 6 (post-learning, n=8) (A). Two object learning sessions were conducted on day 4 using 2 
identical objects, which were placed in either the left (L) or right (R) position of the arena. 
There was 7-hour interval between these two sessions. Basal preference to selected objects 
were assessed over 15-min learning period (B,C). The first 5 min memory test was conducted 
on day 5 using a novel object (D) and the second memory test was conducted on day 7 using 
a different novel object (E). The DI was used to quantify how performance of the rats on 
exploration novel and familiar objects through calculating the differences of exploration time 
on both objects on day 4 (F) and day 7 (G). The data represents the exploration time spent on 
both objects. *p<0.05, **p<0.01 and ****p<0.0001 using repeated two-way analysis of variance 
(ANOVA) followed by Tukey comparison tests; +p<0.05 and ++p<0.01 using unpaired student t 
test. Error bar=SEM, ns=no significance. 
 
7.4 Psychopharmacological effects of IDE in the open field model 
7.4.1 Effect of IDE on physical activity 
Our previous results suggested that IDE treatment has no effect on the physical activity of rats 
(Figure 74). To confirm this effect of IDE on locomotion, the OF model was used. No 
significant differences were observed in the NS (Figure 78B), the IS (Figure 78C) and the 
pre-learning IDE-treated (Figure 78D) groups over all testing sessions, compared to day 2 
within the same groups. The only significant change to moving duration was observed in the 
post-learning IDE rats on day 4, compared to day 2 (day 4: 138.000 ± 26.970 s, day 2: 192.250 
± 11.467 s, p=0.0002) within the group (repeated 2-way ANOVA, time: F (5, 115) = 4.814, 
p=0.0005; treatment: F (3, 23) = 1.361, p=0.2796; time × treatment: F (15, 115) = 1.304, 
p=0.2111) (Figure 78E).  
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Figure 78. Effects of idebenone (IDE) on physical activity. 
The locomotion of rats was measured in the open field test from days 2 to 7 (A). Vehicle-
treated rats received either no stress (B, NS, n=5) or inescapable stress (C, IS, n=6) training on 
days 2 and 3. Stressed rats were treated with IDE (200 mg/kg/day) for 7 days from days -3 to 
3 (D, pre-learning, n=7) or for 3 days from days 4 to 6 (E, post-learning, n=8). The time spent 
moving in the open field area was measured in a 5 min OF test.***p<0.001 versus day 2 within 
the same group using repeated two-way analysis of variance (ANOVA) followed by Dunnett 
comparison tests; Error bar=SEM. 
 
7.4.2 Effect of IDE on anxiety-like symptoms 
In the LH model, IDE treatment did not affect freezing time during the intertrial interval 
(Figure 75). To confirm the effects of IDE on anxiety-like symptoms, we measured the 
percentage of time spent in central area of the OF chamber in the OF model. Similarly, no 
significant changes were found for all groups, compared to day 2 within each group (Figure 
79).  
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Figure 79. Effects of idebenone (IDE) on anxiety-like symptoms. 
Vehicle-treated rats received either no stress (A, NS, n=5) or inescapable stress (B, IS, n=6) 
training on days 2 and 3 (for timeline see Figure 71A). Stressed rats were treated with IDE 
(200 mg/kg/day) for 7 days from days -3 to 3 (C, pre-learning, n=7) or for 3 days from days 4 
to 6 (D, post-learning, n=8). The percentage of time spent in the central area of the open field 
area was measured in a 5 min OF test from days 2 to 7. Statistical significance was calculated 
using repeated two-way analysis of variance (ANOVA) followed by Dunnett  comparison tests; 
Error bar=SEM.  
 
7.5 Effect of IDE on nociception 
Exposure to IS in the LH model can decrease animals’ sensation and increase their fears 
towards the shocks, thus resulting in more escape failures (669). Based on our previous results, 
IDE treatment has no effect on depressive-like symptoms in the LH model (Figure 72B). To 
determine if IDE has potential analgesic effects to interfere with its effects in the LH tests, the 
tail-flick (TF) test was used. Therefore, to test this hypothesis, we investigated the effect of 
IDE on pain perception in the TF test. However, in our model, no significant changes in pain 
perception were observed either between or within all groups (Figure 80).  
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Figure 80. Effects of idebenone on the pain perception. 
Pain perception of rats was measured in the tail-flick (TF) test from days 2 to 7 (A). Vehicle-
treated rats received either no stress (B, n=5) or inescapable stress (C, n=6) training on days 
2 and 3. Stressed rats were treated with IDE (200 mg/kg/day) for 7 days from days -3 to 3 (D, 
pre-learning, n=7) or for 3 days from days 4 to 6 (E, post-learning, n=8). The tail flick latency 
was measured 3 times in each test. Statistical significance was calculated using repeated two-
way analysis of variance (ANOVA) followed by Dunnett comparison tests; Error bar=SEM. 
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7.6 Effect of IDE on food consumption and body weight 
Obesity can impair cognitive and brain health in humans (696). According to our previous 
results, IDE treatment was able to reverse stress-induced memory loss in our NOR model 
(Figure 77), suggesting improving effect on cognitive function. However, effect of IDE on 
body mass is still unknown. In order to assess the effects of IDE on body mass under stressful 
condition, body weight (BW) and food intake (FI) of all groups were measured daily from days 
1 to 7 in our study. FI was standardised on the individual body weight of each rat (=food 
intake/body weight).  
Overall, the BW of all rats increased over the experimental period. In the NS group, the BW 
showed significant increases from day 3 onwards with a maximum on day 7 (day 3: 299.2 ± 
23.483 g, p=0.0004; days 4: 300.4 ± 22.391 g, p<0.0001; day 5: 302.4 ± 21.200 g, p<0.0001; 
day 6: 308.2 ± 21.754 g, p<0.0001; day 7: 312.0 ± 21.274 g, p<0.0001), compared to day 1 
(287.2 ± 23.137 g) within the same group (Figure 81B) (repeated 2-way ANOVA, time: F (3, 
138) = 18.54, p<0.0001; treatment: F (5, 138) = 1.155, p=0.3347; time × treatment: F (15, 138) 
= 0.02404, p>0.9999). Similar results for BW were observed in the IS and both IDE-treated 
groups (Figure 81C, 81D, 81E). However, the FI/BW ratio reduced significantly from days 4 
to 7 in the NS and the post-learning IDE-treated groups (Figure 81B, 81C, 81E). The lowest 
food consumption in the pre-learning IDE-treated rats was observed on day 4, which was 
significant compared to that of day 1 (day 4: 16.000 ± 2.155 g; day 1: 21.875 ± 0.766, 
p=0.0011) (repeated 2-way ANOVA, time: F (3, 138) = 4.249, p<0.0001; treatment: F (5, 138) 
= 5.811, p<0.0001; time × treatment: F (15, 138) = 3.553, p<0.0001) (Figure 81D).  
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Figure 81. Effect of idebenone (IDE) on food consumption under stress. 
Body weight and foot intake of rats were measured from days 1 to 7 (A). Vehicle-treated rats 
received either no stress (B, n=5) or inescapable stress (C, n=6) training on days 2 and 3. 
Stressed rats were treated with IDE (200 mg/kg/day) for 7 days from days -3 to 3 (D, pre-
learning, n=7) or for 3 days from days 4 to 6 (E, post-learning, n=8).   *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001 versus the food intake amount per body weight on day 1 within 
the same group using repeated two-way analysis of variance (ANOVA) followed by Dunnett 
comparison tests, Error bar=SEM. 
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Chapter 8   Investigation of The Effects of Idebenone On 
The Fear Extinction 
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It was interesting to observe that pre-learning IDE-treated rats spent significantly more time 
exploring the novel object in both short-term and long-term memory tests (Figure 77). 
Therefore, to further investigate the effects of IDE on cognitive function under stressful 
conditions, we tested this drug in the FE model. The FE model is a frequently used model to 
study learning and memory functions and serves as a model for PTSD (574). The FE model 
contains four phases: a habituation, FC, FE and PE phase. Rats received either 7-days IDE 
treatment or vehicle before the conduction of the FE procedure.  
In the FC phase, IDE-treated animals showed more freezing behavior compared to the vehicle-
treated group overall. Specifically, significantly more freezing time was observed in the IDE-
treated group in trial 3, compared to the vehicle-treated group (vehicle: 1.863 ± 1.863 %, IDE: 
31.230 ± 10.050 %, p=0.0168) (2-way ANOVA, trial: F (5, 78) = 9.511, p<0.0001; treatment: 
F (1, 78) = 13.07, p=0.0005; trial × treatment: F (5, 78) = 1.487, p=0.2037) (Figure 82C). In 
the FE phase, significantly more freezing time was detected at the 1st extinction trial in the 
IDE-treated rats, compared to untreated rats (vehicle: 12.758 ± 7.665 %, IDE: 20.043 ± 8.007 
%, p=0.0473) (2-way ANOVA, trial: F (5, 78) = 9.511, p<0.0001; treatment: F (1, 78) = 13.07, 
p=0.0005; trial × treatment: F (5, 78) = 1.487, p=0.2037) (Figure 82D). In the post-extinction 
test, no significant differences were observed between the IDE-treated and untreated animals 
(Figure 82E). 
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Figure 82. Effect of idebenone (IDE) on 
the acquisition and extinction of fear. 
Rats were given either vehicle (n=8) or 
IDE (200 mg/kg/day, n=7) from days -7 to 
3 (A). All animals received paired tone 
and shock fear conditioning (FC) training 
on day 1, followed by fear extinction (FE) 
training with no shocks on day 2 (B). The 
percentage of freezing time during each 
tone signal was measured from days 2 to 
4 in the FC training (C), FE training (D) 
and post-extinction (PE) test (E). *p<0.05 
versus the vehicle-treated group in the 
same trial using repeated two-way 
analysis of variance (ANOVA) followed 
by Dunnett multiple comparisons test; 
Error bar=SEM. 
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9.1 Model modification 
Animal models have historically played a critical role in the exploration and characterization 
of disease pathophysiology and in the in-vivo evaluation of novel therapeutic agents and 
treatments (697). Especially, genetic technologies boosted the development of high-throughput 
phenotyping rodent strains to identify the contribution of specific proteins or genes to the 
pathogenesis of human diseases (698). However, numerous novel drugs that demonstrated 
promising preclinical effects subsequently failed in clinical trials. This reflects the uncertainty 
of translating results from animal models to human patients, which in turn raises doubts about 
their ability to recapitulate all features of complex human diseases and questions their 
reliability to identify promising treatment options in general (699). Even though three widely 
accepted criteria, i.e., face validity, construct validity and predictive validity, have been 
established for decades to measure the ability of animal models to represent symptoms and 
mechanisms of human disorders, as well as to predict potential therapeutical effects of novel 
drugs in human trials (423), contradictive results are still reported (460,687). Possible causes 
for this phenomenon are the complexity of preclinical models per se, variances in experimental 
settings across different laboratories as well as individual differences between strains and 
animal gender (427). Therefore, detailed modifications of each animal model and the 
optimization of individual parameters for the specific conditions of a given lab are required to 
ensure reliability and predictive value of the results obtained. 
The physical integration of different tests or models in one single paradigm is thought to 
minimise the bias of short-term and intra-individual variation in the emotional status of rodents. 
In this way, the emotional condition of an animal becomes assessable through a series of 
distinct tasks, contributing to increased reliability and comprehensiveness of behavioural 
testing (700). In the present study, models of depression, anxiety, locomotion, pain and 
cognition were integrated as a single paradigm. This was done, to optimize these models to 
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ensure the validity and synergy of the whole system. This was also done as no systematic 
utilization of the MCS system in this way has been reported so far. During the initial 
optimisation stage, we focused on four behavioural models, the light-dark (LD) model for 
anxiety, the LH model for depression, the NOR for cognitive function and the FE model for 
PTSD, because of their comprehensive neurobiology and the frequently reported 
inconsistencies across different laboratories (427,642,701,702). During the period of 
optimisation, only limited numbers of animals (n = 3) were used to establish the experimental 
conditions due to financial and ethical consideration. In addition, the results of these optimising 
experiments perfectly reproduced previously published data (525,703) and consistent results 
were also obtained from my subsequent experiments that used larger number of animals from 
different litters. Therefore, neither the use of littermates nor the number of animals influenced 
the validity of my results. 
The LD model is based on the natural preference of rodents to darker areas and their tendency 
to explore a novel environment. These two conflicting emotions allow to monitor anxiety-like 
symptoms (704). The advantage of this model is that it does not require prior training or 
punishment such as food deprivation and shock exposure. Instead, only the natural stressor 
light is used. This feature enables the integration of the LD model into the LH model, which 
requires an extensive training phase to induce symptoms by subjecting animals to aversive 
stressors (635). Typically, rodents spend more time in a dark compartment and this behaviour 
will increase with increased anxiety levels. Therefore, establishing baseline anxiety levels of 
rats before exposing them to any type of external stress is essential to evaluate their exploratory 
activity (705). A wide range of light intensities of 10 to 240 Lux have been reported for using 
the LD model (566). Thus, a similar range of illumination intensities was tested to optimize the 
LD model (705). Consistent with previous reports, anxiety levels of non-stressed male SD rats 
increased with increasing light intensity. In our setting, this model was unsuited to measure 
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anxiety-like behaviour under stressful circumstances with light intensities above 50 Lux, since 
the animals failed to explore the illuminated compartment and exhibited maximum baseline 
anxiety levels. It has to be emphasized that until now, criteria to choose specific light intensities 
in this model have not been universally established. Based on our data, 15 Lux was used in all 
subsequent tests, since it represented the brightest tolerated light intensity that did not induce 
anxiety-like behaviour in rats under normal conditions. 
Antidepressant-like effects of drugs can be assessed in the LH model. The typical learned 
helplessness behaviour occurs when an animal or patient is unable to control repeatedly 
presented stressful events. After such an experience, they fail to escape from similar stressful 
situations where their action can stop the stimulus (530). This symptom has also been observed 
in patients with depression (706). In the LH model, rodents are trained to be helpless by 
subjecting them to repeated painful foot shocks under inescapable conditions. Their depressive-
like symptoms are measured when the animal is subsequently exposed to ES. The LH model 
was used in the current study because 1) learned helplessness demonstrates high translation 
across different species including humans and rodents (516) and 2) this model has been widely 
used in recent years, as it produces reasonably reliable results within a 1-week period, 
compared to both short-term depression tests (e.g., the FST) and long-term models (e.g., the 
CMS model) (427). Significant variability has been reported for several key parameters of this 
model such as number of induction sessions, number of shocks and the length of interphase 
intervals (535,707). In the optimisation experiments of this study, depressive-like symptoms 
were successfully induced in male SD rats using parameters that were reported by previous 
studies (708,709,710), indicating the general reproducibility of this model. 
The NOR task for rodents is a non-spatial, non-aversive memory test, which is developed based 
on the spontaneous exploration behaviour of rats towards novel objects (614). This feature 
makes the NOR model compatible with the LH model, which in contrast uses aversive stressors 
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to induce symptoms. Rodents typically respond to environmental changes by preferential 
exploration of novel objects over those that are familiar, suggesting the formation of memories 
regarding the identity of objects (711). Due to the relative simplicity and ethological relevance 
of this model, it was used in the current study to assess drug effects on cognition and to 
investigate the neural mechanisms underlying learning and memory. In our experiments, 
recognition memory towards novel objects only lasted for 3 days in the absence of any stress 
exposure. Parallel to the results of other studies (683,712), stress can result in opposing effects 
on rats’ memory function, which is well demonstrated by our results obtained from two pre-
learning stress experiments. Memory is highly dynamic and formed in distinct stages. 
However, stress can affect all phases of memory formation, including encoding, consolidation, 
retrieval and extinction, depending on when the subject was stressed (645). If an animal is 
subjected to stressors before a learning phase, encoding processes can be changed and the 
subsequent memory formation can be either enhanced or impaired (713). The direction of the 
effect of pre-learning stress is largely influenced by the interval between the stressful episode 
and the learning experience (714). If rats are stressed shortly before a learning task, rapid 
binding of glucocorticoids to non-classical membrane GR facilitates the encoding process. In 
contrast, if rats are exposed to stress at a considerable period before the learning task, stress 
can impede new learning and memory processes through a slow glucocorticoid binding to the 
classic cytosolic GR (715,716).   
In the FE paradigm, rodents are initially trained in a FC phase to imprint fear towards a 
conditioned stressor (CS) (e.g., a tone) by pairing CS with an aversive unconditioned stimulus 
(US) (e.g., foot shocks). As a result, freezing duration during the CS period, indicative of a fear 
response, increases. In a second stage, inhibition of fear is obtained by exposing a previously 
fear conditioned animal to repeated CS in the absence of the aversive US (702). During this 
procedure, the prediction of CS to the occurrence of US decreases, thus the detected freezing 
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response during the CS period diminishes over time. In the present study, the fear response of 
stressed rats only slightly increased during the FC phase, which indicates unsuccessful FC 
training. This may be a consequence of inappropriate tone intensity (i.e., 68 dB) or frequency 
(i.e., 10 kHz). In previously studies, the frequency and intensity of tones were generally set as 
4 kHz and 75 dB respectively (717). Surprisingly, in the first FE phase of our model, rodents’ 
fears towards the tone continually increased, which was in contrast to the FE theory. This result 
could have been a consequence of the white light illumination that was used during the FE 
phase but we did not collect experimental evidence to support this possibility. Previous studies 
showed that the induction of a novel stimulus can reinstate the extinguished fear response 
(718). Even though fear responses were not observed in the post-extinction test, the results are 
not suited to demonstrate the success of the FE training due to of the contradictory behaviour 
in the FE phase.  
 
9.2 Behavioural effects of opioids in animal models 
After the identification of the three classic opioid receptors (719), the behavioural effects of 
opioids in stress-induced mental disorders were studied in multiple animal models (62). The 
analgesic potential of different opioid ligands depends on their agonistic or antagonistic 
activities towards individual opioid receptor types. Furthermore, these ligands also initiate 
other receptor-dependent behavioural effects such as alterations to locomotor activity, 
antidepressant, anxiolytic and  addictive effects (720). Both marketed and experimental opioids 
are reported to exhibit antidepressant-like effects in rodent models of depression. These mood-
modulating effects are mostly transmitted by activation of the MOP and DOP receptors or by 
blocking the KOP receptor. (721). On the other hand, there is also some evidence for an 
analgesic activity of some conventional antidepressants. For example, the tricyclic 
antidepressant desipramine, exhibits analgesic activity in pre-clinical and clinical trials though 
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an opioidergic mechanism (722,723). In addition, pain relief associated with the use of some 
antidepressants may be a secondary effect that involves an interaction of the MOP and DOP 
receptors (724). 
The increasing interest in developing novel opioids as treatments for mental disorders is 
partially due to the involvement of the opioid system in the complex stress circuitry, with 
evidence of the release of endogenous opioid ligands in response to stressor exposure (725). 
For this reason, both endogenous and exogenous opioids are investigated for their potential 
mood control effects, especially their antidepressant effects. In recent years, antidepressant-
like effects of opioid-based analgesics have been demonstrated in variety of stress-based 
murine models of depression, which also imply the endogenous opioid systems in the 
pathological mechanism of depression that is based on stress (465,726,727). Opioid receptors 
widely locate with varying densities throughout the central, peripheral and autonomic nervous 
system as well as several endocrine tissues and target glands  (24). This widespread distribution 
is consistent with the involvement of opioids in a broad range of functions and behaviors, 
including regulating pain, reward, stress control, release of neurotransmitters and 
neuroendocrine modulation (728). For example, decreased expression levels of opioid 
receptors in the HPA axis was reported in patients with depression, indicating their role in 
regulating stress circuitry (729). In the past few decades, the close relationship between the 
opioid systems, stress and the HPA axis has been illustrated in both pre-clinical and clinical 
studies. Transgenic mice with low level of β-endorphin (an endogenous opioid peptide that  
predominantly acts as MOP receptor agonist) showed enlarged adrenal glands and deficits in 
coping with inescapable aversive stress in a depression model (730,731). Furthermore, the 
MOP antagonist naloxone decreased cortisol secretion in depressed rodents by negatively 
influencing the release of hypothalamic corticotropin releasing factor (CRF) and inhibiting the 
HPA axis (731). Moreover, acute morphine administration inhibited the secretion of ACTH at 
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the pituitary level and decreased plasma cortisol in healthy subjects, indicating an inhibitory 
effect of the MOP system on the activity of the HPA axis and the stress response (732,733). 
Similarly, activation of the DOP system also exhibits mood controlling effects. Enkephalins 
(endogenous peptide DOP receptor agonists) are widely distributed through the limbic system, 
including the cingulate cortex, hypothalamus, amygdala and hippocampus, where they are 
mainly responsible for mood control (24). After exposure to a variety of physical and 
psychological stressors, rats exhibited disturbed mood with evidence of decreased mRNA 
expression of pro-enkephalin, a precursor of enkephalins in the pituitary gland (734). In 
addition, the expression of DOP receptors in rats was increased after exposure to chronic stress 
(735). Apart from chronic stress, exposure to acute stress is able to increase the activity of 
membrane enkephalinase in the hippocampus. This leads to a break-down of endogenous DOP 
agonists, which further increased depressive–like symptoms (736). Therefore, the endogenous 
DOP system seems to directly regulate the stress response and attenuate depressive symptoms. 
Dynorphins, which have high affinity to the KOP receptor, are widely distributed in the limbic 
systems and play a critical role in stress-induced mental disorders (737,738). In contrast to the 
effects of MOP and DOP receptors, activation of KOP receptors in the hippocampus and 
nucleus accumbens increase the release of CRH from the hypothalamus and hyperactivate the 
HPA axis, which is associated with the development of depressive symptoms (739,740,741). 
This is evidenced by, increased levels of dynorphins in the hippocampus after prolonged 
immobilisation stress, acute swimming stress or the learned helplessness procedure. Such 
outcomes can be reversed by administration of KOP receptor antagonists (535). Another opioid 
receptor that is involved in mood regulation is the NOP receptor. This receptor is expressed in 
various limbic areas and also contributes to the feedback regulation of the HPA axis (742).  
However, differential effects of NOP receptor system on anxiety and depression have been 
reported. For example, chronic administration of a NOP receptor antagonist reversed increased 
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corticorsterone levels in rats under stressful chronic unpredictable conditions (459). In contrast, 
repeated injections of KOP agonist norciceptin/orphanin FQ (N/OFQ), decreased the 
expression of anxiety-related behaviors in the elevated plus maze without altering the 
corticorsterone levels of stressed rats (743). This discrepancy suggests that the modulating 
effects of the NOP receptor on stress-induced release of corticosterone, as well as its influence 
on HPA axis activity need to be investigated in more detail. 
In our in vitro model, the UTAS-synthesised novel bifunctional opioid 1001 simultaneously 
activates the MOP receptor and blocks the DOP receptor, while in contrast, compound 1003 
simultaneously activates both MOP and DOP receptors (unpublished observation, manuscript 
by A. Paul in preparation). In an in vivo study, 1001 exhibited some promising analgesic effects 
(156) and thus, we hypothesized that the bi-functional opioids might also show antidepressant-
like effects due to their selective activities for specific opioid receptors. 
 
9.2.1 Antidepressant-like effect of morphine 
Chronic pain and depression are well associated, but the mechanisms underlying the effects of 
opiates as antidepressants are still unclear. Collectively, there are two possible mechanisms of 
using opioid-based analgesics as antidepressants. Based on the monoaminergic theory of 
depression, conventional antidepressants block the reuptake of monoamine neurotransmitters. 
At the same time, opioids such as morphine also inhibit the uptake of biogenic amines such as 
noradrenaline and 5-HT (744,745). In mice, a single injection of 20 mg/kg morphine (equal to 
a human equivalent dose of 1.626 mg/kg based on a bodyweight of 70 kg in human) decreased 
the content of DA and NA by 23 % and 32 % respectively in the whole brain homogenate 
(746). In rats, systemically administrated 5 mg/kg morphine (equal to a human equivalent dose 
of 0.806 mg/kg based on a bodyweight of 70 kg in human) stimulated the striatal dopamine 
turnover rate in the presynaptic dopaminergic neurons (747). Similarly, in the slices of rat 
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striatum, 12 nM morphine slowed down the release of DA from the tissue, compared to the 
non-morphine treated control (748). In contrast, only limited studies are conducted so far to 
investigate the direct effects of opioid-based analgesics on neurotransmitter levels in human 
and conflicting results to that of preclinical studies have been reported. For example, a much 
lower single dose of 10 mg in human (i.v.) (assume the average body weight of participants 
was 70 kg to give approximately a dose of 0.143 mg/kg, equal to a rat equivalent dose of 0.887 
mg/kg or a mouse equivalent dose of 1.759 mg/kg) increased, rather than decreased in rodents, 
norephinephrine in the cerebrospinal fluid, which was unrelated to the metabolism, synthesis 
and uptake of the amines (749). Even though, some TCAs such as imipramine convey 
antinociceptive effects on the other hand by binding to the MOP receptor in both humans and 
animals (750,751), it is still uncertain if the monoamines play essential role in opioid-regulated 
pain relief and mood regulating effects due to the above inconsistent results across pre-clinic 
and clinic studies. Another mechanism is based on the distribution of opioid receptors in the 
brain according to rodent studies such as amygdala, hypothalamus, thalamus and ventral 
tegmental area. Since those brain regions control motivation, mood, hormone levels and stress 
regulation, the expression of opioid receptors in these areas suggest a potential role in mood 
control (257,752,753). At present, there is some limited evidence that supports the 
antidepressant-like effect of morphine in the LH model (525,703). However, this effect is still 
not sufficiently explained due to the described effects of morphine on locomotion, pain relief 
and cognition, which could interfere with morphine’s potential antidepressant activity in this 
model (754). 
To gain a more detailed understanding on the antidepressant-like effect of morphine, as well 
as to evaluate the validity of our model to produce depressive-like symptoms and detect 
antidepressants, we assessed the effects of morphine and imipramine side-by-side in our model 
system. Morphine was administered in line with previous reported regimes with minor 
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modifications to avoid the development of tolerance (628). In agreement with previous 
findings, morphine reversed the IS-induced avoidance-escape deficits in our LH model and 
exhibited imipramine-like antidepressant-like effects. However, at same time, morphine also 
enhanced avoidance behaviour and locomotor activity in the rats. Furthermore, it showed 
anxiolytic features in both the LH and LD tests. Because the response to the IS used in the LH 
model can be influenced by pain perception, emotion, cognition and physical activity (755), 
the observed antidepressant-like effect of morphine observed in our model are likely modulated 
by those additional activities of morphine. It can therefore by hypothesized that the 
antidepressant-like effects of morphine in the LH model can at least partially be seen as artefact. 
The first artefact is physical activity. Because the determination of depressive-like symptoms 
highly relies on the physical activity of animals, it is conceivable that higher levels of locomotor 
activity could improve the avoidance-escape performance of rodents. This possibility is 
supported by reports that described “antidepressant-like” effects of psychostimulants in the LH 
model. Those psychostimulants significantly prevented escape deficits by increasing transition 
numbers during intertrial intervals (756), an effect that was also seen in morphine-treated rats. 
In the present study, morphine-treated rats exhibited significantly increased physical activity 
in both the LH model and the OF model. In contrast, in agreement with a previous study, short-
term administration of the antidepressant imipramine did not affect locomotion in the OF test 
(757). Accordingly, our results suggest that the antidepressant-like effects of morphine could 
be at least partially due to its stimulating effect on physical activity.  
Exposure to shocks differentially influences DA activity in the mesolimbic system, based on 
the current, the duration and the controllability of shocks (758). Foot shocks, over 0.55 mA 
induced DA outflow in the nucleus accumbens, leading to reduced motivation to interact with 
the instrumental environment (759). This might partially contribute to reduced escape attempts 
in the IS group. Additionally, exposure to a mild stressor can increase locomotor activity in the 
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OF model, while prolonged foot-shock exposure depresses locomotor activity (760). The 
characteristics of foot-shocks also influence the mesolimbic DA responses. In a previous study, 
mice exposed to a series of controllable foot shocks show increased DA release in the nucleus 
accumbens, otherwise decreased DA release in the same region was demonstrated if the shocks 
were inescapable (761). Conclusively, brief stressor exposure enhances mesolimbic DA release 
and promotes behavioral activation, but prolonged exposure leads to motional and motivational 
impairment. Based on the evidence above, inhibition of mesolimbic DA release is more likely 
relevant in modelling depressive symptoms under laboratory conditions, where severe and 
prolonged stimuli are usually employed in order to induce depressive-like symptoms (762). 
Interestingly, activation on MOP receptors stimulates DA neurons in the ventral tegmental area 
and increases the release of mesolimbic DA. This effect of morphine on regulating 
neurotransmitter release could contribute to both antidepressant-like effects and increased 
locomotion observed in our model. In this context, morphine-stimulated locomotion could be 
considered as dependent on its antidepressant-like activity. Therefore, in current study, we 
cannot finally establish if the antidepressant-like effects of morphine are only mimicked by 
increased physical activity or if both of these effects of morphine are intrinsically linked. 
 The second potential artefact relates to a potential anxiolytic-like effect of morphine. It is 
conceivable that reduced levels of anxiety could help the animals to escape the stressful 
conditions, which would manifest in reduced escape failures. In our model, in contrast to other 
studies (763,764), morphine also showed anxiolytic effects in the LD test after multiple 
injections, indicating an additional effect relevant to comorbid depression-anxiety disorders. In 
contrast, no anxiolytic effects of imipramine were observed in any of our models, which is in 
line with previous studies (765,766). Anxiety exists as two different forms in patients with 
depression; either as anxiety symptoms or as comorbid anxiety disorders, which are associated 
with a distinct pathophysiology, treatments and outcome implications (767). Patients with 
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comorbid anxiety disorders show similar clinical features compared to patients with MDD 
alone, while pure generalized anxiety disorders show different pathological symptoms (768). 
For preclinical studies, the LD model is specifically designed to assess anxiety in rodents 
(568,622) and our results with morphine treatment suggest a role for the MOP receptor in 
regulating anxiety. This is in line with previous reports in other animal models of anxiety where 
anxiolytic effects of MOP receptor agonists have been reported (769,770,771,772). The 
amygdala plays a central role in regulating stress and fear responses and is reportedly involved 
in the anxiolytic effects of MOP agonists (773,774). While in the amygdala a large number of 
enkephalin-immunoreactive neurons are found (775), reduced enkephalin mRNA expression 
in the amygdala was detected in both anxious and/or depressed animals and human patients 
(776,777). Enkephalins are endogenous opioids that activate MOP receptor, indicating that this 
receptors could contribute to the stress-regulating role of the amygdala. Therefore, it is not 
entirely surprising to observe anxiolytic effect of the exogenous MOP agonist morphine in the 
LD model. 
However, in contrast to the LD model, morphine showed no anxiolytic effects in the OF test. 
Our results demonstrated that the morphine-treated animals spent only a short period of time 
in the central area of the OF chamber. Even though, increased moving activity was observed 
in morphine-treated rats, the animals spent the majority of time in the peripheral areas of the 
OF chamber indicative of higher anxiety-like behaviour. It is worth pointing out that the 
validity of the OF model to evaluate anxiety-like symptoms and to detect anxiolytics is still 
questioned, even though this model is increasingly used as a model of anxiety (622). Because 
the measurement of anxiety symptoms in the OF model relies highly on the physical activity 
of the animals, psychostimulants could also produce false anxiolytic effects during the OF tests 
(778). In addition, repeated exposure to the testing environment will also reduce the animals 
fear towards the experimental environment, which in turn could lead to a higher presence in 
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the central area of the OF chamber. Hence the OF model still requires significant verification 
to be used as a valid model of anxiety.  
The third artefact is about the potentially increased learning activity of rats in the LH testing 
phase, which could have been a consequence of the rewarding property of morphine (779). 
Depressive symptoms are partially characterized by profound deficits in reward-related 
behaviors such as anhedonia, loss of motivation and memory impairment (780). The brain’s 
reward system, especially the nucleus accumbens (NAc) and the ventral tegmental area (VTA) 
reward pathway is associated with the development of those reward-related depressive 
symptoms (781). This VTA-NAc reward circuit is essential for the animals to learn the 
association between rewarding stimuli and related outcomes (782,783). In addition, this reward 
circuit also responds to aversive stimuli and is crucial for establishing emotional memory after 
stress exposure (784). Aversive stimuli were demonstrated to slowly increase tonic 
extrasynaptic dopamine levels in animals (785), which further inhibit phasic synaptic dopamine 
release through presynaptic dopamine D2 receptors via negative feedback mechanism (786). 
In the rat LH model, significantly decreased levels of dopamine-1 receptors and dopamine-2 
like receptors in the core and shell of the NAc were only detected in rats that successfully 
established LH symptoms after shock exposure (787), suggesting a role of mesolimbic 
dopaminergic systems in mediating behavioral responses to inescapable stress. 
The VTA region in rats contains a high density of dopaminergic neurons (60 % of all VTA 
neurons) and intermediate levels of GABAergic neurons (35 % all VTA neurons) (788). The 
VTA in the midbrain provides the dopaminergic input to the NAc, which is a target of the 
mesolimbic dopamine system (789). Activation of MOP receptors in the VTA is important for 
the rewarding property of morphine (367),  which occurs either directly or indirectly (790). In 
the indirect mechanism, MOP agonists activate VTA dopaminergic neurons by inhibiting 
GABAergic interneurons and subsequently disinhibiting neighboring dopaminergic neurons 
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(791). Furthermore, MOP receptor-mediated inhibition on GABAergic neuron in the VTA 
projects onto cholinergic interneurons in the NAc (792), stimulating dopamine release through 
nicotinic acetylcholine receptors (793). Given that the VTA contains high concentrations of 
both MOP receptors and endogenous opioid peptides (794), there is the possibility that MOP 
agonists can also directly modulate the activity of dopaminergic neurons. This is supported by 
the preclinical experiments where systemic injected morphine increased the firing rate of 
dopaminergic neurons (795). In addition, systemically administrated MOP agonists increased 
dopamine release in the ventral striatum in rats (796).  Finally, in an ex vivo study, putative 
VTA dopaminergic neurons were activated by the selective MOP agonist DAMGO (797). 
Taken together, MOP agonists can lead to increased mesocorticolimbic dopamine release 
through both dopamine-dependent and -independent pathways, which results in improved 
locomotor activity and positive (or motivational) reinforcement (798,799). Accordingly, in 
present study, morphine-treated rats not only showed increased locomotion, but also exhibited 
better cognitive function or an improved motivational state with increased number of avoidance 
events. However, it is also possible that the stimulating effect of morphine on locomotion may 
falsely lead to the interpretation of increased avoidance events as improved learning. Therefore, 
a significantly more detailed assessment of the effects of opioids on the cognitive function, 
with regards to learning and memory is needed for future pre-clinical studies to understand the 
pleiotropic effects of opioids and prevent their misinterpretation. 
.  . There are two types of learning responses that can be assessed in the LH model: avoidance 
learning and escape learning. Morphine-treated rats showed more avoidance events, suggesting 
those rats were better to predict and avoid the incoming shocks. Similarly, imipramine 
treatment, a drug that has been also reported to improve attention and memory (800), also 
increased avoidance responses. In contrast, neither morphine nor imipramine treatment had 
effect on escape learning. 
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In line with a previous study (801), prior exposure to IS subsequently results in partial 
interference with the acquisition of instrumental avoidance - escape responses in our model. 
The interference phenomenon of IS has been shown to be dependent on the shock intensities 
used. In particular, only high intensities of shocks were able to impair avoidance - escape 
performance (802). In this study, 0.8 mA and 1.0 mA shocks did not affect escape performance 
deficits, while 1.3 mA shocks showed a retarding effect on the mean escape latencies. In 
addition, shock intensities appear to have a U-shaped response curve with regards to escape 
performance such that shock intensities higher than 1.3 mA reversed the shock-induced escape 
deficits in that study (803). Surprisingly, 0.8 mA IS in our model only decreased the mean 
escape latency in the first test but not in the following tests, indicating a short-term facilitating 
effect on the escape performance. This result is in conflict with previous studies but could be 
the result of the larger number of shocks that were used in the induction phase of our paradigm 
compared to other studies.  
Escape learning is known to be dependent on the intensity and number of IS (804,805) . In 
contrast, avoidance learning is not dependent on the characteristics of shocks, but rather 
represents a prediction of the upcoming shocks. In the LH model, the light and shock stimuli 
were presented in the form of CS-US pairing. Therefore, the acquisition of avoidance behaviour 
in the LH testing phase can be seen as a Pavlovian fear conditioning-driven avoidance response, 
which is more likely a motivational coping strategy of rats to avoid a stressful situation (806).     
The fourth artefact is related to the analgesic effect of morphine, since a higher level of escape 
performance could be a consequence of decreased morphine-mediated pain sensitivity. Stress-
induced analgesia (SIA) is a physiological response to aversive stressful events that also 
effectively suppresses pain through either the production of endogenous opiates (endorphins) 
(668) or by a non-opioid mechanism that stimulates the release of endogenous cannabinoid 
compounds in the periaqueductal grey matter of the midbrain (807). Assessing this response 
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using animal models/tests can help to elucidate the fundamental mechanisms of nociception, 
as well as potential therapeutic targets for pain and stress-related disorders. Inescapable foot 
shocks used in the LH model were previously reported to induce SIA if the number of foot 
shocks exceeded 60 and the shock currency was over 0.55 mA (653). Since this study employed 
90 IS at 0.8 mA in a single induction session for two consecutive days, the foot shocks were 
possible to evoke opioid-based SIA. The development of SIA in the LH model parallels clinical 
observations of increased endorphin concentrations in the cerebrospinal fluid of patients with 
MDD (808). In support of this, we observed and increased TF latency 24 h after the first 
induction, which could indicate the release of endogenous opioids in response to the stress. It 
is interesting to note that in our model the nociceptive responses measured by the TF and HP 
tests showed different results, which is likely a consequence of what these two assays actually 
measure. While the TF test detects radiant heat evoked spinal reflex latency and the HP test 
measures a contact heat evoked supraspinal response (638). In the HP test only a non-
significant trend towards an increased nociceptive response was observed, which suggests a 
predominant spinal controlled effect of IS on nociception in our model. In line with a previous 
study (809), our results also demonstrate that the SIA lasts only for a short period of time since 
an increased nociceptive response was not observed at the end of LH experiment.  
It is important to note that the administration of morphine in our model occurred at a time when 
SIA was no longer present. This was necessary to distinguish the source of altered nociception. 
Because morphine was only administrated after shock exposure and nociceptive response was 
only measured at the end of LH experiment (Day 6), no morphine-induced effects on thermal-
induced nociception were observed. Based on these result and considerations, we conclude that 
the analgesic effects of morphine did not interfere with the escape performance of our test 
animals. 
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Another noticeable effect of morphine was related to body weight changes. In this study, foot-
shocks did not have any effects on body weight when compared to the NS group. The results 
of the present study are in line with a previous study (683), while significantly decreased body 
weight was reported in another study (810). These inconsistent effects may be due to 
differences in the protocols used, such as the length of the foot-shock period and the strength 
of the shocks. In contrast to the IS and NS groups, 2 injections of morphine resulted in a 
significant increase in body weight in stressed rats (IS+morphine). Two-way ANOVA analysis 
indicated that both the procedure and treatment per se affected the detected body weight 
increase. Therefore, two explanations for the significant body weight changes in the morphine-
treated group are possible. Firstly, stressors in the LH model have been reported to induce taste 
aversion in SD rats, which subsequently reduce food intake, which could negatively affect 
weight (811). Based on my results, IS may only affect the appetite of the animals in the short-
term, because in the IS group, slightly increased body weight was observed from day 2 
onwards. Therefore, beyond day 2 when the IS were stopped, morphine-treated rats might have 
increased food intake. Secondly, morphine treatment could reverse the IS-induced emotional 
impairment due to its rewarding effects (812),  which subsequently could have resulted in 
increased food intake and body weight. However, a direct evidence for the influence of 
morphine on weight gain in rodents has not been demonstrated so far. In addition, excessive 
plasma glucose is linked to increased body weight (813). However, morphine has been 
demonstrated to stimulate insulin release from pancreatic beta-cells in culture (814), which 
does not support a morphine-induced weight gain after multiple injections. 
Unexpectedly, in the imipramine-group, the rats showed a significant drop in body weight on 
day 2 when the animals had not actually received any imipramine yet. This could have been 
the result of individual differences in the stress response of the animals in this group (815),  
where some rats of this group were more sensitive to the negative emotional impact of the foot-
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shocks. This could indicate that the results from the imipramine group are not necessarily 
directly comparable to the IS and stressed morphine-treated groups due to animal differences. 
However, since the imipramine-treated group showed responses in line with the majority of 
previous reports (683,816,817,818,819), this difference in group composition, if present at all, 
might not be very significant for the overall conclusions of the project. 
 
9.2.2 Antidepressant-like effects of bifunctional opioids 
The opioidergic systems play a central role in pain management, which is mainly transmitted 
via the activation of the MOP receptor (266,820). Over the past decades, morphine has also 
demonstrated that it can improve the mood of patients with chronic pain and cancer (821), 
suggesting a general potential of MOP agonists in mood control. However, MOP activation 
also induces reward behavior, which contributes to its addictive properties (822). In addition, 
long-term use of MOP agonists leads to the development of analgesic tolerance, which reduces 
the effectiveness of pain control (823). Therefore, the pain-killing and behavioural properties 
of other opioid receptors and their corresponding ligands are currently investigated by several 
groups to identify alternatives with less side effects compared to morphine. Recently, DOP 
receptors have gained significant interest due to their dual activities around analgesia and mood 
regulation (289). Focusing on depression, compared to wild-type animals, DOP receptor 
knockout (KO) animals exhibited anxiety-like and depressive-like symptoms. This feature is 
mirrored by the DOP antagonist naltrindole that was able to block the antidepressant-like effect 
of DOP receptor activation in the LH model (531). Based on this evidence, strategies to design 
MOP/DOP-specific bifunctional opioids are underway. Compared to ligands selective for a 
single receptor, these molecules promise to display improved efficacy and reduced side effects 
(368).  
                                                                                                                                     Discussion 
234 
 
Two novel bifunctional opioids have been synthesized at the University of Tasmania and were 
named 1001 and 1003. While 1003 activates both MOP and DOP receptors (unpublished 
observation), 1001 activates only the MOP receptors but acts as an antagonist for the DOP 
receptor (679).  There is some uncertainty about the in vivo toxicity of 1001, since conflicting 
effects have been reported (682,824). In contrast, the safety profile of 1003 has so far not been 
evaluated. In our study, we aimed to compare the effects 1003 on cellular ATP levels in vitro 
as surrogate marker for cellular toxicity (825) against 1001. Over a 24 h incubation period with 
1003, no overt toxicity was detected, compared to 1001, morphine or untreated cells. In 1001-
treated cells, however, significantly decreased ATP levels were detected after 24 h in vitro, 
suggesting the presence of metabolic toxicity. This outcome was in line with previous reported 
result by another group (824). However, this result is in contrast to a previous study where 
1001 was used systemically in rats over 5 days and no toxic effects were reported (682).  The 
demonstrated absence of in vivo toxicity may likely be because drug toxicity was not assessed 
further in sufficient detail in tissue specimens that are susceptible to energy impairment such 
as heart, skeletal muscle or retina. In addition, under physiological conditions organs differ 
with regards to metabolism and detoxification of xenobiotics from cells in vitro, which can 
lead to differential metabolic and toxicity outcomes. Nevertheless, energy-impairment-induced 
toxicity in vivo typically leads to a delayed phenotype after weeks of drug exposure (826). 
Thus, 1001 was still tested in animal models based on the reported short-term safety profile in 
rats (682), even though it remains necessary to re-evaluate the safety of 1001 in much more 
detail over longer time periods in future studies.  
In our models, 1001 and 1003 failed to affect depressive-like symptoms, anxiety-like 
symptoms, nociception  or locomotion. There are several possible reasons for this observation, 
which could be related to the route of administration and the dosing of both drugs.  The 
previously reported analgesic effects of 1001 were obtained using intrathecal injection (682), 
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a method that circumvents the blood-brain-barrier. Therefore, one explanation for the lack of 
behavioural changes could simply be that insufficient drug reached the central nervous system. 
This hypothesis is somewhat supported by the observation that 1001 and 1003 at higher 
concentrations with subcutaneous injection do show some limited analgesic effects 
(unpublished observation by PhD candidate A. Paul). 
In addition, based on the enhanced avoidance behaviour due to morphine treatment, we 
hypothesised that the two bifunctional opioids might also positively affect cognition based on 
their MOP agonistic activity. To support this hypothesis, we measured the cognitive effects of 
1001 and 1003 treatment using the NOR model in rats that were subjected to the LH paradigm. 
In the NOR model, animals of the IS group showed both impaired short-term and long-term 
recognition memory, as previously documented (827). In rats treated with 1001 and 1003 a 
clear trend towards improved memory was observed that however did not reach significance.  
The HPC is considered to be one of the main brain centers involved in mood regulation and it 
is also highly sensitive to stress (828). We therefore measured the density of oxidatively 
damaged cells in the granule cell layer of the hippocampal DG region. Surprisingly, 1001 and 
1003 demonstrated a trend towards reduced oxidative cellular damage compared to the IS 
group similar to the trend described above towards improved memory function. Exposure to IS 
can induce the production of ROS, which can lead to oxidative stress (829), lipid peroxidation 
(830) and HPC-related cognitive dysfunction (831). The DG is the hippocampal region where 
neurogenesis happens during adulthood (832). In particular the granular layers of the DG 
contains large number of granule cells that were mostly generated after birth (833). Those 
adult-born dentate granule cells (DGCs) heavily contribute to learning and memory and 
adverse experiences during a critical period can influence survival and activity of these cells, 
which can have a direct impact on cognitive function (834). The IS used in the LH model have 
been reported to decrease cell proliferation and neurogenesis in the DG of adult rodents (835), 
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which could explain the impairment of learning and memory observed in the IS-exposed rats 
in our study. In addition, stress exposure can also decrease plasticity of the DG, which would 
influence the quality of the formed memory (836). This “blurry” memory is thought to last for 
only short  time periods (837), which would explain the memory performance differences of 
stressed rats 30 min and 24 hours after the learning phase in the preliminary study. 
MOP and DOP receptors are widely expressed in the granule cell layer of the DG (838). There 
is some evidence that blocking MOP receptors can enhance memory in mice (839) and 
activating DOP receptors can improve plasticity and excitability of the DG (840). However, in 
this study, 1001 and 1003 showed similar trend towards reducing oxidative stress in the 
hippocampus, while 1001 seemed to be more effective in enhancing memory compared to 
1003. But given that 1001 and 1003 show no analgesic effects after s.c. injection at the doses 
used in this study, it is questionable if these compound can even enter the brain (841). In this 
context it is, therefore, difficult to hypothesize how activation/inhibition of the MOP and DOP 
receptors could have affected cognitive function in the present study. In previously studies, 
MOP knockout mice were associated with reduced cognition in a NOR model (842), which 
would suggest that activation of the MOP receptor could enhance memory. In support of this 
hypothesis, a single systemic injection of morphine reversed stress-induced memory loss in 
rodents (843). However, improved memory in MOP  knock out mice in a hippocampal-
dependent spatial memory task  was reported previously (844). In this study, the authors 
speculated that this effect was transmitted by increased proliferation of adult-born DGCs. 
Similar inconsistent results were also reported for the DOP receptor system. Both a selective 
DOP agonist (845) and DOP antagonist ICI 174,864 (846) were reported to enhance memory 
function in mice after a single administration. Therefore, the specific effect of the MOP and 
DOP systems on cognition are still largely unclear due to the inconsistent results reported 
across different labs. Additionally, opioids produce a wide range of behavioral effects, and it 
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is not known to what extent the observed influence (either positive or negative) on cognitive 
processes in animal models are directly mediated by a specific opioid system or results 
indirectly from other behavioral effects of opioid ligands. As discussed above, activating the 
MOP receptors can increase the release of mesocorticolimbic dopamine, thus improving 
physical and emotional states of rodents (798,799). Taken the NOR model as an example, it is 
possible that injection of 1001 and 1003 might have increased locomotion, which would have 
resulted in increased exploration activity overall, with the potential to produce false positive 
results interpreted as cognitive enhancement. Together with the effects of 1001 and 1003 on 
oxidative stress damage in the HPC, it would be beneficial to increase animal numbers and 
apply higher doses of both drugs in future studies to increase potential brain levels. This 
approach might lead to significant antioxidant effects and significantly improved recognition 
memory. Since administration of 1001 and 1003 occurred during all stages of memory 
formation,  i.e., encoding (object learning), consolidation (interphase interval) and retrieval 
(memory test using novel objects) (642), our study was unable to pinpoint specific stages of 
memory formation where the bifunctional opioids might be active.  Thus, it would be helpful 
to apply different injection regimes to investigate the specific influence of 1001 and 1003 at 
different stages of memory formation if the experimental conditions allow this approach. 
 
9.3 Monoamine oxidase and reactive oxygen species 
Elevated MAOA density and activity, which directly result in reduced monoamine levels, are 
detected in a variety of brain regions (e.g., cingulate cortex and hippocampus) in patients with 
depression (308,847). Furthermore, in most cell types MAOA localizes to the outer 
mitochondrial membrane (848). As a natural product of MAOA enzymatic activity, the 
cytotoxic product hydrogen peroxide (H2O2) is formed (849,850). In support of this, the 
nonselective MAO substrate tyramine induced a dose-dependent cellular ROS production. The 
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observed selectivity of dyes that were able to detect this ROS production in our cells suggests 
that the produced H2O2 was mainly localized to the cytoplasm and not to any membrane 
compartments. 
MAO-generated H2O2 can be partially converted into highly toxic hydroxyl radicals such as 
OH through reacting with ferrous iron (851). This and subsequent follow up reactions will 
lead to increased levels of oxidative stress which can result in widespread oxidative damage to 
cellular macromolecules. As a consequence, increased oxidative stress can disturb the HPA 
axis function, which is involved in the development of depressive symptoms (852). In our 
experiments, both 1001 and 1003-treated rats showed a trend towards reduced oxidative cell 
damage in the hippocampal DG and slightly improved recognition memory. We therefore 
hypothesised that opioids might enhance cognition by decreasing oxidative damage. In this 
context, it is possible that mitochondrial MAOA, as a known source of oxidative stress, may 
be instrumental in the mechanisms of depression-mediated cognitive improvement.  
Currently, there is some evidence for a mito-protective effect of DOP agonists in-vitro that is 
associated with an ability to reduce cellular levels of oxidative stress (624,853). However, there 
is no direct evidence that demonstrates that mitochondrial MAOA expression is the target of 
opioid-mediated reduction of oxidative stress, which could account for the neuroprotective 
effects of opioids. Therefore, we attempted to measure changes to MAOA expression before 
and after IS exposure and 1001 and 1003 treatment. In the WB analysis, multiple bands that 
ranged between 170 and 55 kDa were detected with no differences across different tissues. 
These bands were also not affected by tissue processing methods and brain regions used. Since 
there is considerable confusion about the expected molecular weight of MAOA by different 
antibody manufacturers, we aimed to establish the expected protein size of MAOA (rat). For 
this purpose, we used three different online calculation tools based on the MAOA protein 
sequence obtained from NCBI protein database (Figure 83)  
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(https://www.ncbi.nlm.nih.gov/protein/EDL97663.1).  
 
Figure 83. Protein sequence of monoamine oxidase A of Sprague-Dawley rats. 
 
The calculated protein size of MAOA is approximately at 59.5 kDa (Figure 84-86), in 
accordance with the reported size in the GeneCard database (59.7 kDa, 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=MAOA&keywords=MAOA).  
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Tool 1: Protein Molecular Weight (http://www.bioinformatics.org/sms/prot_mw.html)  
Figure 84. The protein weight of the monoamine oxidase A of Sprague-Dawley rats 
calculated with Protein Molecular Weight. 
 
Tool 2: Peptide Molecular Weight Calculator –GenScript (https://www.genscript.com/tools/peptide-molecular-weight-
calculator)  
Figure 85. The protein weight of the monoamine oxidase A of Sprague-Dawley rats 
calculated with Protein Calculator v3.4. 
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Tool 3:  ExPASy – compute pl/Mw tool (http://web.expasy.org/compute_pi/)  
Figure 86. The predicted molecular weight of rat mitochondrial monoamine oxidase A 
calculated using ExPASy. 
 
The fact, that we detected a single band of the expected size for MAOA in the rat liver 
microsomes that were used as positive control suggests the appropriateness and function of the 
used antibody and our staining methods. Therefore, one explanation for our inability to detect 
MAOA in the rat brain could be that MAOA in this tissue is heavily post-translational modified 
(PTM) through N-acetylation (854), ubiquitination (855) or phosphorylation (856), which 
would affect its apparent size on a western blot. On the other hand, we cannot exclude that 
MAOA might be exquisitely sensitive to proteolytic degradation in brain tissues and that in our 
experiments MAOA was lost by degradation during dissection or the preparation of brain 
lysates. Finally, another possibility is that MAOA is expressed in brain tissue as alternative 
splice variants of different molecular sizes. However, this possibility is not reported in the 
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literature and we were unable to find any evidence for this in several databases (i.e. Genecards). 
Consequently, we had to conclude that western blot analysis is not suitable for the current 
study. Therefore, we addressed the question by using immunofluorescent staining of tissue 
sections. While a strong fluorescent signal, reminiscent of axonal mitochondrial MAOA-
specific staining was observed, no differences were detected in the HPC of the NS and IS 
treated animals. There is a possibility that MAOA activity rather than its expression could be 
increased in patients with depression (857). Therefore, the potential antioxidant effects of 1001 
and 1003 in rat brains might be due to a direct or indirect inhibitory effect on MAO activity or 
additional uncharacterized ROS-producing systems. Another possibility for this effect could 
be a opioid-dependent regulation of the HPA axis, which also could reduce the levels of 
oxidative stress (858). A final possibility for the observed slight anti-oxidative activity of 1001 
and 1003 lies in their structure. These peptidomimetic opioids share a significant amount of 
structural similarity with so called SS-peptides (named after their inventors) that all contain the 
characteristic di-methyl tyrosine (DMT) moiety (859). Like the test compounds 1001 and 1003, 
these SS-peptides also originate from opioid-receptor ligands but have been described as potent 
antioxidative compounds due to its DMT moiety and have shown promising mitoprotective 
and neuroprotective activity in vivo and are now in clinical development (860). However, since 
we did not assess the plasma concentrations of cortisol, MAO activity or a direct antioxidative 
activity of 1001 or 1003 in the present study, it is not possible to judge, which potential mode 
of action was the underlying reason for the observed trends.  
 
9.4 Behavioural effects of idebenone 
In this study, 200 mg/kg idebenone was tested for its behavioural effects and antioxidant 
property under stressful conditions. In previous studies, idebenone has successfully 
demonstrated neuroprotection of retinal neurons in animals at a dose range of 200 to 2000 
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mg/kg (629). In addition, 100 mg/kg idebenone was proved to distribute widely in brain regions 
of the temporal and occipital cortices, nucleus accumbens, hypothalamus, hippocampus, 
striatum and cerebellum after oral administration using a radioactive labelling technique by 14C 
(861). Given the similarity between the blood-retina and blood-brain barrier penetration of 
drugs (630), 200 mg/kg idebenone is sufficient to reach the brain and the use of this dose was 
fully justified and accurate.  
 
Cognitive effects 
Based on the behavioural and histological data of 1001 and 1003, we postulated that the 
antioxidant effect of a drug could be crucial to their antidepressant-like effect in our animal 
model of depression. To verify this hypothesis, we aimed to employ a much more potent 
antioxidant in our models. Idebenone is a synthetic structural analogue of coenzyme Q and has 
demonstrated antioxidative, mitoprotective and neuroprotective properties in multiple models 
(862). Currently, it is used to improve cognitive function in some dementia patients (694) and 
has been recently approved for the treatment of a mitochondrial disease by the European 
Medicines Agency (EMA) (384). It is thought that the reported neuroprotective effects of 
idebenone are partially due to its antioxidant effect via inhibiting cellular lipid peroxidation 
(863). In line with this well described antioxidative activity, idebenone treatment over both 3 
and 7 days reversed the oxidative cell damage in the anterior HPC that was caused by the IS 
exposure in our study. In the NOR model, untreated rats showed memory deficits due to IS 
exposure. According to the histological analysis, this resulting stress-induced cognitive 
dysfunction was associated with oxidative cell damage in the granule cell layers of the DG 
area, which is essential for learning and memory. In support of our hypothesis, idebenone not 
only reduced oxidative damage but also reversed the memory loss in our model. However, this 
cognitive effect of idebenone in the NOR model was only observed after 7-day administration, 
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even though significant reduction on oxidative cell damage was also detected after 3-day 
treatment. Because our study did not assess cell proliferation in the DG, the effect of different 
treatment periods with idebenone on neurogenesis in the context of recognition memory is 
unclear. It is also notable that significant idebenone-dependent reduction of oxidative damage 
was only detected in the anterior HPC. There is still some controversy over the exact function 
of the anterior versus the posterior HPC. Some studies argue that the anterior HPC processes 
primarily stress, emotion and affect, while the posterior HPC is heavily involved in cognitive 
function, such as spatial memory (864). In our model, IS caused similar levels of oxidative cell 
damage in both HPC regions, which suggests an overlapping role of both hippocampal regions 
in stress response. However, based on our results, the anterior HPC appears to play the major 
role in processing non-spatial information, such as recognition of different objects at the same 
location in the NOR model.   
 
Antidepressant-like effects 
In our study, idebenone showed no effects on depression, anxiety, food intake/body weight or 
locomotion, and clearly showed the independence between the antioxidant and antidepressant-
like properties of idebenone, which significantly questions the general use of antioxidants as 
antidepressant alternatives (689). However, since our rats only received idebenone treatment 
for up to 7 days, we cannot exclude the possibility that longer treatment periods with 
antioxidants could still have some antidepressant effect. To explore this aspect appropriately, 
long-term studies with multiple potent antioxidants in animal models of long-term stress 
exposure, such as the CMS model, would be more appropriate. 
 
Pain 
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Currently, analgesic effects of antioxidant supplements have been reported in patients with 
chronic pancreatitis and rheumatoid arthritis (865,866). Since idebenone is a potent 
antioxidant, we hypothesized that idebenone might also have some analgesic effect.  In fact, 
there is some limited evidence that idebenone could indeed have some intrinsic analgesic 
activity. In a study that looked at inflammation and pain in a rat model of carrageenan-induced 
inflammatory pain, the authors described some “anti-inflammatory” activity of idebenone 
(867). However, the nature of the model system was unable to differentiate if the protective 
effects were due to anti-inflammatory or analgesic properties of idebenone (867). When we 
measured the pain threshold of idebenone-treated rats in the TF test, we did not observe any 
changes to the pain perception in our test animals. However, this result might be due to the 
relatively short treatment period of this study as previous studies, showed analgesic effects of 
antioxidant supplements only after weeks or even months of treatment (865,868).  
 
Fear extinction 
To confirm the effect of idebenone on cognitive function under stressful conditions, we 
additionally employed the model of fear extinction (FE), which is widely used to assess the 
information processing ability after stress exposure (646). The FE model is closely related to 
the commonly used exposure therapy for anxiety disorders, such as PTSD (869). This 
cognition-based therapy involves exposure of patients repeatedly to their feared objects without 
real exposure to danger, in order for the patient to overcome their fear to the stimuli (870). It 
has to be stressed that clinically used FE learning is based on an active learning process to 
separate the connection between a traumatic event and possible triggers. Given that PTSD 
patients are under chronic stress, their ability to learn is significantly reduced and hence FE 
learning is reportedly only effective in a small group of PTSD patients (871). Therefore, 
pharmacological interventions that are able to enhance learning and memory could be improve 
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success rates of FE therapy treatment. Based on the results of idebenone in the NOR model, 
we hypothesized that idebenone could enhance the active learning process under stressful 
conditions, hence, inhibiting the return of fear. For this purpose, we first needed to modify the 
model of FE using the MCS. Unexpectedly, an increased fear response was detected during 
two FE sessions in the model-optimization experiment. The white-light illumination used 
during FE training could have acted as a novel stimulus and to enhance the fear of our test 
animals towards the shocks (871). In addition, the use of a grid floor in the FE phase may have 
also reminded the rats of the aversive shock, thus inducing fear to the experimental 
environment. Therefore, in the idebenone experiment, we applied three major strategies to 
improve the validity of our FE model. First, we adjusted the length of shocks and tones in order 
to enhance the strength of fear conditioning (FC) training. We observed that the presence of 
the grid floor initiated a freezing response as soon as they were placed into a new environment 
that has a grid floor. Therefore, as a second measure, to distinguish the influence of shocks and 
environment on freezing behaviour, a solid floor instead of a grid was used to increase the 
discrimination between the chamber in which rats have received shocks and the chamber 
without shocks. Finally, the same lighting conditions were used for all phases, in order to avoid 
inducing extra stimuli that could produce more fear. 
When we tested idebenone in this model, we used the same 7 day pre-treatment that showed 
significant effects in the cognition model. However, this meant that idebenone was already 
present during the FC phase. This was an experimental problem, we could not avoid at this 
point, as shorter exposure times with idebenone would have likely shown no response. 
Therefore, we were only partially surprised that idebenone-treatment in the modified FE model 
produced significantly increased conditioning (= increased fear response) compared to the 
untreated group. It appeared that the idebenone-treated animals after only 2 rounds of 
conditioning had already learned the connection between sound and shocks, while the untreated 
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animals required significantly more sessions. In fact, in the FE phase the untreated animals 
showed only a low fear response, which suggests insufficient memory consolidation. In 
contrast, the idebenone-treated animals showed a significantly better fear response in the first 
round of FE, reflective of a more efficient learning process during the FC phase, which on the 
one hand, supported our hypothesis that idebenone can significantly improve learning 
behaviour under stress. Unfortunately, on the other hand, this meant that the FE experiment 
was unable to provide us with the answer we required as the two groups (treated and untreated) 
did not start with the same level of anxiety at the start of the FE paradigm. To overcome the 
insufficient FC in the untreated animals a longer interphase interval between FC and FE phases 
could be more appropriate for future studies. In fact, there is some evidence that the FC 
response might persist for 14 days (872), which suggests that idebenone treatment for 7 days 
after the FC training phase might be able to provide sufficient memory consolidation, and  also 
restrict drug effects to the extinction learning phase.  
 
9.5 General conclusion 
9.5.1 Limitations of this study 
This study investigated the psychopharmacological effects of opioids and antioxidants in a 
complex integrated model of different behaviours to provide a possible explanation for the 
relationship between oxidative stress, depression and depression-related cognitive deficits. 
Although this study addressed all the initial aims and objectives, there are limitations that have 
to be considered.  
In the in vitro study, we confirmed that activating MAOA induces ROS. However, this study 
did not demonstrate any effects of opioids or idebenone on MAO activity in the ROS assay. 
Hence, we are not sure if opioids and mitochondrial-based drugs can influence MAOA activity 
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in term of ROS production. In addition, we did not establish a real dose-effect relation for the 
toxicity of morphine and bifunctional opioids in vitro.  
In the ex vivo assays, we only showed that the levels of MAOA were not affected by exposure 
to inescapable foot shocks, which is in contrast to increased MAOA activity and expression 
levels reported in patients with MDD (873). This discrepancy has never been reported for the 
LH model before and although it points to a major limitation of the depression model used in 
this study, it also highlights that this problem has to be investigated for other pre-clinical 
models of depression to judge their predictive value. This leaves the possibility that in our 
model not MAOA expression was altered but its activity. In addition, this study noticed a 
potential uncertainty around MAOA antibody specificity when used for western blotting. This 
could either have been the consequence of too little MAOA protein in total brain extracts or a 
true problem with antibody specificity. This issue could have been addressed by testing the 
antibody on rat neuronal cultures in vitro. For this purpose in isolated brain cells, MAOA 
expression could have been modulated in vitro using either overexpression and/or 
antisense/siRNA technology, which could have confirmed antibody specificity but was not 
used in the current study. Therefore, this omission has to be regarded as a potential limitation 
of the current study. Furthermore, it is established that mitochondrial ROS is generated by 
MAOA-dependent metabolism of catecholamines as well as the mitochondrial respiratory 
chain (874). However, we did not directly assess mitochondrial ROS production or tried to 
establish which oxygen radicals were specifically produced during the state of LH-induced 
depressive symptoms as in vivo ROS measurements still presents with nearly unsurmountable 
technical difficulties. We also did not specifically assess HPA function. Therefore we have no 
causal proof for our hypothesis that oxidative cell damage is associated with mitochondrial 
dysfunction and HPA axis dysfunction.  In this context, future studies are needed to investigate 
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the effects of IS and drugs on neurogenesis in the hippocampal DG, in order to identify the 
possible underlying mechanisms of oxidative stress-related memory deficits in depression. 
In the in vivo study, the experiments were not performed in a blinded manner. Since I was not 
working within a team and was responsible to look after the animals, perform all treatments 
and the daily behavioural testing on my own, this an unavoidable limitation. However, all 
calculations and scoring processes were automatically performed by the acquisition and 
analysis software of the Multiple Conditioning System based on investigator defined 
parameters. These parameters were informed by reports described in the literature (875) and 
the manufacturers recommendations and were kept constant for all experiments. This approach 
was seen to effectively minimize investigator bias. Nevertheless, investigator blinding to the 
treatment groups could have increased quality of the data and should be considered for future 
testing. In addition, the discrepancy in animal body weights between different groups, 
especially between the control group and the treatment groups of the morphine experiment may 
potentially have affected the results of the drug-treatment experiment. It is possible that body 
weight changes are a result of alterations of hormonal status (876). On the other hand, higher 
body weight has been found to result in larger pituitary and adrenal glands in male rats (877). 
Since these two hormone glands are involved in the regulation of stress hormone secretion 
(878), stressed rats with larger body weight might show more EFs. In addition, a recent study 
reported that rats with higher body mass showed more exploratory behaviour (879). Based on 
this evidence, hypothetically rats in the NS and IS groups of the morphine-imipramine 
experiment might exhibited more movement in the OF test due to their large body weight. 
However, in my study, neither more EFs nor increased physical activity was observed, when 
compared to the control groups of the idebenone experiment. Therefore, I believe that this 
potential limitation was not of major concern in the present study.     
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Another limitation is about the effect of morphine on learning and memory. Morphine 
improved avoidance learning in rats, but this cognitive effect was not assessed in the NOR 
model in contrast to the cognition effects of idebenone that were tested in this model. This 
makes a direct comparison of the effects of both drugs impossible based on the variability seen 
in the results from both cognition models. Due to the sequence of experiments in this project 
and the preparation of brain samples of morphine treated rats for western blotting, we did not 
measure effect of morphine on oxidative cell damage in the HPC either. Therefore, we cannot 
confirm that the effects of morphine on learning and memory are related to ROS and oxidative 
damage in the HPC similar to the effects of the novel bifunctional opioids.  We also have to 
acknowledge that we did not test higher doses of both bifunctional opioids 1001 and 1003 in 
the LH model. This was mainly a consequence of the limited availability of compound for in 
vivo studies as these compounds involved a difficult synthesis and hence we did not have 
access to unlimited amounts. Nevertheless, as a consequence, we are unable to confirm or 
refute that higher concentrations would have resulted in any antidepressant effects comparable 
to morphine. Unfortunately, we were unable to show if idebenone improves fear extinction in 
the FE model, which was on the one hand a problem of the experimental design with regards 
to the idebenone pre-treatment period and also the consequence of time restriction to further 
improve the model. Hence, whether idebenone could indeed be used to facilitate extinction 
learning will have to be addressed in future studies.  Due to this time restriction, we were also 
unable to test different doses and treatment periods of idebenone to establish a possible time 
and dose-dependency. Overall, this study now serves as the basis for future trials to optimize 
experimental conditions and to generate detailed concentration and time-dependent data that 
are necessary to potentially translate our results into a clinical setting. 
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9.5.2 Summary 
Based on to the distribution and function of different types of opioid receptors and their specific 
endogenous ligands/drugs, previous studies widely proposed to develop novel opioids for 
mood control (282,724,725,777,880). This project was initially developed based on those 
points of view. On the basis of the reported antidepressant-like effects of morphine in the LH 
model (525), we established and verified an integrated model by evaluating the effects of 
morphine on different interference factors of the LH model. In line with previous results, 
morphine-treated rats exhibited promising antidepressant-like effect in our model. However, 
this study was able to show that at least part of this activity could be an artefact based on the 
anxiolytic, physical stimulating and cognitive effects of morphine.   
The results of initial tests of morphine and imipramine against depression nevertheless led us 
to investigate two novel bifunctional opioids. In our laboratory, those two bifunctional opioids 
1001 and 1003 showed affinity towards both MOP and DOP receptors. Since the toxicity in 
vivo of both novel opioids are uncertain, we tested both drugs in regards to cellular 
bioenergetics and proliferation. Surprisingly, we found that 1001 which activates the DOP 
receptor was toxic to liver cells, which was contradictory to previous report (881). However, 
the same drug entity has been previously tested in vivo and while one study reported no toxicity 
(682), there was some information about toxicity reported later (824). Although both 
bifunctional opioids showed no effects on depression, anxiety, pain and locomotion, both 1001 
and 1003 showed a slight non-significant reduction of oxidative damage in the HPC (Figure 
6). At the same time both drugs also showed a trend towards improved memory function. These 
results highlight a link between oxidative stress and depression-associated memory loss. Based 
on this potential connection, we tested the psychopharmacological effects of the potent 
antioxidant idebenone in the same models. Similar to the bifunctional opioids, idebenone did 
not have any effects on depression, anxiety, pain or locomotion, but it ameliorated oxidative 
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damage in the HCP and effectively reversed stress-induced memory deficits. This strongly 
suggests that oxidative damage in the hippocampal DG presents a direct cause of cognitive 
deficits in depression.  
Mitochondrial MAOA, as one of the main targets for current anti-depressant therapy, not only 
directly contributes to the decrease in synaptic catecholamines that is characteristic of MDD 
(294,308), but is also a source of ROS (882) (Figure 6). MAOA generates H2O2 during the 
metabolism of catecholamines, which is further converted into a varierty of oxygen radicals 
(883) that damage to cellular macromolecules and lead to mitochondrial dysfunction, which 
represents a vicious cycle that exacerbates oxidative stress (884) (Figure 6). ROS and 
mitochondrial dysfunction are highly associated with the development of mental disorders and 
neurocognitive deficits (882). Before this study, it was unclear if ROS are causally involved in 
the pathogenesis of the MDD and its related memory loss or if ROS represent an indirect 
consequence of depression (885). The results of this study now highlight that antioxidant 
strategies are unlikely to be effective against depression but have a clear potential to alleviate 
the depression-associated cognitive impairment. Therefore, antioxidant strategies are likely to 
be developed in the future as novel treatment paradigms against depression-associated 
cognitive dysfunction but also for additional indications that are associated with impaired 
cognition under stressful conditions (Figure 87). 
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Figure 87. Possible mechanisms of the effects of opioids and idebenone on oxidative 
stress, depression and memory. 
The levels of monoamines reduce followed by the activation of monoamine oxidase (MAO). 
Based on the monoamine theory, reduced monoamines causes depression. As consequences 
of depression, reduced locomotion and increased reactive oxygen species were observed. 
ROS further lead to damages and mitochondrial dysfunction, which return generated more 
ROS. In our study, oxidative stress damage resulted in memory loss in rats. This oxidative 
stress damage-induced memory loss can be reversed (in solid green line) or slightly reduced 
(in blue dash line) by antioxidant idebenone and novel bifunctional opioids (i.e., 1001 and 
1003) respectively. On the other hand, exposure to stress contributes to the development of 
both depression and anxiety. In addition, anxiety and pain co-existence in depression. In our 
model, morphine treatment produced artificial antidepressant-like effect that were partially 
due to its effects on locomotion (in solid red line), anxiety (in solid red line) and cognitive 
function (in red dash line). However, the effect of morphine on memory function was not 
further confirmed in the novel object recognition model, a model of cognition (in red dash 
line). 
 
9.5.3 Implications and future direction 
The LH model as one of the frequently used models of depression was selected to investigate 
the antidepressant-like effects of both novel and conventional drugs in this study. In addition, 
in order to study depression-associated comorbidities, I developed a complex integrated animal 
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model based on the LH model. This is the first time such comprehensive model has been used 
to test the effects of drugs on different behaviours and the validity of this model was confirmed 
by including a known antidepressant (i.e., imipramine). Particularly, we evaluated different 
interference factors of the antidepressant-like effect of morphine in the LH model, including 
the number of avoidance events, mean escape latency, intertrial interval transfers and freezing. 
In this way, the results of this study are more accurate in terms of identifying artefacts and 
determining interfering factors, compared to previously published data (525,886). Therefore, 
my our results provide useful guidelines for future studies to modify and extend existing 
preclinical depression models and offers ideas on how to interpret data based on multiple 
behavioural paradigms.  
In addition, our study sheds light on the puzzling relationships between oxidative stress, 
depression and depression-associated memory loss. In particular, it was surprising to observe 
that the cognitive effects of idebenone were restricted to recognition memory rather than the 
avoidance or escape learning. While the IS exposure per se impairs all three cognitive aspects 
in our model, which reflect both information encoding and recall, our idebenone data suggest 
that antioxidants may only be effective to normalize memory retrieval. To translate these 
results to clinical practice, based on our results we could conclude that trying to treat depression 
with antioxidants might not be a successful strategy. In contrast, a more promising approach 
would be to use antioxidants in patients with MDD to protect their cognitive function. This 
strategy might only be useful at a very early stage of cognitive dysfunction and might maintain 
their long-term memory or at least prevent further memory loss. It will be essential to test this 
hypothesis in careful controlled clinical trials to substantiate this claim. Given that idebenone 
has shown a very good safety profile in clinical trials (395), it offers itself as a promising 
starting point with minimal adverse effects for this type of therapeutic intervention in MDD 
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patients. In addition, this strategy could also be of great value under similar conditions where 
cognition is impaired due to elevated levels of stress such as in PTSD patients.
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Appendix 
A1. Demonstration of missing contemporaneous controls for  the 1001 and 1003 effects 
Table 8. Mean ± S.E.M. of different controls that conducted in different calendar years and with 
different administration methods. 
Conditions Conducted in 2016, for idebenone experiment, oral administration 
 NS IS 
Test sessions EFs S.E.M. n EFs S.E.M. n 
T1 6 1.843909 5 23 2.67083 6 
T2 3 1.048809 5 24.83333 1.720788 6 
T3 8 3.507136 5 23.66667 1.256096 6 
Conditions Conducted in May 2015, for morphine experiment, s.c. 
 NS IS 
Test sessions EFs S.E.M. n EFs S.E.M. n 
T1 9.2 2.853069 5 25.875 1.125 6 
T2 5.4 1.989975 5 24.25 1.600781 6 
T3 5.4 3.264966 5 22.5 1.4516 6 
Conditions Conducted in 2015, for optimisation, no injection 
 NS IS 
Test sessions EFs S.E.M. n EFs S.E.M. n 
T1 6 1.073937 3 22.5 2.50383 3 
T2 7 3.267427 3 23 5.794723 3 
T3 6 2.193393 3 24.5 1.530273 3 
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Table 9. Multiple comparison between different controls. 
No significance was found using repeated two-way ANOVA followed by Tukey comparison tests. 
(p<0.05 was considered as statistical significant) 
 
Stat Tukey's multiple comparisons test, repeated 2-way ANOVA Mean Diff. Significant 
Adjusted P 
Value 
NS groups 
T1 
morphine, 2015 vs. opt., 2015 3.2 No 0.7688 
morphine, 2015 vs. idebenone, 2016 3.2 No 0.6335 
opt., 2016 vs. idebenone, 2016 0 No > 0.9999 
T2 
morphine, 2015 vs. opt., 2015 -1.6 No 0.9359 
morphine, 2015 vs. idebenone, 2016 2.4 No 0.7719 
opt., 2016 vs. idebenone, 2016 4 No 0.6647 
T3 
morphine, 2015 vs. opt., 2015 -0.6 No 0.9907 
morphine, 2015 vs. idebenone, 2016 -2.6 No 0.7384 
opt., 2016 vs. idebenone, 2016 -2 No 0.9018 
IS groups 
T1 
morphine, 2015 vs. opt., 2015 3.375 No 0.5976 
morphine, 2015 vs. idebenone, 2016 2.875 No 0.4520 
opt., 2016 vs. idebenone, 2016 -0.5 No 0.9893 
T2 
morphine, 2015 vs. opt., 2015 1.25 No 0.9309 
morphine, 2015 vs. idebenone, 2016 -0.5833 No 0.9671 
opt., 2016 vs. idebenone, 2016 -1.833 No 0.8659 
T3 
morphine, 2015 vs. opt., 2015 -2 No 0.8331 
morphine, 2015 vs. idebenone, 2016 -1.167 No 0.8752 
opt., 2016 vs. idebenone, 2016 0.8333 No 0.9706 
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A2. Receptor activity of UTA1003 
(The protocol and following unpublished results were provided by Alok Paul (PhD candidate, 
School of Medicine, University of Tasmania). 
 
Opioid receptors belong to the inhibitory Gi linked G-protein coupled receptor subfamily (237). G 
proteins consist of three protein subunits, including α, β, γ subunits.  In the inactive state the α, β and 
γ subunits form a heterotrimeric complex. In this complex, the α subunit binds guanosine diphosphate 
(GDP) (238). After opioid agonists bind to their specific opioid receptors, GDP is released from the 
α-subunit of Gi protein and was replaced by Guanosine-5'-triphosphate (GTP). The binding of GTP 
activates the α-subunit, leading to its disassociation from the βγ-complex.  Subsequently, this Gi-α 
protein inhibits adenylyl cyclases, which further prevents the conversion of ATP to cAMP (239). 
Therefore, the activation of opioid receptors lead to a reduction of cellular cAMP. Based on this 
mechanism of using cAMP as a surrogate marker, the receptor activities of UTA1001 and UTA1003 
were measured in Chinese Hamster Ovary (CHO) cell-lines expressing recombinant human opioid 
receptors (i.e., CHO-MOP (Figure 88) and CHO-DOP (Figure 89)). In addition, CHO wild type 
(CHO-WT) cells were used to confirm the receptor specificity of these two drugs (Figure 87). In this 
assay, CHO cells were incubated with 100 µM of UTA-opioids, the MOP agonist DAMGO or the 
DOP agonist DPDPE for 20 min in the presence of 1 µM of forskolin, which activates adenylyl cyclase 
and increases intracellular levels of cAMP. Control cells were only incubated with 1 µM of forskolin 
for same time period. Data was represented as % inhibition of forskolin-induced cAMP production. 
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Figure 88. Opioid receptor specificity assessment of UTA-opioids using wild-type cells. 
No significant differences were detected in all treated groups, compared to the non-treated cells.  
 
 
 
Figure 89. Effects of UTA-opioids and DAMGO on µ-opioid (MOP) receptor expressing cells. 
Statistically significant differences (p<0.0001) against the effect of 1 µM forskolin (no drug) were 
calculated using one-way ANOVA with Dunnett’s multiple comparisons test. Values represent the 
mean ± SEM (n = 6).  
 
Figure 90. Effects of UTA-opioids and DPDPE on δ-opioid (DOP) receptor expressing cells. 
Statistically significant differences against the effect of 1 µM forskolin (no drug) were calculated 
using one-way ANOVA with Dunnett’s multiple comparisons test. Values represent the mean ± SEM 
(n = 6).  
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A3. Antinociceptive effects of 1001 and 1003 in vivo 
The testing protocol and the unpublished results of the tail flick (TF) assay to measure antinociception 
were provided by Alok Paul (PhD candidate, School of Medicine, University of Tasmania). 
Baseline antinociception of male SD rats (8 weeks old) was measured before drug administration. 
Equimolar concentrations of UTA1001 (27.1 mg/kg) and UTA1003 (24.6 mg/kg) were injected once 
and their antinociceptive effects were evaluated in the TF assay 15, 30, 60 and 120 min after injection. 
MPE (maximum possible effect, defined as MPE % or antinociception = 100 × [(test latency – baseline 
latency) / (cut-off time (15 s) – baseline latency)]) was used to simplify the comparison between 
different drugs at different time points against the basal level.  
Figure 91. Antinociceptive effects of UTA1001 (UFP-505) and 1003. 
Statistical significance against the effect of vehicle at the same testing point was calculated using 
student’s t-test and is shown as *p<0.05, **p<0.01 in the UTA1003-treated group and #p<0.01 in the 
UTA1001 (UFP-505)-treated group. Values represent mean ± SEM (n = 6 animals per group). 
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A4. Animal batches of the morphine-imipramine experiment and the allocations of 
animals 
Table 10. Animal numbers in weekly batches and excluded rats in each group. 
Batch Animal numbers 
Delivery 
week 1 180, 181,183, 185 
week 2 213, 214, 215, 216 
week 3 242, 243, 244, 245 
week 4 252, 253, 254 
week 5 276, 277, 278, 280 
week 6 336, 337, 338, 339 
week 7 367, 368, 369 
week 8 402, 403, 404 
week 9 453, 454, 455, 456 
week 10 468, 469, 470, 471 
week 11 512, 513, 514 
Excluded rats 
NS SD 242, 243, 256 
IS SD 253, 278 
ES SD 216, 454, 513 
MOR SD 455 
IMI SD 339, 404 
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Table 11. Rat numbers and body weights in each group 
(Colour coding is the same as that in the Table 10, aiming to exhibit the weekly rat allocations from 
week 1 to 5) 
Experimental Period 
Rat IDs D1 D2 D4 D5 D6 
IS group 
SD180 258 248 246 254 256 
SD185 264 256 256 262 264 
SD214 304 296 290 296 286 
SD244 278 278 280 280 284 
SD245 284 286 286 286 288 
SD254 306 306 306 306 308 
NS group 
SD183 264 252 248 252 268 
SD215 326 320 312 312 318 
SD252 356 354 346 356 348 
SD276 346 348 342 342 350 
SD277 304 306 312 308 312 
IS+MOR group 
SD336 206 198 192 200 204 
SD367 204 198 198 204 206 
SD368 230 226 222 230 232 
SD402 210 204 204 212 220 
SD403 178 176 176 182 184 
SD453 246 246 242 248 250 
SD468 216 210 200 202 210 
IS+IMI group 
SD369 204 204 188 204 204 
SD456 258 254 244 248 250 
SD469 214 206 196 198 202 
SD470 212 206 198 200 200 
SD471 218 216 184 208 210 
SD512 218 220 204 208 208 
ES group 
SD181 264 258 256 260 268 
SD213 302 290 286 291 298 
SD280 368 358 354 360 362 
SD337 204 204 201 201 205 
SD338 210 208 204 207 210 
SD514 214 214 208 210 214 
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A5. Animal Ethics Approval Permit
University of Tasmania 
Animal Ethics Committee 
ETHICS APPROVAL PERMIT
University of Tasmania 
Office of Research Services
Ph: 03 62267283 Fax: 03  
62267148 
animal.ethics@utas.edu.au 
To: Dr Nikolaos Dietis 
From: Marilyn Pugsley Executive Officer Animal Ethics 
Date: 2 June 2014 
Project: A13857 – The effects of novel bifunctional opioids in a rat- 
model of depression 
Approved on: 2 June 2014 
Approval expires: 2 June 2017 
1st Annual Report
due before: 2 June 2015 
Please read this permit carefully as approval may be withdrawn
for projects that do not comply with the conditions 
The Animal Ethics Committee has approved the above project and a copy of the 
document is attached. The approval is subject to the review and approval of an annual 
report which is due before the approval anniversary. Please note this date in your 
diary.
This approval constitutes ethical clearance by the Animal Ethics Committee. If this 
project involves the conduct of a Veterinary Service or Other Animal Service as 
defined in the Veterinary Surgeons Act 1987 (Tas) and Veterinary Surgeons 
Regulations 2012 (Tas), it is your responsibility to ensure that the project is 
conducted in accordance with the provisions of the Act and Regulations. Please 
contact the Animal Welfare Officer, Dr Sue Ottomanski (6226 7491 or 
sue.ottomanski@utas.edu.au) to discuss veterinary procedure competency 
accreditation. 
As the Responsible Investigator, you MUST ensure that: 
(a) all aspects of the work conform to the requirements of the
current edition of the Australian code of practice for the care and
use of animals for scientific purposes 8th edition 2013
(b) a full record is maintained of all animals used in this project. If at any
stage you anticipate the need to use additional animals this must be
communicated to the committee before use. Using additional animals without
AEC approval is a breach of your ethics permit.
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(c) you contact the Animal Welfare Officer, Dr Sue Ottomanski
(sue.ottomanski@utas.edu.au) to advise her when and where
your experiments will be conducted. Sufficient notice needs to
be given so that if the AWO wishes to make an inspection, this
can be easily arranged.
(d) That all investigators attend Ethics training sessions every three years.
Contact the Executive Officer Animal Ethics for the next available session.
The Animal Ethics Committee is to be promptly notified of any unexpected events which 
occur during the period of the approved project and impact on the welfare of the animals. 
Autopsy should be performed by a qualified veterinarian when animals die 
unexpectedly. Any foreseeable departure from this requirement must have been 
outlined and approved in the initial application. 
If the project is to continue past the expiry date, a new initial application will 
need to be submitted. A project can only be approved for a maximum of 3 
years. 
If the investigation necessitates a Parks & Wildlife permit you are required to 
send a copy of this permit to the AEC Secretary before commencing work. 
Marilyn Pugsley 
Executive Officer Animal Ethics 
University of Tasmania 
Animal Ethics Committee
Ethics Number A13857 
The effects of novel bifunctional opioids in 
Project Name a rat-model of depression 
Chief Investigator Dr Nikolaos Dietis 
School Pharmacy 
Person responsible 
for 
day-to-day care 
Ethics start date 2 June 2014 
Ethics approved to 2 June 2017 (with annual renewal) 
Emergency Contact 
